Coronavirus immunogen compositions and uses thereof

By developing cyclic polyribonucleotides and immunogenic compositions that encode coronavirus immunogens, polyclonal antibodies are generated, solving the difficulties in preventing and treating coronavirus infections, and achieving effective immune responses and symptoms to coronavirus Reduce.

CN118900845APending Publication Date: 2024-11-05FLAGSHIP PIONEERING INNOVATIONS VI LLC
View PDF 100 Cites 0 Cited by

Patent Information

Application Number
CN202280087072.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2021-11-24
Filing Date
2022-11-23
Publication Date
2024-11-05

AI Technical Summary

Technical Problem

The prior art is difficult to effectively prevent and treat coronavirus infections, especially diseases caused by COVID-19, and there is a lack of effective vaccines and therapeutic agents.

Method used

Develop cyclic polyribonucleotides and immunogenic compositions containing coronavirus immunogens for the generation of polyclonal antibodies for the prevention and treatment of coronavirus infections, including the use of these antibodies in high-risk populations and infected individuals middle.

Benefits of technology

By generating polyclonal antibodies against coronavirus, effective prevention and treatment of coronavirus infections, the frequency and severity of related symptoms are reduced, and an immune response to coronavirus is provided.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure GDA0005074033030000331
    Figure GDA0005074033030000331
  • Figure GDA0005074033030000341
    Figure GDA0005074033030000341
  • Figure GDA0005074033030000351
    Figure GDA0005074033030000351
Patent Text Reader

Abstract

The present disclosure provides compositions and methods comprising a cyclic polyribonucleotide comprising a sequence encoding a coronavirus immunogen, as well as compositions and methods comprising a linear polyribonucleotide comprising a sequence encoding one or more coronavirus immunogens. Compositions and methods related to the generation of polyclonal antibodies, for example, using the disclosed cyclic polyribonucleotides or the disclosed linear polyribonucleotides, are provided.
Need to check novelty before this filing date? Find Prior Art

Description

Background Art

[0001] COVID-19 is a human respiratory disease caused by infection with SARS-CoV-2, which was declared a pandemic by the World Health Organization on March 11, 2020 and has resulted in millions of deaths worldwide. Therefore, vaccines and therapeutic agents active against coronaviruses and their uses are urgently needed. Summary of the invention

[0002] The present disclosure generally relates to cyclic polyribonucleotides comprising sequences encoding coronavirus immunogens and to immunogenic compositions comprising the cyclic polyribonucleotides. The present disclosure further relates to methods using cyclic polyribonucleotides and immunogenic compositions comprising sequences encoding coronavirus immunogens. In certain embodiments, the cyclic polyribonucleotides and immunogenic compositions of the present disclosure are used in methods for generating polyclonal antibodies. The polyclonal antibodies produced can be used in the prevention methods of subjects (e.g., human subjects) or in the treatment methods of subjects (e.g., human subjects) infected with coronavirus. The polyclonal antibodies produced can be applied to subjects at high risk of being exposed to coronavirus infection.

[0003] In a first aspect, the disclosure provides a cyclic polyribonucleotide comprising an open reading frame encoding a coronavirus immunogen, wherein the coronavirus immunogen comprises an amino acid sequence having at least 85% sequence identity (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity) with the amino acid sequence of any one of SEQ ID NOs: 63-111 and 283-291. In some embodiments, the coronavirus immunogen comprises an amino acid sequence having at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity) sequence identity with the amino acid sequence of any one of SEQ ID NOs: 63-111 and 283-291. In some embodiments, the coronavirus immunogen comprises an amino acid sequence having at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or 100% sequence identity) sequence identity to the amino acid sequence of any one of SEQ ID NOs: 63-111 and 283-291. In some embodiments, the coronavirus immunogen comprises an amino acid sequence of any one of SEQ ID NOs: 63-111 and 283-291.

[0004] In certain embodiments, the coronavirus immunogen is a RBD immunogen having at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity) identity to the amino acid sequence of any one of SEQ ID NOs: 63-68, 74, 79, 81-86 and 98-111. In some embodiments, the coronavirus immunogen is a RBD immunogen having at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity) identity to the amino acid sequence of any one of SEQ ID NOs: 63-68, 74, 79, 81-86 and 98-111. In some embodiments, the coronavirus immunogen is a RBD immunogen having at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or 100% sequence identity) identity to the amino acid sequence of any one of SEQ ID NOs: 63-68, 74, 79, 81-86 and 98-111. In some embodiments, the coronavirus immunogen is a RBD immunogen having an amino acid sequence of any one of SEQ ID NOs: 63-68, 74, 79, 81-86 and 98-111.

[0005] In certain embodiments, the coronavirus immunogen is a spike immunogen that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity) identical to the amino acid sequence of any one of SEQ ID NOs: 69-73, 75-78, 80, 87-97, and 283-286. In some embodiments, the coronavirus immunogen is a spike immunogen that is at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity) identical to the amino acid sequence of any one of SEQ ID NOs: 69-73, 75-78, 80, 87-97, and 283-286. In some embodiments, the coronavirus immunogen is a spike immunogen having at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or 100% sequence identity) identity to the amino acid sequence of any one of SEQ ID NOs: 69-73, 75-78, 80, 87-97, and 283-286. In some embodiments, the coronavirus immunogen is a spike immunogen having an amino acid sequence of any one of SEQ ID NOs: 69-73, 75-78, 80, 87-97, and 283-286.

[0006] In certain embodiments, the coronavirus immunogen is a nonstructural protein (nsp) having at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity) identity to the amino acid sequence of any one of SEQ ID NOs: 291-295. In some embodiments, the coronavirus immunogen is a nsp immunogen having at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity) identity to the amino acid sequence of any one of SEQ ID NOs: 291-295. In some embodiments, the coronavirus immunogen is an nsp immunogen having at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or 100% sequence identity) identity to the amino acid sequence of any one of SEQ ID NOs: 291-295. In some embodiments, the coronavirus immunogen is an nsp immunogen having an amino acid sequence of any one of SEQ ID NOs: 291-295.

[0007] In some embodiments, the open reading frame comprises a nucleic acid sequence having at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity) sequence identity to the nucleic acid sequence of any one of SEQ ID NOs: 112-174 and 292-300. In some embodiments, the open reading frame comprises a nucleic acid sequence having at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity) sequence identity to the nucleic acid sequence of any one of SEQ ID NOs: 112-174 and 292-300. In some embodiments, the open reading frame comprises a nucleic acid sequence having at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or 100% sequence identity) sequence identity to the nucleic acid sequence of any one of SEQ ID NOs: 112-174 and 292-300. In some embodiments, the open reading frame comprises a nucleic acid sequence of any one of SEQ ID NOs: 112-174 and 292-300.

[0008] In some embodiments, the coronavirus immunogen is a RBD immunogen having at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity) identity to the nucleic acid sequence of any one of SEQ ID NOs: 112-117, 123, 128, 133-138, and 163-174. In some embodiments, the coronavirus immunogen is a RBD immunogen having at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity) identity to the nucleic acid sequence of any one of SEQ ID NOs: 112-117, 123, 128, 133-138, and 163-174. In some embodiments, the coronavirus immunogen is a RBD immunogen having at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or 100% sequence identity) identity to the nucleic acid sequence of any one of SEQ ID NOs: 112-117, 123, 128, 133-138 and 163-174. In some embodiments, the coronavirus immunogen is a RBD immunogen having a nucleic acid sequence of any one of SEQ ID NOs: 112-117, 123, 128, 133-138 and 163-174.

[0009] In some embodiments, the coronavirus immunogen is a spike immunogen that is at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity) identical to the nucleic acid sequence of any one of SEQ ID NOs: 118-122, 124-127, 129-132, 139-162, and 287-291. In some embodiments, the coronavirus immunogen is a spike immunogen that is at least 90% identical (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity) to the nucleic acid sequence of any one of SEQ ID NOs: 118-122, 124-127, 129-132, 139-162, and 287-291. In some embodiments, the coronavirus immunogen is a spike immunogen that is at least 95% identical (e.g., at least 95%, 96%, 97%, 98%, 99%, or 100% sequence identity) to the nucleic acid sequence of any one of SEQ ID NOs: 118-122, 124-127, 129-132, 139-162, and 287-291. In some embodiments, the coronavirus immunogen is a spike immunogen having a nucleic acid sequence of any one of SEQ ID NOs: 118-122, 124-127, 129-132, 139-162, and 287-291.

[0010] In some embodiments, the coronavirus immunogen is an nsp immunogen having at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity) identity to the nucleic acid sequence of any one of SEQ ID NOs: 296-300, and an nsp nsp immunogen having at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity) identity to the nucleic acid sequence of any one of SEQ ID NOs: 296-300. In some embodiments, the coronavirus immunogen is an nsp immunogen having at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99% or 100% sequence identity) identity to the nucleic acid sequence of any one of SEQ ID NOs: 296-300. In some embodiments, the coronavirus immunogen is an nsp immunogen having a nucleic acid sequence of any one of SEQ ID NOs: 296-300.

[0011] In some embodiments, the open reading frame encoding the coronavirus immunogen is operably connected to the IRES. In some embodiments, the open reading frame encoding the coronavirus immunogen encodes a second polypeptide. In some embodiments, the coronavirus immunogen and the second polypeptide are separated by: a polypeptide linker, a 2A self-cleaving peptide, a protease cleavage site, or a 2A self-cleaving peptide in series with a protease cleavage site. In some embodiments, the protease cleavage site is a furin cleavage site.

[0012] In some embodiments, the cyclic polyribonucleotide further includes a second open reading frame encoding a second polypeptide operably connected to the second IRES. In some embodiments, the second polypeptide is a polypeptide immunogen. In some embodiments, the second polypeptide is a viral immunogen. In some embodiments, the second polypeptide is a coronavirus immunogen. In some embodiments, the second coronavirus immunogen includes an amino acid sequence with at least 95% identity (e.g., at least 95%, 96%, 97%, 98%, 99% or 100% identity) to any one of SEQ ID NO: 1-10, 53, 55, 57, 63-111 and 283-291. In some embodiments, the second coronavirus immunogen includes an amino acid sequence of any one of SEQ ID NO: 1-10, 53, 55, 57, 63-111 and 283-291. In some embodiments, the second polypeptide is an influenza immunogen.

[0013] In certain embodiments, the second polypeptide is a polypeptide adjuvant.In certain embodiments, the adjuvant is a component of a cytokine, a chemokine, a costimulatory molecule, an innate immune stimulator, a signal transduction molecule, a transcription activator, a cytokine receptor, a bacterial component or an innate immune system.In certain embodiments, the cyclic polyribonucleotide further includes a non-coding ribonucleic acid sequence as an innate immune system stimulator.In certain embodiments, the innate immune system stimulator is selected from a motif rich in GU, a motif rich in AU, a structured region including dsRNA or an aptamer.

[0014] On the other hand, the present disclosure provides a cyclic polyribonucleotide comprising a first sequence encoding a coronavirus immunogen and a second sequence encoding a polypeptide adjuvant. In some embodiments, the sequence encoding the coronavirus immunogen is operably connected to the first IRES, and the sequence encoding the polypeptide adjuvant is operably connected to the second IRES. In some embodiments, the coronavirus immunogen and the polypeptide adjuvant are encoded by a single open reading frame operably connected to an IRES. In some embodiments, the coronavirus immunogen and the polypeptide adjuvant are separated by: a polypeptide linker, a 2A self-cleaving peptide, a protease cleavage site, or a 2A self-cleaving peptide in series with a protease cleavage site.

[0015] In some embodiments, the polypeptide adjuvant is a cytokine, a chemokine, a co-stimulatory molecule, an innate immune stimulator, a signaling molecule, a transcription activator, a cytokine receptor, a bacterial component, or a component of the innate immune system. In some embodiments, the second coronavirus immunogen includes an amino acid sequence having at least 95% identity (e.g., at least 95%, 96%, 97%, 98%, 99% or 100% identity) with any one of SEQ ID NO: 1-10, 53, 55, 57, 63-111, and 283-291. In some embodiments, the second coronavirus immunogen includes an amino acid sequence of any one of SEQ ID NO: 1-10, 53, 55, 57, 63-111, and 283-291.

[0016] On the other hand, the present disclosure provides a cyclic polyribonucleotide, which includes an open reading frame encoding a coronavirus immunogen and a non-coding ribonucleic acid sequence as an innate immune system stimulating factor. In some embodiments, the innate immune system stimulating factor is selected from a motif rich in GU, a motif rich in AU, a structured region including dsRNA, or an aptamer. In some embodiments, the second coronavirus immunogen includes an amino acid sequence with at least 95% identity (e.g., at least 95%, 96%, 97%, 98%, 99% or 100% identity) to any one of SEQ ID NO: 1-10, 53, 55, 57, 63-111 and 283-291. In some embodiments, the second coronavirus immunogen includes an amino acid sequence of any one of SEQ ID NO: 1-10, 53, 55, 57, 63-111 and 283-291.

[0017] In some embodiments, the open reading frame encodes a concatemer coronavirus immunogen. In some embodiments, the open reading frame comprises 2-100 coronavirus immunogens directly connected to each other or separated by a linker. In other embodiments, the immunogen is a concatemer peptide immunogen consisting of multiple peptide epitopes. In some embodiments, the cyclic polyribonucleotide encodes 2-10 coronavirus immunogens. In some embodiments, the cyclic polyribonucleotide encodes at least 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100 coronavirus immunogens. In some embodiments, the coronavirus immunogen is separated by: a polypeptide linker, a 2A self-cleaving peptide, a protease cleavage site, or a 2A self-cleaving peptide in series with a protease cleavage site. In some embodiments, the concatameric coronavirus immunogen comprises an amino acid sequence that is at least 85% identical (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical) to any one of SEQ ID NOs: 63-111 and 283-291. In some embodiments, the concatameric coronavirus immunogen comprises an amino acid sequence that is at least 95% identical (e.g., at least 95%, 96%, 97%, 98%, 99% or 100% identical) to any one of SEQ ID NOs: 63-111 and 283-291. In some embodiments, the concatameric coronavirus immunogen comprises an amino acid sequence that is at least 95% identical (e.g., at least 95%, 96%, 97%, 98%, 99% or 100% identical) to any one of SEQ ID NOs: 63-111 and 283-291. In some embodiments, the concatameric coronavirus immunogen comprises a nucleic acid sequence having at least 85% identity (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity) to any one of SEQ ID NOs: 112-174 and 292-300. In some embodiments, the concatameric coronavirus immunogen comprises a nucleic acid sequence having at least 95% identity (e.g., at least 95%, 96%, 97%, 98%, 99% or 100% identity) to any one of SEQ ID NOs: 112-174 and 292-300. In some embodiments, the concatameric coronavirus immunogen comprises a nucleic acid sequence of any one of SEQ ID NOs: 112-174 and 292-300.

[0018] On the other hand, the present disclosure provides a cyclic polyribonucleotide comprising a first sequence encoding a coronavirus immunogen and a second sequence encoding a multimerization domain. In some embodiments, the multimerization domain comprises a T4foldon domain. In some embodiments, the multimerization domain comprises a ferritin domain. In some embodiments, the multimerization domain comprises a beta loop peptide. In some embodiments, the multimerization domain is located at the N-terminus of the coronavirus immunogen. In some embodiments, the multimerization domain is located at the C-terminus of the coronavirus immunogen.

[0019] On the other hand, present disclosure provides immunogenic compositions, it includes any one of cyclic polyribonucleotides as described herein, pharmaceutically acceptable excipients, and does not contain any carrier.On the other hand, present disclosure provides immunogenic compositions, it includes any one of cyclic polyribonucleotides as described herein and pharmaceutically acceptable carriers or excipients.In certain embodiments, compositions further includes the second cyclic polyribonucleotides.In certain embodiments, the second cyclic polyribonucleotides include an open reading frame encoding the second polypeptide immunogen.In certain embodiments, the second cyclic polyribonucleotides include a non-coding ribonucleic acid sequence as an innate immune system stimulating factor.

[0020] In another aspect, the disclosure provides a linear polyribonucleotide comprising an open reading frame encoding a coronavirus immunogen, wherein the coronavirus immunogen comprises an amino acid sequence having at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) sequence identity to the amino acid sequence of any one of SEQ ID NOs: 63-111 and 283-291. In some embodiments, the coronavirus immunogen comprises an amino acid sequence having at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) sequence identity to the amino acid sequence of any one of SEQ ID NOs: 63-111 and 283-291. In some embodiments, the coronavirus immunogen comprises an amino acid sequence having at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or 100%) sequence identity to the amino acid sequence of any one of SEQ ID NOs: 63-111 and 283-291. In some embodiments, the coronavirus immunogen comprises an amino acid sequence having the amino acid sequence of any one of SEQ ID NOs: 63-111 and 283-291.

[0021] In some embodiments, the open reading frame comprises a nucleic acid sequence having at least 85% (e.g., at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) sequence identity to the nucleic acid sequence of any one of SEQ ID NOs: 112-174 and 292-300. In some embodiments, the open reading frame comprises a nucleic acid sequence having at least 90% (e.g., at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) sequence identity to the nucleic acid sequence of any one of SEQ ID NOs: 112-174 and 292-300. In some embodiments, the open reading frame comprises a nucleic acid sequence having at least 95% (e.g., at least 95%, 96%, 97%, 98%, 99%, or 100%) sequence identity to the nucleic acid sequence of any one of SEQ ID NOs: 112-174 and 292-300. In some embodiments, the open reading frame comprises a nucleic acid sequence having the nucleic acid sequence of any one of SEQ ID NOs: 112-174 and 292-300.

[0022] In some embodiments, the open reading frame encoding the coronavirus immunogen is operably connected to the IRES. In some embodiments, the open reading frame encoding the coronavirus immunogen encodes a second polypeptide. In some embodiments, the coronavirus immunogen and the second polypeptide are separated by: a polypeptide linker, a 2A self-cleaving peptide, a protease cleavage site, or a 2A self-cleaving peptide in series with a protease cleavage site. In some embodiments, the protease cleavage site is a furin cleavage site.

[0023] In certain embodiments, the cyclic polyribonucleotide further includes a second open reading frame encoding a second polypeptide operably connected to the second IRES. In certain embodiments, the second polypeptide is a polypeptide immunogen. In certain embodiments, the second polypeptide is a coronavirus immunogen. In certain embodiments, the second polypeptide is a polypeptide adjuvant. In certain embodiments, the adjuvant is a component of a cytokine, a chemokine, a co-stimulatory molecule, an innate immune stimulator, a signaling molecule, a transcription activator, a cytokine receptor, a bacterial component or an innate immune system. In certain embodiments, the linear polyribonucleotide further includes a non-coding ribonucleic acid sequence as an innate immune system stimulator. In certain embodiments, the innate immune system stimulator is selected from a motif rich in GU, a motif rich in AU, a structured region including dsRNA or an aptamer.

[0024] On the other hand, the present disclosure provides a linear polyribonucleotide comprising a first sequence encoding a coronavirus immunogen and a second sequence encoding a multimerization domain. In some embodiments, the multimerization domain comprises a T4foldon domain. In some embodiments, the multimerization domain comprises a ferritin domain. In some embodiments, the multimerization domain comprises a beta loop peptide. In some embodiments, the multimerization domain is located at the N-terminus of the coronavirus immunogen. In some embodiments, the multimerization domain is located at the C-terminus of the coronavirus immunogen.

[0025] On the other hand, present disclosure provides immunogenic compositions, which include any one of the linear polyribonucleotides described herein and a pharmaceutically acceptable excipient, and do not contain any carrier. On the other hand, present disclosure provides immunogenic compositions, which include any one of the linear polyribonucleotides described herein and a pharmaceutically acceptable carrier and excipient. In certain embodiments, the composition further includes a second linear polyribonucleotide. In certain embodiments, the second linear polyribonucleotide includes an open reading frame encoding a second polypeptide immunogen. In certain embodiments, the second linear polyribonucleotide includes an open reading frame encoding a polypeptide adjuvant. In certain embodiments, the second linear polyribonucleotide includes a non-coding ribonucleic acid sequence as an innate immune system stimulating factor.

[0026] In another aspect, the present disclosure provides a method for inducing an immune response to a coronavirus immunogen in a non-human animal or human subject by: a) administering any of the immunogenic compositions described herein to the non-human animal or human subject, and b) collecting antibodies to the coronavirus immunogen from the non-human animal or human subject. In some embodiments, further comprising administering an adjuvant to the non-human animal or human subject.

[0027] In another aspect, the disclosure provides a method of treating a subject having or suspected of having a SARS-CoV-2 infection, the method comprising administering to the subject any of the cyclic polyribonucleotides or immunogenic compositions described herein.

[0028] On the other hand, the disclosure provides a method for preventing SARS-CoV-2 infection in a subject, the method comprising administering any of the cyclic polyribonucleotides or immunogenic compositions described herein to the subject. In some embodiments, a human subject is at risk of SARS-CoV-2 infection. In some embodiments, a human subject is a person over 50 years old, an immunocompromised person, a person with a chronic health condition, or a health care worker. In some embodiments, administration of a cyclic polyribonucleotide or an immunogenic composition reduces the frequency or severity of symptoms associated with SARS-CoV-2 infection. In some embodiments, the subject is a human subject. In some embodiments, the method further comprises administering an adjuvant to the subject.

[0029] definition

[0030] The present invention will be described with respect to particular embodiments and with reference to certain drawings but the invention is not limited thereto but only by the claims.The terms set out below should generally be understood in their common sense unless otherwise stated.

[0031] As used herein, the term "adaptive immune response" refers to a humoral or cell-mediated immune response. For the purposes of this disclosure, a "humoral immune response" refers to an immune response mediated by antibody molecules, while a "cellular immune response" is an immune response mediated by T lymphocytes and / or other white blood cells.

[0032] As used herein, the term "adjuvant" refers to a composition (e.g., a compound, polypeptide, nucleic acid or lipid) that increases an immune response, such as a specific immune response to an immunogen. Increasing an immune response includes strengthening or amplifying the specificity of either or both of an antibody and cellular immune response.

[0033] As used herein, the terms "circRNA", "cyclic polyribonucleotide", "circular RNA" and "cyclic polyribonucleotide molecule" are used interchangeably and refer to polyribonucleotide molecules with a structure without free ends (i.e., without free 3' and / or 5' ends), such as polyribonucleotide molecules that form a ring or annular structure by covalent bonds (e.g., covalently closed) or non-covalent bonds. Circular polyribonucleotides can be covalently closed polyribonucleotides.

[0034] As used herein, the term "cyclization efficiency" is a measure of the resulting circular polyribonucleotide relative to its non-cyclic starting material.

[0035] The term "diluent" means a medium containing an inactive solvent in which a composition as described herein (e.g., a composition containing cyclic polyribonucleotides) can be diluted or dissolved. The diluent can be an RNA solubilizing agent, a buffer, an isotonic agent, or a mixture thereof. The diluent can be a liquid diluent or a solid diluent. Non-limiting examples of liquid diluents include water or other solvents, solubilizing agents, and emulsifiers, such as ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oil (particularly cottonseed oil, groundnut oil, corn oil, germ oil, olive oil, castor oil, and sesame oil), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycol, and fatty acid esters of sorbitan and 1,3-butylene glycol. Non-limiting examples of solid diluents include calcium carbonate, sodium carbonate, calcium phosphate, dicalcium phosphate, calcium sulfate, dibasic calcium phosphate, sodium phosphate lactose, sucrose, cellulose, microcrystalline cellulose, kaolin, mannitol, sorbitol, inositol, sodium chloride, dry starch, corn starch or powdered sugar.

[0036] As used herein, the term "epitope" refers to a portion or all of an immunogen that is recognized, targeted, or bound by an antibody or T cell receptor. An epitope can be a linear epitope, such as a continuous sequence of nucleic acids or amino acids. An epitope can be a conformational epitope, for example, an epitope containing amino acids that form an epitope in a folded conformation of a protein. A conformational epitope can contain non-contiguous amino acids from a primary amino acid sequence. For another example, a conformational epitope includes a nucleic acid that forms an epitope in a folded conformation of an immunogenic sequence based on its secondary structure or tertiary structure.

[0037] As used herein, the term "expressed sequence" is a nucleic acid sequence or regulatory nucleic acid encoding a product, e.g., a polypeptide (e.g., an immunogen). An exemplary expressed sequence encoding a polypeptide may comprise a plurality of nucleotide triplets, each of which may encode an amino acid and is referred to as a "codon."

[0038] As used herein, the term "fragment" with respect to a polypeptide or nucleic acid sequence (e.g., a polypeptide immunogen or a nucleic acid sequence encoding a polypeptide immunogen) refers to a contiguous, less than complete portion of a polypeptide or nucleic acid sequence. For example, a fragment of a polypeptide immunogen or a nucleic acid sequence encoding a polypeptide immunogen refers to a contiguous, less than complete portion (e.g., at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or 99% of the entire length) of a sequence (such as a sequence disclosed herein). It should be understood that all aspects of the present disclosure contemplate fragments (e.g., immunogenic fragments) of all immunogens disclosed herein.

[0039] As used herein, the term "GC content" refers to the percentage of guanine (G) and cytosine (C) in a nucleic acid sequence. The formula for calculating GC content is (G+C) / (A+G+C+U)×100% (for RNA) or (G+C) / (A+G+C+T)×100% (for DNA). Similarly, the term "uridine content" refers to the percentage of uridine (U) in a nucleic acid sequence. The formula for calculating uridine content is U / (A+G+C+U)×100%. Similarly, the term "thymidine content" refers to the percentage of thymidine (T) in a nucleic acid sequence. The formula for calculating thymidine content is T / (A+G+C+T)×100%.

[0040] As used herein, the term "innate immune system stimulator" refers to a substance that induces an innate immune response in part by inducing the expression of one or more genes involved in innate immunity, including but not limited to type I interferons (e.g., IFNα, INFβ and / or IFNγ), proinflammatory cytokines (e.g., IL-1, IL-12, IL-18, TNF-α and / or GM-CSF), retinoic acid-inducible gene-I (RIG-I, also known as DDX58), melanoma differentiation-associated gene 5 (MDA5, also known as IFIH1), 2'-5' oligoadenylate synthase 1 (OAS1), OAS-like protein (OASL) and / or protein kinase R (PKR). Innate immune system stimulators can act as adjuvants, for example, when administered in combination with ribonucleotides encoding immunogens or formulated together. Innate immune system stimulator can be a separate molecular entity (e.g., not encoded by polyribonucleotides or incorporated into polyribonucleotides as a sequence), such as STING (e.g., caSTING), TLR3, TLR4, TLR9, TLR7, TLR8, TLR7, RIG-I / DDX58 and MDA-5 / IFIH1 or its constitutively active mutant. Innate immune system stimulator can be encoded by polyribonucleotides (e.g., expressed by polyribonucleotides). Polyribonucleotides can alternatively or further include a ribonucleotide sequence (e.g., a GU-rich motif, an AU-rich motif, a structured region including dsRNA, or an aptamer) that acts as an innate immune system stimulator.

[0041] As used herein, the terms "human antibody," "human immunoglobulin," and "human polyclonal antibody" are used interchangeably and refer to one or more antibodies produced in a non-human animal that are otherwise indistinguishable from antibodies produced in a human vaccinated with the same circular RNA preparation. This is in contrast to "humanized antibodies," which are modified to have human characteristics (such as by generating chimeras) but retain the properties of the host animal in which they were produced. Because the human antibodies prepared according to the methods disclosed herein are composed of fully human IgG, no enzymatic treatment is required to eliminate the risk of allergic reactions and serum sickness associated with heterologous species IgG.

[0042] As used herein, the term "immunogen" refers to any molecule or molecular structure comprising one or more epitopes recognized, targeted or bound by an antibody or T cell receptor. In particular, an immunogen induces an immune response in a subject (e.g., immunogenic as defined herein). An immunogen is capable of inducing an immune response in a subject, wherein the immune response refers to a series of molecules, cells and biological events induced when the immunogen encounters the immune system. The immune response can be a humoral and / or cellular immune response. These can include the production of antibodies and the amplification of B cells and T cells. In order to determine whether an immune response has occurred and track its progress, the appearance of immune responses of immune subjects to a specific immunogen can be monitored. The immune response to most immunogens induces the production of both specific antibodies and specific effector T cells. In some embodiments, the immunogen is exogenous to the host. In some embodiments, the immunogen is not exogenous to the host. The immunogen can include all or part of a polypeptide, polysaccharide, polynucleotide or lipid. The immunogen can also be a mixed polypeptide, polysaccharide, polynucleotide and / or lipid. For example, the immunogen can be a polypeptide modified by translation. "Polypeptide immunogen" refers to an immunogen comprising a polypeptide. The polypeptide immunogen may also include one or more post-translational modifications, and / or may form a complex with one or more other molecules, and / or may assume a tertiary or quaternary structure, each of which may determine or influence the immunogenicity of the polypeptide.

[0043] As used herein, the term "immunogenicity" is the potential to induce a response to a substance that exceeds a predetermined threshold in a specific immune response assay. The assay can be, for example, the expression of certain inflammatory markers, the production of antibodies, or an assay of immunogenicity as described herein. In some embodiments, an immune response can be induced when the immune system of an organism or a certain type of immune cell is exposed to an immunogen.

[0044] Total antibody assay, confirmation test, titration and isotype analysis of antibodies and neutralizing antibody assessment can be used to evaluate the antibodies in the subject's plasma or serum, thereby evaluating the immunogenic response. The total antibody assay measures all antibodies generated as part of the immune response in the serum or plasma of the subject to which the immunogen has been applied. The most commonly used test for detecting antibodies is ELISA (enzyme-linked immunosorbent assay), which detects antibodies bound to the target antibody in the test serum, including IgM, IgD, IgG, IgA and IgE. The immunogenic response can be further assessed by the confirmation assay. After the total antibody assessment, the confirmation assay can be used to confirm the result of the total antibody assay. Competitive assays can be used to confirm that antibodies specifically bind to the target, and the positive findings in the screening assay are not the result of non-specific interactions between the test serum or the detection reagent and other substances in the assay.

[0045] Immunogenic responses can be assessed by isotyping and titration. Isotyping can be used to assess only the isotype of the relevant antibody. For example, the expected isotypes may be IgM and IgG, which can be specifically detected and quantified by isotyping and titration and then compared to the total antibodies present.

[0046] Immunogenic response can be assessed by neutralizing antibody assay (nAb). Neutralizing antibody assay (nAb) can be used to determine whether the antibody produced in response to an immunogen neutralizes the immunogen, thereby inhibiting the immunogen from acting on the target and causing abnormal pharmacokinetic behavior. The nAb assay is typically a cell-based assay in which the target cells are incubated with the antibody. A variety of cell-based nAb assays can be used, including but not limited to cell proliferation, viability, antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), inhibition of cytopathic effect (CPE), apoptosis, ligand-stimulated cell signaling, enzyme activity, reporter gene assay, protein secretion, metabolic activity, stress, and mitochondrial function. Detection readings include absorbance, fluorescence, luminescence, chemiluminescence, or flow cytometry readings. Ligand binding assays can also be used to measure the binding affinity of immunogens and antibodies in vitro to evaluate neutralization efficacy.

[0047] In addition, the induction of cellular immune response can be assessed by measuring T cell activation in a subject using cell markers on T cells obtained from a subject. Blood samples, lymph node biopsy samples or tissue samples can be collected from a subject, and one or more (e.g., 2, 3, 4 or more) activation markers from the T cells of the sample are evaluated: CD25, CD71, CD26, CD27, CD28, CD30, CD154, CD40L, CD134, CD69, CD62L or CD44. T cell activation can also be assessed using the same method in an in vivo animal model. It is also possible to measure this to assess T cell activation by adding immunogens to in vitro T cells (e.g., T cells obtained from a subject, an animal model, a reservoir or a commercial source) and measuring the above-mentioned markers. Similar methods can be used to assess the effects on activation of other immune cells such as eosinophils (markers: CD35, CD11b, CD66, CD69, and CD81), dendritic cells (markers: IL-8, MHC class II, CD40, CD80, CD83, and CD86), basophils (CD63, CD13, CD4, and CD203c), and neutrophils (CD11b, CD35, CD66b, and CD63). These markers can be assessed using flow cytometry, immunohistochemistry, in situ hybridization, and other assays that allow for the measurement of cell markers. Comparison of results before and after administration of the immunogen can be used to determine its effects.

[0048] As used herein, the term "impurity" is an unwanted substance present in a composition, such as a pharmaceutical composition as described herein. In certain embodiments, impurities are process-related impurities. In certain embodiments, impurities are substances related to products in the final composition except the desired product, such as active pharmaceutical ingredients as described herein (e.g., cyclic or linear polyribonucleotides). As used herein, the term "process-related impurities" is an unwanted substance used, present or generated in the manufacture of a composition, preparation or product, except linear polyribonucleotides as described herein, in the final composition, preparation or product. In certain embodiments, process-related impurities are enzymes used in the synthesis or cyclization of polyribonucleotides. As used herein, the term "product-related substances" are substances or by-products produced during the synthesis of a composition, preparation or product or any of its intermediates. In certain embodiments, the product-related substance is a deoxyribonucleotide fragment. In certain embodiments, the product-related substance is a deoxyribonucleotide monomer. In certain embodiments, the material relevant to the product is one or more of the following: a derivative or a fragment of a polyribonucleotide as described herein, for example a fragment of 10, 9, 8, 7, 6, 5 or 4 ribonucleic acids, monoribonucleic acids, diribonucleic acids or triribonucleic acids.

[0049] As used herein, the term "induce an immune response" refers to initiating, amplifying or maintaining an immune response in a subject. Inducing an immune response may refer to an adaptive immune response or an innate immune response. Induction of an immune response may be measured as discussed above.

[0050] As used herein, the terms "linear RNA", "linear polyribonucleotide" and "linear polyribonucleotide molecule" are used interchangeably and refer to a monoribonucleotide molecule or polyribonucleotide molecule having a 5' end and a 3' end. One or both of the 5' end and the 3' end can be a free end or can be connected to another part. In some embodiments, the linear RNA has a 5' end or a 3' end that is modified or protected from degradation (e.g., protected by a 5' end protecting agent or a 3' end protecting agent). In some embodiments, the linear RNA has a non-covalently linked 5' or 3' end. Linear RNA can be used as a starting material for cyclization by, for example, splint connection or chemical, enzymatic, ribozyme or splicing catalyzed cyclization methods.

[0051] As used herein, term " linear counterpart " is to have identical or similar nucleotide sequence (for example, 100%, 95%, 90%, 85%, 80%, 75% or any percentage sequence similarity therebetween) with cyclic polyribonucleotide and have polyribonucleotide molecule (and fragment thereof) (that is, the uncyclized form (and fragment thereof) of cyclic polyribonucleotide).In certain embodiments, linear counterpart (for example, form before cyclization) is to have identical or similar nucleotide sequence (for example, 100%, 95%, 90%, 85%, 80%, 75% or any percentage sequence similarity therebetween) with cyclic polyribonucleotide and have identical or similar nucleic acid modification, and have polyribonucleotide molecule (and fragment thereof) (that is, the uncyclized form (and fragment thereof) of cyclic polyribonucleotide) with two free ends. In some embodiments, the linear counterpart is a polyribonucleotide molecule (and its fragment) having the same or similar nucleotide sequence (e.g., 100%, 95%, 90%, 85%, 80%, 75% or any percentage sequence similarity therebetween) as the cyclic polyribonucleotide and having different nucleic acid modifications or not having nucleic acid modifications, and having two free ends (i.e., the uncyclized form (and its fragment) of the cyclic polyribonucleotide). In some embodiments, the fragment of the polyribonucleotide molecule as the linear counterpart is any part of the linear counterpart polyribonucleotide molecule shorter than the linear counterpart polyribonucleotide molecule. In some embodiments, the linear counterpart further comprises a 5' cap. In some embodiments, the linear counterpart further comprises a polyadenosine tail. In some embodiments, the linear counterpart further comprises a 3'UTR. In some embodiments, the linear counterpart further comprises a 5'UTR.

[0052] As used herein, the term "modified ribonucleotide" is a nucleotide having at least one modification to the sugar, the nucleobase, or the internucleoside linkage.

[0053] As used herein, the term "multimerization domain" refers to a polypeptide domain that self-assembles to form a multimer (e.g., a dimer, trimer, tetramer, or oligomer). In a particular embodiment, the multimerization domain can be fused to a polypeptide (e.g., a polypeptide immunogen). In such a case, fusion with the multimerization domain results in the formation of a multimeric immunogen complex with more than one immunogen when expressing a polypeptide including an immunogen covalently attached to the multimerization domain.

[0054] As used herein, the term "naked", "naked delivery" and its homologues mean that the preparation is delivered to the cell without the aid of a carrier and is not covalently modified to the part that helps to be delivered to the cell. The naked delivery preparation does not contain any transfection reagent, cationic carrier, carbohydrate carrier, nanoparticle carrier or protein carrier. For example, the naked delivery preparation of cyclic polyribonucleotides is a preparation comprising cyclic polyribonucleotides without covalent modification and without a carrier. The naked delivery preparation can include a non-carrier pharmaceutical excipient or a diluent.

[0055] As used herein, the term "naked delivery" means that the formulation is delivered to the cell without the aid of a carrier and without covalently modifying the part that contributes to being delivered to the cell. The naked delivery formulation does not contain any transfection reagent, cationic carrier, carbohydrate carrier, nanoparticle carrier or protein carrier. For example, the naked delivery formulation of cyclic polyribonucleotides is a formulation that includes cyclic polyribonucleotides without covalent modification and does not contain a carrier.

[0056] As used herein, the terms "nicked RNA" and "nicked linear polyribonucleotide" and "nicked linear polyribonucleotide molecule" can be used interchangeably and mean the polyribonucleotide molecule with 5' end and 3' end produced due to circular RNA nicking or degradation.

[0057] As used herein, the term "non-circular RNA" refers to total nicked RNA and linear RNA.

[0058] Term " pharmaceutical composition " is intended to also disclose that the cyclic polyribonucleotide included in the pharmaceutical composition can be used for treating human or animal body by therapy.Therefore, this means being equal to " cyclic polyribonucleotide for use in therapy ".

[0059] As used herein, the term "polynucleotide" means a molecule comprising one or more nucleic acid subunits or nucleotides, and can be used interchangeably with "nucleic acid" or "oligonucleotide". Polynucleotides may include one or more nucleotides selected from adenosine (A), cytosine (C), guanine (G), thymine (T) and uracil (U) or variants thereof. Nucleotides may include nucleosides and at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more phosphate (PO3) groups. Nucleotides may include a nucleoside, a pentose (ribose or deoxyribose) and one or more phosphate groups. Ribonucleotides are nucleotides in which the sugar is ribose. Polyribonucleotides or ribonucleic acids or RNA may refer to macromolecules comprising a plurality of ribonucleotides polymerized via phosphodiester bonds. Deoxyribonucleotides are nucleotides in which the sugar is deoxyribose.

[0060] "Polydeoxyribonucleotide", "deoxyribonucleic acid" and "DNA" mean a macromolecule comprising a plurality of deoxyribonucleotides polymerized via phosphodiester bonds. A nucleotide may be a nucleoside monophosphate or a nucleoside polyphosphate. A nucleotide means a deoxyribonucleoside polyphosphate comprising a detectable label (such as a luminescent label) or a marker (e.g., a fluorophore), such as, for example, a deoxyribonucleoside triphosphate (dNTP), which may be selected from deoxyadenosine triphosphate (dATP), deoxycytidine triphosphate (dCTP), deoxyguanosine triphosphate (dGTP), uridine triphosphate (dUTP) and deoxythymidine triphosphate (dTTP) dNTP. A nucleotide may include any subunit that may be incorporated into a growing nucleic acid chain. Such subunits may be A, C, G, T or U, or any other subunit that is specific for one or more complementary A, C, G, T or U or is complementary to a purine (i.e., A or G or a variant thereof) or a pyrimidine (i.e., C, T or U or a variant thereof). In some instances, the polynucleotide is deoxyribonucleic acid (DNA), ribonucleic acid (RNA) or its derivatives or variants. In some cases, just to name a few, the polynucleotide is short interfering RNA (siRNA), microRNA (miRNA), plasmid DNA (pDNA), short hairpin RNA (shRNA), small nuclear RNA (snRNA), messenger RNA (mRNA), precursor mRNA (pre-mRNA), antisense RNA (asRNA), and encompasses nucleotide sequences and any structural embodiments thereof, such as single-stranded, double-stranded, triple-stranded, spiral, hairpin, etc. In some cases, the polynucleotide molecule is circular. The polynucleotide can have various lengths. Nucleic acid molecules can have a length of at least about 10 bases, 20 bases, 30 bases, 40 bases, 50 bases, 100 bases, 200 bases, 300 bases, 400 bases, 500 bases, 1 kilobase (kb), 2kb, 3kb, 4kb, 5kb, 10kb, 50kb or more. Polynucleotides can be isolated from cells or tissues. As embodied herein, polynucleotide sequences can include isolated and purified DNA / RNA molecules, synthetic DNA / RNA molecules, and synthetic DNA / RNA analogs.

[0061] A polynucleotide, such as a polyribonucleotide or a polydeoxyribonucleotide, can include one or more nucleotide variants, including non-standard nucleotides, non-natural nucleotides, nucleotide analogs, and / or modified nucleotides. Examples of modified nucleotides include, but are not limited to, diaminopurine, 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxymethyl)uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, β-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyluracil, 5-(3-amino-3-N-2-carboxypropyl) uracil, 3-(3-amino-3-carboxypropyl) uridine, 2,6-diaminopurine, etc. In some cases, the nucleotides may include modifications in the phosphate portion thereof, including modifications to the triphosphate portion. Non-limiting examples of such modifications include longer phosphate chains (e.g., phosphate chains with 4, 5, 6, 7, 8, 9, 10 or more phosphate moieties) and modifications with thiol moieties (e.g., α-thiotriphosphates and β-thiotriphosphates). Nucleic acid molecules may also be modified at the base moiety (e.g., at one or more atoms that are typically available for hydrogen bonding with complementary nucleotides and / or at one or more atoms that are typically unable to hydrogen bond with complementary nucleotides), the sugar moiety, or the phosphate backbone. Nucleic acid molecules may also contain amine-modified groups, such as aminoallyl 1-dUTP (aa-dUTP) and aminohexyl acrylamide-dCTP (aha-dCTP), to allow covalent attachment of amine-reactive moieties such as N-hydroxysuccinimide ester (NHS).Substitution of standard DNA base pairs or RNA base pairs in the oligonucleotides of the present disclosure may provide higher density (in bits / m3), greater safety (against accidental or purposeful synthesis of natural toxins), easier discrimination of photo-programmed polymerases, or lower secondary structure. Such alternative base pairs compatible with natural and mutant polymerases for de novo and / or amplification synthesis are described in Betz K, Malyshev DA, Lavergne T, Welte W, Diederichs K, Dwyer TJ, Ordoukhanian P, Romesberg FE, Marx A. Nat. Chem. Biol. 2012 Jul; 8(7): 612-4, which is incorporated herein by reference for all purposes.

[0062] As used herein, "polypeptide" means a polymer of amino acid residues (natural or non-natural) most often linked together by peptide bonds. As used herein, the term refers to proteins, polypeptides and peptides of any size, structure or function. Polypeptides can include gene products, naturally occurring polypeptides, synthetic polypeptides, homologs, orthologs, paralogs, fragments of the foregoing substances and other equivalents, variants and analogs. Polypeptides can be unimolecular or can be multimolecular complexes, such as dimers, trimers or tetramers. They can also contain single-chain or multi-chain polypeptides, such as antibodies or insulin, and can be associated or linked. The most common disulfide bonds are present in multi-chain polypeptides. The term polypeptide can also be applied to amino acid polymers in which one or more amino acid residues are artificial chemical analogs of the corresponding naturally occurring amino acids.

[0063] As used herein, the term "prevent" means reducing the likelihood of developing a disease, disorder, or condition, or alternatively, reducing the severity or frequency of symptoms in a subsequently developed disease or disorder. Therapeutic agents can be administered to subjects at an increased risk of developing a disease or disorder relative to the general population in order to prevent the development of a disease or disorder or to reduce the severity of a disease or disorder. Therapeutic agents can be administered as a prophylactic, for example, before any symptoms or manifestations of a disease or disorder develop.

[0064] As used interchangeably herein, the terms "poly A" and "poly A sequence" refer to a non-translated continuous region of a nucleic acid molecule that is at least 5 nucleotides long and consists of adenosine residues. In some embodiments, the length of the poly A sequence is at least 10, at least 15, at least 20, at least 30, at least 40, or at least 50 nucleotides. In some embodiments, the poly A sequence is located 3' (e.g., downstream) of an open reading frame (e.g., an open reading frame encoding a polypeptide), and the poly A sequence is located 3' of a termination element (e.g., a stop codon) such that the poly A is not translated. In some embodiments, the poly A sequence is located 3' of the termination element and is a 3' non-translated region.

[0065] As used herein, the term "regulatory element" is a moiety, such as a nucleic acid sequence, that modifies the expression of an expressed sequence within a circular polyribonucleotide.

[0066] As used herein, the term "replication element" is a sequence and / or motif that can be used to replicate or initiate transcription of a circular polyribonucleotide.

[0067] As used herein, the term "RNA equivalent" refers to an RNA sequence that is the RNA equivalent of a DNA sequence. Therefore, the RNA equivalent of a DNA sequence refers to a DNA sequence in which each thymidine (T) residue is replaced by a uridine (U) residue. For example, the disclosure provides a DNA sequence of a ribozyme identified by a bioinformatics method. The disclosure specifically contemplates that any of these DNA sequences can be converted into a corresponding RNA sequence and included in the RNA molecules described herein.

[0068] As used herein, the term "sequence identity" is determined by comparing two peptides or two nucleotide sequences using a global or local alignment algorithm. When a sequence (for example, when the default parameters are used by the program GAP or BESTFIT to perform the best comparison) has at least a certain minimum percentage of sequence identity, then they can be referred to as "substantially identical" or "substantially similar". GAP uses the Needleman and Wunsch global alignment algorithm to compare the entire length of the two sequences, thereby maximizing the number of matches and minimizing the number of gaps. Typically, using the GAP default parameters, gaps generate penalty points = 50 (nucleotides) / 8 (proteins), and gap extension penalty points = 3 (nucleotides) / 2 (proteins). For nucleotides, the default scoring matrix used is the nwsgapdna.cmp scoring matrix, and for proteins, the default scoring matrix is ​​Blosum62 (Henikoff & Henikoff, 1992, PNAS [Proceedings of the National Academy of Sciences of the United States] 89, 915-919). Sequence alignments and percentage sequence identity scores can be determined using computer programs, such as the GCG Wisconsin software package version 10.3 or EmbossWin version 2.10.0 (using the program "needle") available from Accelrys Inc., 9685 Scranton Road, San Diego, CA, USA 92121-3752 (Accelrys Inc., 9685 Scranton Road, San Diego, CA). Alternatively, or in addition, percent identity can be determined by searching a database using algorithms such as FASTA, BLAST, etc. Sequence identity refers to sequence identity over the entire length of the sequence.

[0069] A "signal sequence" refers to a polypeptide sequence, for example, between 10 and 45 amino acids in length, which is present at the N-terminus of the polypeptide sequence of a nascent protein and targets the polypeptide sequence to the secretory pathway.

[0070] As used herein, the terms "treat" and "treating" refer to the therapeutic treatment of a disease or disorder (e.g., an infectious disease, cancer, toxicity, or allergic reaction) of a subject. The effect of treatment can include reversing, alleviating, reducing the severity of the disease, curing the disease, inhibiting the progression of the disease, reducing the likelihood of recurrence of the disease, or one or more symptoms or manifestations of the disease or disorder, stabilizing (i.e., not worsening) the state of the disease or disorder, and / or preventing the spread of the disease or disorder, as compared to the state and / or condition of the disease or disorder without therapeutic treatment.

[0071] As used herein, the term "termination element" is a moiety, such as a nucleic acid sequence, that terminates translation of an expressed sequence in a circular polyribonucleotide.

[0072] As used herein, the term "total ribonucleotide molecules" means the total amount of any ribonucleotide molecules measured by the gross mass of ribonucleotide molecules, including linear polyribonucleotide molecules, cyclic polyribonucleotide molecules, monomeric ribonucleotides, other polyribonucleotide molecules, fragments thereof, and modified variants thereof.

[0073] As used herein, the term "translation efficiency" is the rate or amount of protein or peptide produced from ribonucleotide transcripts. In some embodiments, translation efficiency can be expressed as the amount of protein or peptide produced from a given amount of transcripts encoding a protein or peptide, such as within a given time period, such as in a given translation system, such as an in vitro translation system (such as rabbit reticulocyte lysate) or an in vivo translation system (such as eukaryotic cells or prokaryotic cells).

[0074] As used herein, the term "translation initiation sequence" is a nucleic acid sequence in a circular polyribonucleotide that initiates translation of an expressed sequence.

[0075] As used herein, "variant" refers to a polypeptide comprising at least one change, such as substitution, insertion, deletion and / or fusion, at one or more residue positions compared to a parent or wild-type polypeptide. A variant may comprise 1 to 10, 10 to 20, 20 to 50, 50 to 100 or more changes. BRIEF DESCRIPTION OF THE DRAWINGS

[0076] Figure 1 Exemplary cyclic polyribonucleotides comprising sequences encoding coronavirus immunogens (e.g., spike proteins, receptor binding domain (RBD) proteins of spike proteins) are shown.

[0077] Figure 2 Exemplary polyribonucleotide constructs encoding a coronavirus immunogen and one or more multimerization domains are shown.

[0078] Figure 3 is a schematic diagram of an exemplary circular RNA comprising two expressed sequences, each expressed sequence is operably linked to an IRES, and wherein at least one of the expressed sequences is a coronavirus immunogen.

[0079] Figure 4 is a schematic diagram of an exemplary circular RNA comprising two expressed sequences separated by a cleavage domain (e.g., 2A, furin site, or furin-2A), wherein at least one of the expressed sequences is a coronavirus immunogen, and all of the expressed sequences are operably linked to an IRES.

[0080] Figure 5A schematic diagram of multiple circular RNAs is shown, wherein the first circular RNA includes an ORF encoding a coronavirus immunogen, and the second circular RNA includes an ORF encoding a second immunogen or a polypeptide adjuvant.

[0081] Fig. 6A Multiple immunogen expression of circular polyribonucleotides is shown. RBD immunogen expression was detected from circular RNA encoding SARS-CoV-2 RBD immunogen and GLuc.

[0082] Figure 6B Multiple immunogen expression from circular polyribonucleotides is shown. GLuc activity was detected from circular RNA encoding SARS-CoV-2 RBD immunogen and GLuc.

[0083] Fig. 7A The immunogenicity of multiple immunogens derived from circular RNA in a mouse model was demonstrated. Mice were inoculated with a first circular RNA encoding the SARS-CoV-2 RBD immunogen and a second circular RNA encoding GLuc. Anti-RBD antibodies were obtained 17 days after injection.

[0084] Figure 7B The immunogenicity of multiple immunogens from circular RNA in a mouse model was demonstrated. Mice were inoculated with a first circular RNA encoding the SARS-CoV-2 RBD immunogen and a second circular RNA encoding GLuc. GLuc activity was detected 2 days after injection.

[0085] Fig. 8A The immunogenicity of multiple immunogens derived from circular RNA in a mouse model was demonstrated. Mice were inoculated with a first circular RNA encoding the SARS-CoV-2 RBD immunogen and a second circular RNA encoding the influenza virus hemagglutinin (HA) immunogen. Anti-RBD antibodies were obtained 17 days after injection.

[0086] Figure 8B The immunogenicity of multiple immunogens from circular RNA in a mouse model was demonstrated. Mice were inoculated with a first circular RNA encoding the SARS-CoV-2 RBD immunogen and a second circular RNA encoding the influenza virus hemagglutinin (HA) immunogen. Anti-HA antibodies were obtained 17 days after injection.

[0087] Fig.9A The immunogenicity of multiple immunogens from circular RNA in a mouse model was demonstrated. Mice were inoculated with a first circular RNA encoding the SARS-CoV-2 spike immunogen and a second circular RNA encoding the influenza virus hemagglutinin (HA) immunogen. Anti-RBD (spike domain) antibodies were obtained 17 days after injection.

[0088] Fig. 9BThe immunogenicity of multiple immunogens derived from circular RNA in a mouse model was demonstrated. Mice were inoculated with a first circular RNA encoding the SARS-CoV-2 spike immunogen and a second circular RNA encoding the influenza virus hemagglutinin (HA) immunogen. Anti-HA antibodies were obtained 17 days after injection.

[0089] Fig.10 Anti-HA antibody responses in mice administered with circular RNA encoding multiple immunogens were shown. Circular RNA encoding the following was administered to mice: SARS-CoV-2 RBD immunogen, SARS-CoV-2 spike immunogen, influenza HA immunogen, SARS-CoV-2 RBD immunogen and influenza HA immunogen, SARS-CoV-2 RBD immunogen and GLuc protein, or SARS-CoV-2 RBD immunogen and SARS-CoV-2 spike immunogen. Anti-influenza HA antibodies were measured using a hemagglutination inhibition assay (HAI). Fig.10 It is shown that HAI titers appeared in samples administered with circular RNA preparations encoding influenza HA immunogens when administered alone or in combination with SARS-CoV-2 immunogens (e.g., RBD or spike).

[0090] Fig.11 IL-12 expression by circular RNA in mammalian cells measured using an IL-12-specific ELISA is shown. A circular RNA encoding the SARS-CoV-2 RBD immunogen was included as a negative control.

[0091] Fig. 12A It is shown that in a mouse model, IL-12 expression was detected in serum 2 days after injection of a circular RNA formulation comprising a first circular RNA encoding IL-12 and a second circular RNA encoding a SARS-CoV-2 RBD immunogen. Formulations including injection of PBS or circular RNA encoding only the SARS-CoV-2 RBD immunogen served as controls.

[0092] Fig. 12B It is shown that in a mouse model, an increase in serum IFN-γ (directly downstream of IL12 signaling) was detected in serum 2 days after injection of a circular RNA formulation comprising a first circular RNA encoding IL-12 and a second circular RNA encoding a SARS-CoV-2 RBD immunogen. Formulations that included injection of PBS or circular RNA encoding only the SARS-CoV-2 RBD immunogen served as controls.

[0093] Fig.13AIt is shown that the administration of a circular RNA preparation including a first circular RNA encoding IL-12 and a second circular RNA encoding a SARS-CoV-2RBD immunogen increases the number of SARS-CoV-2RBD-specific CD4 T cells. The administration of PBS or a preparation including only a circular RNA encoding a SARS-CoV-2RBD immunogen was used as a control. The asterisk indicates the statistical significance determined by the Tukey post-hoc test protected by a two-way RMANOVA.

[0094] Fig. 13B It is shown that administration of a circular RNA formulation comprising a first circular RNA encoding IL-12 and a second circular RNA encoding a SARS-CoV-2 RBD immunogen did not produce a change in the number of RBD-specific CD8 T cells. Formulations including administration of PBS or circular RNA encoding only the SARS-CoV-2 RBD immunogen were used as controls.

[0095] Fig. 13C It is shown that the administration of a circular RNA preparation including a first circular RNA encoding IL-12 and a second circular RNA encoding a SARS-CoV-2 RBD immunogen increases the IFN-γ production of CD4 T cells. The administration of PBS or a preparation including only a circular RNA encoding a SARS-CoV-2 RBD immunogen was used as a control. The asterisk indicates statistical significance determined by an unpaired t-test.

[0096] Fig.13D It is shown that the administration of a circular RNA formulation comprising a first circular RNA encoding IL-12 and a second circular RNA encoding a SARS-CoV-2 RBD immunogen increases the IFN-γ production of CD8 T cells. The administration of PBS or a formulation comprising only a circular RNA encoding a SARS-CoV-2 RBD immunogen was used as a control. Asterisks indicate statistical significance determined by an unpaired t-test.

[0097] Fig.14 Shown is the expression of SARS-CoV-2 spike immunogen in cynomolgus monkey serum following administration of a 100 μg dose of lipid nanoparticle (LNP) formulated circular RNA via intramuscular injection on day 0 (prime) and day 28 (boost).

[0098] Fig.15 Shown is the expression of SARS-CoV-2 RBD immunogen fused to the T4 foldon multimerization domain in cynomolgus monkey serum following administration of a 100 μg dose of LNP-formulated circRNA or a 1000 μg dose of adjuvanted circRNA via intramuscular injection.

[0099] Fig.16AShown is the elicitation of spike-specific binding antibodies in cynomolgus monkeys on day 42 after administration of an initial dose of LNP-formulated or adjuvanted circular RNA encoding the SARS-CoV-2 spike immunogen or the SARS-CoV-2 RBD immunogen fused to the T4 foldon multimerization domain.

[0100] Fig. 16B RBD-specific binding antibodies were elicited in cynomolgus monkeys on day 42 after administration of an initial dose of LNP-formulated or adjuvanted cyclic polyribonucleotides encoding the SARS-CoV-2 spike immunogen or the SARS-CoV-2 RBD immunogen fused to the T4 foldon multimerization domain.

[0101] Fig.17A Shown is the elicitation of SARS-CoV-2 neutralizing antibodies in cynomolgus monkeys on day 42 after administration of an initial 30 μg or 100 μg dose of LNP-formulated circular RNA encoding the SARS-CoV-2 spike immunogen.

[0102] Fig. 17B SARS-CoV-2 neutralizing antibodies were elicited in cynomolgus monkeys on day 42 after administration of an initial dose of LNP-formulated cyclic polyribonucleotides encoding the SARS-CoV-2RBD immunogen fused to the T4 foldon multimerization domain or adjuvanted cyclic polyribonucleotides encoding the SARS-CoV-2RBD immunogen fused to the T4 foldon multimerization domain. DETAILED DESCRIPTION

[0103] The present disclosure provides compositions, pharmaceutical preparations and methods related to polyribonucleotides (e.g., cyclic polyribonucleotides or linear polyribonucleotides) encoding one or more immunogens and / or epitopes from coronaviruses. The present disclosure also provides methods using cyclic polyribonucleotides encoding one or more immunogens and / or epitopes from coronaviruses. Compositions and pharmaceutical preparations of cyclic polyribonucleotides as described herein can induce an immune response in a subject after administration. Compositions and pharmaceutical preparations of cyclic polyribonucleotides as described herein can be used to treat or prevent a disease, disorder or illness (e.g., SARS-CoV, e.g., SARS-CoV-1 or SARS-CoV-2) of a subject.

[0104] Cyclic polyribonucleotide

[0105] As disclosed herein, the cyclic polyribonucleotide comprises one or more expressed sequences encoding one or more immunogens and / or epitopes from coronavirus.This cyclic polyribonucleotide expresses the sequence encoding one or more immunogens and / or epitopes from coronavirus in the subject.In certain embodiments, the cyclic polyribonucleotide comprising one or more coronavirus immunogens and / or epitopes is used to produce an immune response in the subject.In certain embodiments, the cyclic polyribonucleotide comprising one or more coronavirus immunogens and / or epitopes is used to produce a polyclonal antibody as described herein.

[0106] Coronavirus immunogens and epitopes

[0107] Circular polyribonucleotides as described herein include at least one expressed sequence encoding coronavirus immunogen and / or epitope. Circular polyribonucleotides as described herein may include multiple expressed sequences, wherein at least one expressed sequence encoding coronavirus immunogen and / or epitope. Circular polyribonucleotides as described herein may include two or more (two, three, four, five, six or more) expressed sequences, wherein each expressed sequence encoding coronavirus immunogen and / or epitope. Circular polyribonucleotides as described herein may include a first expressed sequence encoding coronavirus immunogen and / or epitope and a second expressed sequence encoding an adjuvant. Circular polyribonucleotides as described herein may include an expressed sequence encoding coronavirus immunogen and / or epitope and a non-coding sequence stimulating the innate immune system.

[0108] In some embodiments, the coronavirus is a pathogenic coronavirus. In some embodiments, the coronavirus is a respiratory pathogen. In some embodiments, the coronavirus is a blood-borne pathogen. In some embodiments, the coronavirus is an intestinal pathogen.

[0109] Non-limiting examples of coronaviruses disclosed herein include severe acute respiratory syndrome-related coronaviruses (SARS-CoV, such as SARS-CoV-1, SARS-CoV-2), Middle East respiratory syndrome coronavirus (MERS-CoV), bat coronaviruses, zoonotic coronaviruses that can infect humans or other animals, newly emerging or newly discovered coronaviruses, and other coronaviruses.

[0110] In some embodiments, the cyclic polyribonucleotide comprises a severe acute respiratory syndrome-related coronavirus (SARS-CoV) immunogen and / or epitope. In some embodiments, the cyclic polyribonucleotide comprises a SARS-CoV-1 immunogen and / or epitope. In some embodiments, the cyclic polyribonucleotide comprises a SARS-CoV-2 immunogen and / or epitope. In some embodiments, the cyclic polyribonucleotide comprises a Middle East respiratory syndrome coronavirus (MERS-CoV) immunogen and / or epitope. In some embodiments, the cyclic polyribonucleotide comprises a zoonotic coronavirus immunogen and / or epitope that can infect humans or other animals. In some embodiments, the cyclic polyribonucleotide comprises an immunogen and / or epitope from an emerging coronavirus.

[0111] In some embodiments, the circular polyribonucleotide comprises a Coronaviridae immunogen and / or epitope.

[0112] In certain embodiments, the cyclic polyribonucleotide comprises an immunogen and / or an epitope from the genus or subgenus of alpha coronavirus (Alphacoronavirus), beta coronavirus (Betacoronavirus), gamma coronavirus (Gammacoronavirus), delta coronavirus (Deltacoronavirus), Merbecovirus (Merbecovirus) or Sarbecovirus (Sarbecovirus). In certain embodiments, the cyclic polyribonucleotide comprises a beta coronavirus immunogen and / or an epitope. In certain embodiments, the cyclic polyribonucleotide comprises a Sarbecovirus immunogen and / or an epitope. In certain embodiments, the cyclic polyribonucleotide comprises a Merbecovirus immunogen and / or an epitope.

[0113] In some embodiments, the cyclic polyribonucleotide comprises an immunogen and / or epitope from the genus or subgenus of Omicron Coronavirus variant (B.1.1.529). In some embodiments, the Omicron coronavirus variant can be a sublineage of BA.2, BA.2.75, BA.4.1, BA.4.1.8, BA.4.6.1, BA.4.6.4, BA.5, BA.5.1, BA.5.1.12, BA.5.1.25, BA.5.10.1, BA.5.2, BA.5.2.1, BA.5.2.6, BA.5.3, BA.5.3.1, BA.5.3.5, BA.5.5., BA5.6, BA.5.6.1, BA.5.7, BE.1.1, BF.10, BF.16, BF.31, BF.31.1, BF.7, BQ.1, BQ.1.1, BQ.1.8, XBB or XBB.1.

[0114] In some embodiments, the cyclic polyribonucleotide comprises a sequence of an immunogen from a coronavirus that is a biosafety level 2 (BSL-2) pathogen. In some embodiments, the cyclic polyribonucleotide comprises a sequence from a coronavirus that is a biosafety level 3 (BSL-3) pathogen. In some embodiments, the coronavirus is a biosafety level 4 (BSL-4) pathogen. In some embodiments, no approved drug (e.g., antiviral or antibiotic drug) can be used to treat coronavirus infection, and the immunogen expressed by the cyclic polyribonucleotide is derived from the coronavirus. In some embodiments, no approved vaccine can be used to prevent or reduce the risk of coronavirus infection, and the immunogen expressed by the cyclic polyribonucleotide is derived from the coronavirus.

[0115] The immunogen and / or epitope can be from a coronavirus surface protein, a coronavirus membrane protein, a coronavirus envelope protein, a coronavirus capsid protein, a coronavirus nucleocapsid protein, a coronavirus spike protein, a coronavirus receptor binding domain (RBD) of the spike protein, a coronavirus entry protein, a coronavirus membrane fusion protein, a coronavirus structural protein, a coronavirus non-structural protein, a coronavirus regulatory protein, a coronavirus accessory protein, a secreted coronavirus protein, a coronavirus polymerase protein, a coronavirus RNA polymerase, a coronavirus protease, a coronavirus glycoprotein, a coronavirus fusionogen, a coronavirus helical capsid protein, a coronavirus icosahedral capsid protein, a coronavirus matrix protein, a coronavirus replicase, a coronavirus transcription factor or a coronavirus enzyme.

[0116] Immunogen and / or epitope from any number of coronaviruses are expressed by cyclic polyribonucleotides. In some cases, immunogen and / or epitope are associated with or expressed by a coronavirus disclosed herein. In certain embodiments, immunogen and / or epitope are associated with or expressed by two or more coronaviruses disclosed herein.

[0117] In some cases, two or more coronaviruses are phenotypically related. For example, the compositions and methods of the present disclosure can utilize immunogens and / or epitopes from: two or more coronaviruses as respiratory pathogens, two or more coronaviruses associated with severe disease, two or more coronaviruses associated with adverse outcomes in immunocompromised subjects (e.g., subjects to be immunized), two or more coronaviruses associated with acute respiratory distress syndrome (ARDS), two or more coronaviruses associated with severe acute respiratory syndrome (SARS), two or more coronaviruses associated with Middle East respiratory syndrome (MERS), or a combination thereof.

[0118] Circular polyribonucleotide can comprise or encode for example from at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 15, at least 20, at least 25, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100 or more immunogens and / or epi-positions of coronaviruses. In some embodiments, the circular polyribonucleotide comprises or encodes immunogens and / or epitopes from at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 15, at least 20, at least 25, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100 or more targets other than coronavirus (e.g., viruses other than coronavirus, such as influenza virus).

[0119] In some embodiments, the circular polyribonucleotide comprises or encodes immunogens and / or epitopes from up to 2, up to 3, up to 4, up to 5, up to 6, up to 7, up to 8, up to 9, up to 10, up to 15, up to 20, up to 25, up to 30, up to 40, up to 50, up to 60, up to 70, up to 80, up to 90, up to 100 or less coronaviruses. In some embodiments, the circular polyribonucleotide comprises or encodes immunogens and / or epitopes from up to 2, up to 3, up to 4, up to 5, up to 6, up to 7, up to 8, up to 9, up to 10, up to 15, up to 20, up to 25, up to 30, up to 40, up to 50, up to 60, up to 70, up to 80, up to 90, up to 100 or less targets other than coronavirus (e.g., viruses other than coronavirus, such as influenza virus).

[0120] In certain embodiments, circular polyribonucleotide comprises or encodes immunogen and / or epi-position from about 1,2,3,4,5,6,7,8,9,10,15,20,25,30,40,50,60,70,80,90 or 100 kinds of coronaviruses.In certain embodiments, circular polyribonucleotide comprises or encodes immunogen and / or epi-position from about 1,2,3,4,5,6,7,8,9,10,15,20,25,30,40,50,60,70,80,90 or 100 kinds of targets except coronavirus (for example, virus except coronavirus, such as influenza virus).

[0121] In some embodiments, the immunogen and / or epitope is from a coronavirus, e.g., a severe acute respiratory syndrome-related coronavirus (SARS-CoV, e.g., SARS-CoV-1, SARS-CoV-2), a Middle East respiratory syndrome coronavirus (MERS-CoV), or another coronavirus. In some embodiments, the immunogen and / or epitope of the present disclosure is from a predicted open reading frame from a coronavirus genome.

[0122] New SARS isolates can be identified by the percentage homology of 99%, 98%, 97%, 95%, 92%, 90%, 85% or 80% homology between the polynucleotide sequence of the specific genomic region of the new virus and the polynucleotide sequence of the specific genomic region of the known SARS virus. In addition, new SARS isolates can be identified by the percentage homology of 99%, 98%, 97%, 95%, 92%, 90%, 85% or 80% homology between the polypeptide sequence encoded by the polynucleotide of the specific genomic region of the new SARS virus and the polypeptide sequence encoded by the polynucleotide of the specific genomic region of the known SARS virus. These genomic regions can include regions that are typically shared among many coronaviruses (e.g., gene products or ORFs), as well as group-specific regions (e.g., immunogenic groups), such as, for example, any of the following genomic regions readily identified by a virologist skilled in the art: 5' untranslated region (UTR), leader sequence, ORF1a, ORF1b, nonstructural protein 2 (NS2), hemagglutinin esterase glycoprotein (HE) (also known as E3), spike glycoprotein (S) (also known as E2), ORF3a, ORF3b, nonstructural protein 4 (NS4), envelope (small membrane) protein (E) (also known as sM), membrane glycoprotein (M) (also known as E1), ORF5a, ORF5b, nucleocapsid phosphoprotein (N), ORF6, ORF7a, ORF7b, ORF8, ORF8a, ORF8b, ORF9a, ORF9b, ORF10, intergenic sequences, receptor binding domain (RBD) of the spike protein, 3'UTR, or RNA-dependent RNA polymerase (pol). The SARS virus may have an identifiable genomic region and one or more genomic regions identified above. The SARS virus immunogen includes a protein encoded by any of these genomic regions. The SARS virus immunogen may be a protein or a fragment thereof that is highly conserved with a coronavirus. The SARS virus immunogen may be a protein or a fragment thereof that is specific (compared to known coronaviruses) to the SARS virus.

[0123] In some embodiments, the immunogens and / or epitopes disclosed herein are derived from predicted transcripts from the SARS-CoV genome. In some embodiments, the immunogens and / or epitopes disclosed herein are derived from proteins encoded by open reading frames from the SARS-CoV genome. Non-limiting examples of open reading frames in the SARS-CoV genome may include ORF1a, ORF1b, spike (S), ORF3a, ORF3b, envelope (E), membrane (M), ORF6, ORF7a, ORF7b, ORF8, ORF8a, ORF8b, ORF9a, ORF9b, nucleocapsid (N), and ORF10.

[0124] ORF1a and ORF1b encode 16 nonstructural proteins (nsp), for example, nsp1, nsp2, nsp3, nsp4, nsp5, nsp6, nsp7, nsp8, nsp9, nsp10, nsp11, nsp12, nsp13, nsp14, nsp15 and nsp16. For example, nonstructural proteins contribute to viral replication, viral assembly, immune response regulation or a combination thereof. In some embodiments, the immunogen is a nonstructural protein or an immunogenic sequence encoding a nonstructural protein. In some embodiments, the epitope is from a coronavirus nonstructural protein.

[0125] Spike (S) encodes a spike protein, which in some embodiments facilitates binding to a host cell receptor, fusion of the virus with a host cell membrane, entry of the virus into a host cell, or a combination thereof. The spike protein can be an immunogen. In some embodiments, the epitope of the present disclosure is from the spike protein. In some embodiments, the epitope of the present disclosure comprises a receptor binding domain of the spike protein. In some embodiments, the epitope of the present disclosure comprises an ACE2 binding domain of the spike protein.

[0126] Envelope (E) encodes an envelope protein, which in some embodiments contributes to viral assembly and morphogenesis. The envelope protein can be an immunogen. In some embodiments, the epitope disclosed herein is from a coronavirus envelope protein.

[0127] Membrane (M) encodes a membrane protein, which in some embodiments helps virus assembly. A membrane protein can be an immunogen. In some embodiments, the epitope disclosed herein is from a coronavirus membrane protein.

[0128] Nucleocapsid (N) encodes a nucleocapsid protein, which in some embodiments can form a complex with the genomic RNA and contribute to viral assembly, and / or interact with the M protein. The nucleocapsid protein can be an immunogen. In some embodiments, the epitope disclosed herein is from a coronavirus nucleocapsid protein.

[0129] ORF3a, ORF3b, ORF6, ORF7a, ORF7b, ORF8, ORF8a, ORF8b, ORF9a, ORF9b and ORF10 encode auxiliary proteins. In some embodiments, auxiliary proteins can modulate host cell signaling, modulate host cell immune responses, be incorporated into mature virions as secondary structural proteins, or a combination thereof. The auxiliary protein can be an immunogen. In some embodiments, the epitope disclosed herein is from a coronavirus auxiliary protein.

[0130] The compositions and methods disclosed herein can utilize immunogens and / or epitopes encoded by or derived from one or more open reading frames of the SARS-CoV genome. For example, the immunogens and / or epitopes can be encoded by or derived from: ORF1a, ORF1b, spike (S), ORF3a, ORF3b, envelope (E), membrane (M), ORF6, ORF7a, ORF7b, ORF8, ORF8a, ORF8b, ORF9a, ORF9b, nucleocapsid (N), ORF10, or any combination thereof.

[0131] In some embodiments, the epitope of the present disclosure is from the spike protein. In some embodiments, the epitope of the present disclosure is from the Omicron coronavirus spike protein. The Omicron coronavirus spike protein has the amino acid sequence of SEQ ID NO: 283. In some embodiments, the epitope of the present disclosure comprises the receptor binding domain (RBD) of the spike protein. In some embodiments, the epitope of the present disclosure comprises the ACE2 binding domain of the spike protein. In some embodiments, the epitope of the present disclosure comprises the S1 subunit of the spike protein, the S2 subunit of the spike protein, or a combination thereof. In some embodiments, the epitope of the present disclosure comprises the extracellular domain of the spike protein. In some embodiments, the epitope of the present disclosure comprises Gln498, Thr500, Asn501, or a combination thereof from the coronavirus spike protein. In some embodiments, the epitope of the present disclosure comprises Lys417, Tyr453, or a combination thereof from the coronavirus spike protein. In some embodiments, the epitope of the present disclosure comprises Gln474, Phe486, or a combination thereof from the coronavirus spike protein. In some embodiments, the epitope disclosed herein comprises Gln498, Thr500, Asn501, Lys417, Tyr453, Gln474, Phe486, one or more equivalent amino acids from a spike protein variant or derivative or a combination thereof of a coronavirus spike protein. In some embodiments, the spike protein disclosed herein comprises a D614G mutation, i.e., an amino acid glycine (G) instead of aspartic acid (D) at position 614. In some embodiments, the epitope disclosed herein comprises Gly614 from a spike protein variant or derivative or a combination thereof of a coronavirus spike protein. In some cases, the D614G mutation may result in reduced S1 shedding and increased coronavirus infectivity. In some embodiments, compared to the wild-type spike protein, the spike protein of the present disclosure may include one or more of the following: T19I, L24del, P25del, P26del, A27S, H69del, V70del, V213G, G229D, R346T, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, K444T, L452R, N460K, S477N, T478K, E484A, F486V, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, N969K, Y144del, P251L, and S256L mutations.In some embodiments, compared to the wild-type spike protein, the spike protein of the present disclosure comprises the mutations T19I, L24del, P25del, P26del, A27S, H69del, V70del, V213G, G229D, R346T, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, K444T, L452R, N460K, S477N, T478K, E484A, F486V, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, N969K, Y144del, P251L and S256L. In some embodiments, compared to the wild-type spike protein, the spike protein of the present disclosure may include one or more of the following: T19I, L24del, P25del, P26del, A27S, G142D, K147E, W152R, F157L, I210V, V213G, G257S, G339H, R346T, K356T, S371F, S373P, T376A, D405N, R408S, K417N, N440K, G446S, N4 60K, S477N, T478K, E484A, F486S, F490S, Q498R, N501Y, Y505H, D574V, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, N969K, D1199N, M177T, N185D, N211del, L212I, K444T, N450D, L452R, F486P, F486I, S494P and H1101Y mutations. In some embodiments, compared to the wild-type spike protein, the spike protein of the present disclosure may include mutations T19I, L24del, P25del, P26del, A27S, G142D, K147E, W152R, F157L, I210V, V213G, G257S, G339H, R346T, K356T, S371F, S373P, T376A, D405N, R408S, K417N, N440K, G446S, N460K , S477N, T478K, E484A, F486S, F490S, Q498R, N501Y, Y505H, D574V, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, N969K, D1199N, M177T, N185D, N211del, L212I, K444T, N450D, L452R, F486P, F486I, S494P, and H1101Y.

[0132] In some embodiments, compared to the wild-type spike protein, the spike protein of the present disclosure comprises one or more of the following: T19I, L24del, P25del, P26del, A27S, H69del, V70del, G142D, Y144del, V213G, G339D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, K444T, L452R, N460K, S477N, T478K, E484A, F486V, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H and N969K, and P251H mutations. In some embodiments, compared to the wild-type spike protein, the spike protein of the present disclosure comprises the mutations T19I, L24del, P25del, P26del, A27S, H69del, V70del, G142D, Y144del, V213G, G339D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, K444T, L452R, N460K, S477N, T478K, E484A, F486V, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H and N969K.

[0133] In some embodiments, compared to the wild-type spike protein, the spike protein of the present disclosure may include one or more of the following: T19I, L24del, P25del, P26del, A27S, V83A, G142D, Y144del, H146Q, Q183E, V213E, G252V, G339H, R346T, L368I, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, V445P, G446S, N460K, S477N, T478K, E484A, F486S, F490S, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, N969K, and H146K mutations. In some embodiments, compared to the wild-type spike protein, the spike protein of the present disclosure may include mutations T19I, L24del, P25del, P26del, A27S, V83A, G142D, Y144del, H146Q, Q183E, V213E, G252V, G339H, R346T, L368I, S371F, S373P, S375F, T37 6A, D405N, R408S, K417N, N440K, V445P, G446S, N460K, S477N, T478K, E484A, F486S, F490 S, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, N969K and H146K.

[0134] In some embodiments, the immunogen and / or epitope is encoded by or derived from ORF1a. In some embodiments, the immunogen and / or epitope is encoded by or derived from SARS-CoV ORF1b. In some embodiments, the immunogen and / or epitope is encoded by or derived from SARS-CoV spike. In some embodiments, the immunogen and / or epitope is encoded by or derived from SARS-CoV ORF3a. In some embodiments, the immunogen and / or epitope is encoded by or derived from SARS-CoV ORF3b. In some embodiments, the immunogen and / or epitope is encoded by or derived from SARS-CoV envelope (E). In some embodiments, the immunogen and / or epitope is encoded by or derived from SARS-CoV membrane (M). In some embodiments, the immunogen and / or epitope is encoded by or derived from SARS-CoV ORF6. In some embodiments, the immunogen and / or epitope is encoded by or derived from SARS-CoV ORF7a. In some embodiments, the immunogen and / or epitope is encoded by or derived from SARS-CoV ORF7b. In some embodiments, the immunogen and / or epitope is encoded by or derived from SARS-CoV ORF8. In some embodiments, the immunogen and / or epitope is encoded by or derived from SARS-CoV ORF8a. In some embodiments, the immunogen and / or epitope is encoded by or derived from SARS-CoV ORF9a. In some embodiments, the immunogen and / or epitope is encoded by or derived from SARS-CoV ORF9b. In some embodiments, the immunogen and / or epitope is encoded by or derived from SARS-CoV nucleocapsid (N). In some embodiments, the immunogen and / or epitope is encoded by or derived from SARS-CoV ORF10. In some embodiments, the immunogen and / or epitope is encoded by or derived from SARS-CoV spike (S), envelope (E), membrane (M) and nucleocapsid (N).

[0135] In some embodiments, the immunogen and / or epitope is not encoded by or derived from SARS-CoV ORF1a. In some embodiments, the immunogen and / or epitope is not encoded by or derived from SARS-CoV ORF1b. In some embodiments, the immunogen and / or epitope is not encoded by or derived from SARS-CoV spike. In some embodiments, the immunogen and / or epitope is not encoded by or derived from SARS-CoV ORF3a. In some embodiments, the immunogen and / or epitope is not encoded by or derived from SARS-CoV ORF3b. In some embodiments, the immunogen and / or epitope is not encoded by or derived from SARS-CoV envelope (E). In some embodiments, the immunogen and / or epitope is not encoded by or derived from SARS-CoV membrane (M). In some embodiments, the immunogen and / or epitope is not encoded by or derived from SARS-CoV ORF6. In some embodiments, the immunogen and / or epitope is not encoded by or derived from SARS-CoV ORF7a. In some embodiments, the immunogen and / or epitope is not encoded by or derived from SARS-CoV ORF7b. In some embodiments, the immunogen and / or epitope is not encoded by SARS-CoV ORF8 or is not derived from it. In some embodiments, the immunogen and / or epitope is not encoded by SARS-CoV ORF8a or is not derived from it. In some embodiments, the immunogen and / or epitope is not encoded by SARS-CoV ORF9a or is not derived from it. In some embodiments, the immunogen and / or epitope is not encoded by SARS-CoV ORF9b or is not derived from it. In some embodiments, the immunogen and / or epitope is not encoded by SARS-CoV nucleocapsid (N) or is not derived from it. In some embodiments, the immunogen and / or epitope is not encoded by SARS-CoV ORF10 or is not derived from it. In some embodiments, the immunogen and / or epitope is not encoded by SARS-CoV spike (S), envelope (E), membrane (M) and nucleocapsid (N) or is not derived from it.

[0136] The immunogens and / or epitopes may be encoded by or derived from SARS-CoV2.

[0137] A non-limiting example of a SARS-CoV-2 genome is provided in DB Source Accession No. MN908947.3, which is the complete genome sequence of a SARS-CoV2 isolate, the contents of which are incorporated herein by reference in their entirety. DB Source Accession No. MN908947.3:21563-25384 corresponds to the S protein, the contents of which are incorporated herein by reference in their entirety. A non-limiting example of a SARS-CoV-2 spike protein is provided in GenBank sequence: QHD43416.1, which is the sequence of the spike protein of a severe acute respiratory syndrome coronavirus 2 isolate, the contents of which are incorporated herein by reference in their entirety.

[0138] A non-limiting example of a SARS-CoV-2 genome is provided in the sequence NCBI Reference Sequence Accession No. NC_045512, Version NC_045512.2, which is the complete genome sequence of the SARS-CoV2 isolate Wuhan-Hu-1, the contents of which are incorporated herein by reference in their entirety.

[0139] A non-limiting example of a SARS-CoV-2 genome is provided in the sequence NCBI Reference Sequence Accession No. MW450666, which is the complete genome sequence of a SARS-CoV2 isolate, the contents of which are incorporated herein by reference in their entirety.

[0140] A non-limiting example of a SARS-CoV-2 genome is provided in the sequence NCBI Reference Sequence Accession No. MW487270, which is the complete genome sequence of the SARS-CoV2 lineage B.1.1.7 virus, the contents of which are incorporated herein by reference in their entirety.

[0141] A non-limiting example of a SARS-CoV-2 genome is provided in the sequence GISAID Reference Sequence Accession No. EPI_-SL_10894052-EPI_ISL_10894090, which is the complete genome sequence of severe acute respiratory syndrome coronavirus 2, the contents of which are incorporated herein by reference in their entirety.

[0142] A non-limiting example of a SARS-CoV-2 genome is provided in sequence GISAID Reference Sequence Accession No. EPI_ISL_792683, which is the complete genome sequence of the SARS-CoV2 lineage P.1 virus, the contents of which are incorporated herein by reference in their entirety.

[0143] A non-limiting example of a SARS-CoV-2 genome is provided in sequence GISAID Reference Sequence Accession No. EPI_ISL_678615, which is the complete genome sequence of the SARS-CoV2 lineage B.1.351 virus, the contents of which are incorporated herein by reference in their entirety.

[0144] Non-limiting examples of SARS-CoV-2 genomes are provided in the sequences NCBI Reference Sequence Accession Nos. MW972466-MW974550, which are the complete genome sequences of SARS-CoV2 lineages B.1.427 and B.1.429 viruses, the contents of which are incorporated herein by reference in their entirety.

[0145] A non-limiting example of a SARS-CoV-2 genome is provided in the sequence NCBI Reference Sequence Accession Nos. MZ156756-MZ226428, which is the complete genome sequence of the SARS-CoV2 virus, the contents of which are incorporated herein by reference in their entirety.

[0146] In some embodiments, the SAR-CoV-2 genome is provided in the GISAID database at www.gisaid.org. In some embodiments, the SARS-CoV-2 genome is provided in the International Nucleotide Sequence Database Collaboration (INSDC) at www.insdc.org.

[0147] In some embodiments, the immunogens and / or epitopes disclosed herein are from predicted transcripts of the SARS-CoV-2 genome. In some embodiments, the immunogens and / or epitopes disclosed herein are from proteins encoded by open reading frames from the SARS-CoV-2 genome or derivatives thereof. Non-limiting examples of open reading frames in the SARS-CoV-2 genome include ORF1a, ORF1b, spikes (S), ORF3a, envelope (E), membrane (M), ORF6, ORF7a, ORF7b, ORF8, nucleocapsid (N) and ORF10. In some embodiments, the SARS-Co V-2 genome encodes ORF3b, ORF9a, ORF9b or a combination thereof. In some embodiments, the SARS-CoV-2 genome does not encode ORF3b, ORF9a, ORF9b or any combination thereof.

[0148] Non-limiting examples of amino acid sequences are provided in Table 1. In some embodiments, the immunogen comprises a sequence having at least about 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% sequence identity to a sequence from Table 1.

[0149] Table 1: Examples of amino acid sequences of proteins encoded by the SARS-CoV-2 genome.

[0150]

[0151]

[0152]

[0153] Additional non-limiting examples of proteins encoded by the SARS-CoV-2 genome include those having the following NCBI accession numbers: MT334522, MT334523, MT334524, MT334525, MT334526, MT334527, MT334528, MT334529, MT334530, MT334531, MT334532, MT334533, MT334534, MT334535, MT334536, MT334537, MT334538, MT334539, MT334540, MT334541, MT334542, MT334543. 3. MT334544, MT334545, MT334546, MT334555, MT334547, MT334548, MT334549, MT334550, MT334551, MT334552, MT334553, MT334554, MT334556, MT3345 57. MT334558, MT334559, MT334560, MT334561, MT334562, MT334563, MT334564, MT334565, MT334566, MT334567, MT334568, MT334569, MT334570, MT334 571, MT334572, MT334573, MT326097, MT326106, MT326107, MT326116, MT326117, MT326124, MT326125, MT326126, MT326127, MT326134, MT326135, MT3 26136, MT326137, MT326138, MT326139, MT326140, MT326141, MT326142, MT326143, MT326144, MT326145, MT326146, MT326148, MT326149, MT326150, MT 326152 T326180, MT326181, MT326182, MT326183, MT326188, MT326189, MT326190, MT326191, MT326129, MT326121, MT326120, MT326119, MT326118, MT326111,<h2 style=";text-align:left;direction:ltr">MT326023, MT326025, MT326033, MT326035, MT326036, MT326040, MT326043, MT326045, MT326053, MT326055, MT326056, MT326063, MT326066, MT32607 0, MT326071, MT326072, MT326075, MT326076, MT326078, MT326079, MT326089, MT325563, MT325565, MT325566, MT326155, MT326163, MT326177, MT3261 30, MT326128, MT326110, MT326109, MT326108, MT326101, MT326100, MT326099, MT326098, MT326094, MT326093, MT326092, MT325568, MT325569, MT325 590, MT325640, MT325606, MT325607, MT325608, MT325609, MT325610, MT325611, MT325616, MT325618, MT325619, MT325620, MT325622, MT325623, MT32 5624, MT325599, MT325600, MT325601, MT325602, MT325612, MT325613, MT325615, MT325617, MT325625, MT324062, MT324684, MT325573, MT325574, MT3 25577、MT325579、MT325586、MT325592、MT325593、MT325594、MT325598、MT 325605、MT325626、MT325627、MT325633、MT325634、MT326028、MT326031、MT 326091、MT326090、MT326085、MT326084、MT326083、MT326082、MT326081、M T326080、MT326077、MT326067、MT326057、MT326024、MT326026、MT326027、M T326032、MT326034、MT326037、MT326039、MT326041、MT326042、MT326044、 MT326046、MT326047、MT326049、MT326050、MT326051、MT326052、MT326054、<h2 style=";text-align:left;direction:ltr">MT326059, MT326060, MT326061, MT326062, MT326064, MT326065, MT326068, MT326069, MT326073, MT326074, MT326088, MT327745, MT324679, MT32556 1, MT325571, MT325572, MT325575, MT325583, MT325587, MT325588, MT325589, MT325596, MT325597, MT325603, MT325604, MT325614, MT325621, MT3256 29, MT325630, MT325631, MT325632, MT325635, MT325636, MT325637, MT325638, MT325639, MT326086, MT326096, MT326102, MT326104, MT326105, MT326 112, MT326113, MT326114, MT326115, MT326122, MT328034, MT325564, MT325567, MT326164, MT326165, MT326173, MT326174, MT326184, MT326185, MT32 6186, MT326187, MT325584, MT325585, MT326087, MT326095, MT326103, MT326123, MT326131, MT326132, MT326133, MT328033, MT325562, MT326147, MT3 26153、MT326154、MT326156、MT326157、MT326166、MT326167、MT326175、MT 326176、MT324680、MT325570、MT325576、MT325578、MT325580、MT325581、MT 325582、MT325591、MT325595、MT325628、MT326029、MT326030、MT326038、M T326048、MT326058、MT324681、MT324682、MT324683、MT328032、MT328035、M T322404, MT039874, MT322398, MT322409, MT322421, MT322423, MT322408, MT322413, MT322417, MT322394, MT322407, MT322418, MT322424, MT322411<h2 style=";text-align:left;direction:ltr">MT077125, MT322395, MT322396, MT322397, MT322399, MT322400, MT322401, MT322402, MT322403, MT322405, MT322406, MT322414, MT322416, MT32241 9, MT322420, MT322410, MT322412, MT322415, MT322422, MT320538, MT320891, MT308692, MT308693, MT308695, MT308696, MT308698, MT308699, MT3087 01, MT308703, MT308704, MT308694, MT308697, MT308700, MT308702, MT293547, MT304476, MT304474, MT304475, MT304477, MT304478, MT304479, MT304 481, MT304482, MT304484, MT304485, MT304486, MT304487, MT304488, MT304491, MT304480, MT304483, MT304489, MT304490, MT300186, MT292571, MT29 2576, MT292578, MT293186, MT292570, MT292573, MT293173, MT292575, MT293179, MT293180, MT293184, MT293189, MT293192, MT293193, MT293194, MT2 93201, MT293202, MT292572, MT292577, MT293185, MT293187, MT293188, MT291826, MT291832, MT291833, MT291835, MT291836, MT291831, MT293170, MT 292574, MT293178, MT293181, MT293183, MT293195, MT293196, MT293197, MT293203, MT293204, MT293223, MT293212, MT293214, MT293215, MT293216, M T293219, MT293224, MT293225, MT293206, MT293208, MT293209, MT293221, MT295464, MT293160, MT293166, MT293171, MT293190, MT293161, MT293167<h2 style=";text-align:left;direction:ltr">MT293168, MT293174, MT293175, MT293182, MT293191, MT293158, MT293162, MT293163, MT293164, MT293156, MT293157, MT293159, MT291834, MT29182 9, MT291827, MT291830, MT291828, MT293169, MT293200, MT293210, MT293211, MT293217, MT293218, MT295465, MT293198, MT293205, MT293207, MT2932 13, MT293220, MT293222, MT292581, MT292569, MT293172, MT293177, MT293176, MT293199, MT292580, MT292582, MT293165, MT292579, MT273658, MT281 577, MT281530, MT276597, MT276598, MT276323, MT276328, MT276331, MT276329, MT276330, MT276324, MT276325, MT276327, MT276326, MT263388, MT26 3392, MT262900, MT262902, MT262906, MT262908, MT262912, MT262913, MT262914, MT262993, MT263074, MT263381, MT263391, MT262901, MT262903, MT2 62907、MT262909、MT262911、MT262899、MT262904、MT262915、MT262916、MT 262897、MT262898、MT262905、MT262910、MT263400、MT263382、MT263383、MT 263384、MT263385、MT262896、MT263407、MT263415、MT263406、MT263408、M T263422、MT263469、MT263439、MT263457、MT263459、MT263432、MT263450、M T263458, MT263467, MT263401, MT263411, MT263413, MT263426, MT263421, MT263443, MT263412, MT263416, MT263417, MT263423, MT263431, MT263461<h2 style=";text-align:left;direction:ltr">MT263410, MT263424, MT263425, MT263427, MT263442, MT263402, MT263405, MT263409, MT263418, MT263419, MT263398, MT263399, MT263403, MT26340 4, MT263414, MT263430, MT263390, MT263434, MT263436, MT263446, MT263448, MT263452, MT263453, MT263456, MT263462, MT263463, MT263386, MT2633 87, MT263389, MT263428, MT263429, MT263433, MT263435, MT263437, MT263438, MT263440, MT263447, MT263449, MT263455, MT263444, MT263445, MT263 451, MT263466, MT263420, MT263441, MT263454, MT263464, MT263465, MT263468, MT263460, MT263393, MT263394, MT263395, MT263396, MT263397, MT25 9226, MT259275, MT259276, MT259279, MT259247, MT258377, MT258378, MT258379, MT259231, MT259228, MT259238, MT259248, MT256917, MT259227, MT2 59236, MT256918, MT258380, MT259235, MT259237, MT259239, MT259281, MT259282, MT259283, MT259240, MT259243, MT259249, MT259250, MT259251, MT 259256, MT259258, MT259266, MT259267, MT259274, MT259286, MT259287, MT259241, MT259242, MT258381, MT259257, MT259261, MT259262, MT259263, M T259264, MT259268, MT259269, MT259270, MT259271, MT259272, MT259273, MT259277, MT259278, MT259280, MT258383, MT258382, MT259246, MT256924<h2 style=";text-align:left;direction:ltr">MT259244, MT259245, MT259252, MT259253, MT259254, MT259255, MT259259, MT259284, MT259229, MT259230, MT259265, MT259260, MT259285, LC53441 9, LC534418, MT253710, MT253709, MT253705, MT253708, MT253701, MT253702, MT253703, MT253704, MT253706, MT253707, MT251972, MT251974, MT2519 75, MT251973, MT251976, MT251979, MT253697, MT253699, MT253696, MT253698, MT253700, MT251977, MT251978, MT251980, MT246451, MT246461, MT246 471、MT246472、MT246474、MT246483、MT246450、MT246453、MT246454、MT24 6462、MT246463、MT246464、MT246470、MT246473、MT246480、MT246484、MT24 6449、MT246455、MT246456、MT246478、MT246485、MT246488、MT246452、MT2 46460、MT246465、MT246481、MT246482、MT246490、MT246459、MT246468、MT2 46475、MT246477、MT246479、MT246457、MT246458、MT246466、MT246467、MT 246469、MT246476、MT246486、MT246487、MT246489、MT233526、MT246667、MT 240479、MT232870、MT232871、MT233523、MT232869、MT232872、MT233519、M T233521、MT233522、MT233520、MT226610、MT198653、MT198651、MT198652、M T192773, MT192758, MT192772, MT192765, MT192759, MT188341, MT188340, MT188339, MT186676, MT186681, MT186677, MT186678, MT187977, MT186680MT186682、MT186679、MT184909、MT184911、MT184912、MT184913、MT184910、MT184907、MT184908、CADDYA000000000、MT163718、MT163719、MT163720、MT163714、MT163715、MT163721、MT163717、MT163737、MT163738、MT163712、MT163716、MT159706、MT159716、MT159719、MT159707、MT159717、MT159709、MT159715、MT159718、MT159722、MT159708、MT161607、MT159705、MT159710、MT159711、MT159712、MT159713、MT159714、MT159720、MT159721、MT121215、MT159778、MT066156、LC529905、MT050493、MT012098、MT152900、MT152824、MT135044、MT135042、MT135041、MT135043、MT126808、MT127113、MT127114、MT127116、MT127115、LC528232、LC528233、MT123293、MT123291、MT123290、MT123292、MT118835、MT111896、MT111895、MT106052、MT106053、MT106054、MT093571、MT093631、MT081061、MT081063、MT081066、MT081062、MT081064、MT081065、MT081067、MT081059、MT081060、MT081068、MT072667、MT072668、MT072688、MT066157、MT066176、MT066159、MT066175、MT066158、LC523809、LC523807、LC523808、MT044258、MT044257、MT050416、MT050417、MT042773、MT042774、MT042775、MT042776、MT049951、MT050414、MT050415、MT042777、MT042778、MT039887、MT039888、MT039890、MT039873、LC522350、MT027062, MT027063, MT027064, MT020881, MT019530, MT019531, MT019533, MT020880, MT019532, MT019529, MT020781, LR757995, LR75 7998, LR757996, LR757997, MT007544, MT008022, MT008023, MN996531, MN996530, MN996527, MN996528, MN996529, MN997409, MN988668, MN988669, MN994467, MN994468, MN988713, MN938384, MN975262, MN985325, MN938386, MN938388, MN938385, MN938387, MN938390, MN938389, MN975263, MN975267, MN975268, MN975265, MN975264, MN975266, MN970004, MN970003, MN908947, OL672836.1, each of which is incorporated herein by reference in its entirety.

[0154] In certain embodiments, the cyclic polyribonucleotide comprises a SARS-CoV-2 immunogen described in Table 2. In some embodiments, the immunogen comprises a sequence having at least about 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% sequence identity to a sequence from Table 2.

[0155] Table 2. Description of constructs and SARS-CoV-2 ORFs

[0156]

[0157]

[0158]

[0159]

[0160] In Table 2, "proline substitution" means that the proline at residues 986 and 987 replaces, and "GSAS" at furin cleavage site (residue 682-685) replaces. For "clone optimization", single base substitution is carried out at coordinate 2541 to destroy the BsaI site to assist the Golden Gate cloning construction of plasmid DNA template. For "cyclization optimization": four mononucleotides-at positions 2307, 2790, 159 and 315-are replaced to destroy the site that can potentially bind the splint nucleic acid sequence cyclization element, thereby potentially suppressing effective connection. For the construct (for example, p33, p35, p36, p39, p41, p44 and p45) having removed the II type terminator: two mononucleotides-at positions 1047, 1049, are replaced to destroy the II type terminator site. For the construct (for example, p39 and p41) with GC optimization, GC optimization is carried out to make the GC content be about 50%. All single base pair substitutions were designed to be translationally silent. Additionally, in Table 2, the IRES was either EMCV (SEQ ID NO: 31) or CVB3 (SEQ ID NO: 45).

[0161] In some embodiments, the circular polyribonucleotide includes an open reading frame encoding a SARS-CoV-2 immunogen having an amino acid sequence that is at least about 80% (e.g., about 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to any one of SEQ ID NOs: 63-111 and 283-291. In some embodiments, the cyclic polyribonucleotide comprises an open reading frame encoding a SARS-CoV-2 immunogen having an amino acid sequence that is at least about 90% (e.g., about 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) identical to any one of SEQ ID NOs: 63-111 and 283-291. In some embodiments, the cyclic polyribonucleotide comprises an open reading frame encoding a SARS-CoV-2 immunogen having an amino acid sequence that is at least about 95% (e.g., about 96%, 97%, 98%, 99% or 100%) identical to any one of SEQ ID NOs: 63-111 and 283-291. In some embodiments, the cyclic polyribonucleotide comprises an open reading frame encoding a SARS-CoV-2 immunogen having an amino acid sequence that is at least about 95% (e.g., about 96%, 97%, 98%, 99% or 100%) identical to any one of SEQ ID NOs: 63-111 and 283-291. In some embodiments, the SARS-CoV-2 immunogen is an immunogenic fragment comprising a continuous stretch of at least 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1100, 1200, 1300, 1400, or 1500 amino acids of any one of SEQ ID NOs: 63-111 and 283-291. In some embodiments, the SARS-CoV-2 immunogen is an immunogenic fragment comprising a continuous stretch of at least 50%, 60%, 70%, 80%, 90%, or 95% of the amino acids of any one of SEQ ID NOs: 63-111 and 283-291.

[0162] In certain embodiments, the circular polyribonucleotide comprises an open reading frame having a nucleic acid sequence encoding a SARS-CoV-2 immunogen, wherein the nucleic acid sequence has at least about 80% (e.g., about 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 112-174 and 292-300. In some embodiments, the cyclic polyribonucleotide comprises an open reading frame having a nucleic acid sequence encoding a SARS-CoV-2 immunogen, wherein the nucleic acid sequence has at least about 90% (e.g., about 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) sequence identity to any one of SEQ ID NOs: 112-174 and 292-300. In some embodiments, the cyclic polyribonucleotide comprises an open reading frame having a nucleic acid sequence encoding a SARS-CoV-2 immunogen, wherein the nucleic acid sequence has at least about 95% (e.g., about 96%, 97%, 98%, 99% or 100%) sequence identity to any one of SEQ ID NOs: 112-174 and 292-300. In certain embodiments, the cyclic polyribonucleotide comprises an open reading frame having a nucleic acid sequence encoding a SARS-CoV-2 immunogen, wherein the nucleic acid sequence is any one of SEQ ID NOs: 112-174 and 292-300. In some embodiments, the polyribonucleotide sequence encoding a SARS-CoV-2 immunogen is a continuous stretch of at least 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1500, 2000, 2500, 3000, 3500, 4000, or 4500 nucleotides of any one of SEQ ID NOs: 112-174 and 292-300. In some embodiments, the polyribonucleotide sequence encoding the SARS-CoV-2 immunogen is a fragment of a continuous stretch of at least 50%, 60%, 70%, 80%, 90% or 95% of the amino acids of any one of SEQ ID NOs: 112-174 and 292-300.

[0163] In certain embodiments, the cyclic polyribonucleotide comprises an open reading frame having a nucleic acid sequence encoding a SARS-CoV-2 immunogen, wherein the nucleic acid sequence has at least about 80% (e.g., about 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) sequence identity with any one of SEQ ID NOs: 219-281. In some embodiments, the cyclic polyribonucleotide comprises an open reading frame having a nucleic acid sequence encoding a SARS-CoV-2 immunogen, wherein the nucleic acid sequence has at least about 90% (e.g., about 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) sequence identity with any one of SEQ ID NOs: 219-281. In some embodiments, the cyclic polyribonucleotide comprises an open reading frame having a nucleic acid sequence encoding a SARS-CoV-2 immunogen, wherein the nucleic acid sequence has at least about 95% (e.g., about 96%, 97%, 98%, 99% or 100%) sequence identity with any one of SEQ ID NOs: 219-281. In certain embodiments, the cyclic polyribonucleotide comprises an open reading frame having a nucleic acid sequence encoding a SARS-CoV-2 immunogen, wherein the nucleic acid sequence is any one of SEQ ID NOs: 219-281. In some embodiments, the polyribonucleotide sequence encoding a SARS-CoV-2 immunogen is a fragment of a continuous stretch of at least 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1500, 2000, 2500, 3000, 3500, 4000 or 4500 nucleotides of any one of SEQ ID NOs: 219-281. In some embodiments, the polyribonucleotide sequence encoding the SARS-CoV-2 immunogen is a fragment of a continuous stretch of at least 50%, 60%, 70%, 80%, 90% or 95% of the amino acids of any one of SEQ ID NOs: 219-281.

[0164] In certain embodiments, the cyclic polyribonucleotide comprises a SARS-CoV-2 RBD immunogen described in Table 3. In some embodiments, the immunogen comprises a sequence having at least about 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% sequence identity with a sequence from Table 3. In some embodiments, the cyclic polyribonucleotide comprises an open reading frame encoding a SARS-CoV-2 RBD immunogen having an amino acid sequence at least about 80% (e.g., about 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) identical to any one of SEQ ID NOs: 63-68, 74, 79, 81-86 and 98-111. In some embodiments, the cyclic polyribonucleotide comprises an open reading frame encoding a SARS-CoV-2RBD immunogen having an amino acid sequence that is at least about 90% (e.g., about 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) identical to any one of SEQ ID NOs: 63-68, 74, 79, 81-86 and 98-111. In some embodiments, the cyclic polyribonucleotide comprises an open reading frame encoding a SARS-CoV-2RBD immunogen having an amino acid sequence that is at least about 95% (e.g., about 96%, 97%, 98%, 99% or 100%) identical to any one of SEQ ID NOs: 63-68, 74, 79, 81-86 and 98-111. In some embodiments, the circular polyribonucleotide comprises an open reading frame encoding a SARS-CoV-2 immunogen having an amino acid sequence of any one of SEQ ID NOs: 63-68, 74, 79, 81-86, and 98-111. In some embodiments, the SARS-CoV-2 RBD immunogen is an immunogenic fragment comprising a continuous stretch of at least 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1100, 1200, 1300, 1400, or 1500 amino acids of any one of SEQ ID NOs: 63-68, 74, 79, 81-86, and 98-111.In some embodiments, the SARS-CoV-2 RBD immunogen is an immunogenic fragment comprising a contiguous stretch of at least 50%, 60%, 70%, 80%, 90% or 95% of the amino acids of any one of SEQ ID NOs: 63-68, 74, 79, 81-86 and 98-111.

[0165] In a particular embodiment, the cyclic polyribonucleotide comprises an open reading frame having a nucleic acid sequence encoding a SARS-CoV-2 RBD immunogen, wherein the nucleic acid sequence has at least about 80% (e.g., about 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 112-117, 123, 128, 133-138, and 163-174. In some embodiments, the cyclic polyribonucleotide comprises an open reading frame having a nucleic acid sequence encoding a SARS-CoV-2 RBD immunogen, wherein the nucleic acid sequence has at least about 90% (e.g., about 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) sequence identity with any one of SEQ ID NOs: 112-117, 123, 128, 133-138 and 163-174. In some embodiments, the cyclic polyribonucleotide comprises an open reading frame having a nucleic acid sequence encoding a SARS-CoV-2 RBD immunogen, wherein the nucleic acid sequence has at least about 95% (e.g., about 96%, 97%, 98%, 99% or 100%) sequence identity with any one of SEQ ID NOs: 112-117, 123, 128, 133-138 and 163-174. In certain embodiments, the cyclic polyribonucleotide comprises an open reading frame having a nucleic acid sequence encoding a SARS-CoV-2 RBD immunogen, wherein the nucleic acid sequence is any one of SEQ ID NOs: 112-117, 123, 128, 133-138, and 163-174. In some embodiments, the polyribonucleotide sequence encoding the SARS-CoV-2 RBD immunogen is a fragment of a continuous stretch of at least 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1500, 2000, 2500, 3000, 3500, 4000, or 4500 nucleotides of any one of SEQ ID NOs: 112-117, 123, 128, 133-138, and 163-174. In some embodiments, the polyribonucleotide sequence encoding the SARS-CoV-2 RBD immunogen is a fragment of a continuous stretch of at least 50%, 60%, 70%, 80%, 90% or 95% of the amino acids of any one of SEQ ID NOs: 112-117, 123, 128, 133-138 and 163-174.

[0166] In certain embodiments, the cyclic polyribonucleotide comprises more than one SARS-CoV-2 RBD as described in Table 5. In some embodiments, the cyclic polyribonucleotide comprises an open reading frame described in Table 5.

[0167] In certain embodiments, the cyclic polyribonucleotide comprises a SARS-CoV-2 spike immunogen described in Table 4. In some embodiments, the immunogen comprises a sequence having at least about 80%, 85%, 90%, 95%, 97%, 98%, 99%, or 100% sequence identity to a sequence from Table 4. In some embodiments, the cyclic polyribonucleotide comprises an open reading frame encoding a SARS-CoV-2 spike immunogen having an amino acid sequence at least about 80% (e.g., about 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to any one of SEQ ID NOs: 69-73, 75-78, 80, 87-97, and 283-286. In some embodiments, the cyclic polyribonucleotide comprises an open reading frame encoding a SARS-CoV-2 spike immunogen having an amino acid sequence that is at least about 90% (e.g., about 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) identical to any one of SEQ ID NOs: 69-73, 75-78, 80, 87-97 and 283-286. In some embodiments, the cyclic polyribonucleotide comprises an open reading frame encoding a SARS-CoV-2 spike immunogen having an amino acid sequence that is at least about 95% (e.g., about 96%, 97%, 98%, 99% or 100%) identical to any one of SEQ ID NOs: 69-73, 75-78, 80, 87-97 and 283-286. In some embodiments, the circular polyribonucleotide comprises an open reading frame encoding a SARS-CoV-2 immunogen having an amino acid sequence of any one of SEQ ID NOs: 69-73, 75-78, 80, 87-97, and 283-286. In some embodiments, the SARS-CoV-2 spike immunogen is an immunogenic fragment comprising a continuous stretch of at least 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1100, 1200, 1300, 1400, or 1500 amino acids of any one of SEQ ID NOs: 69-73, 75-78, 80, 87-97, and 283-286.In some embodiments, the SARS-CoV-2 spike immunogen is an immunogenic fragment that includes a contiguous stretch of at least 50%, 60%, 70%, 80%, 90% or 95% of the amino acids of any of SEQ ID NOs: 69-73, 75-78, 80, 87-97 and 283-286.

[0168] In certain embodiments, the cyclic polyribonucleotide comprises an open reading frame having a nucleic acid sequence encoding a SARS-CoV-2 spike immunogen, wherein the nucleic acid sequence has at least about 80% (e.g., about 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 118-122, 124-127, 129-132, 139-162, and 287-291. In some embodiments, the circular polyribonucleotide comprises an open reading frame having a nucleic acid sequence encoding a SARS-CoV-2 spike immunogen, wherein the nucleic acid sequence has at least about 90% (e.g., about 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 118-122, 124-127, 129-132, 139-162, and 287-291. In some embodiments, the cyclic polyribonucleotide includes an open reading frame having a nucleic acid sequence encoding a SARS-CoV-2 spike immunogen, wherein the nucleic acid sequence is at least about 95% (e.g., about 96%, 97%, 98%, 99% or 100%) sequence identity to any one of SEQ ID NO: 118-122, 124-127, 129-132, 139-162 and 287-291. In certain embodiments, the cyclic polyribonucleotide includes an open reading frame having a nucleic acid sequence encoding a SARS-CoV-2 spike immunogen, wherein the nucleic acid sequence is any one of SEQ ID NO: 118-122, 124-127, 129-132, 139-162 and 287-291. In some embodiments, the polyribonucleotide sequence encoding the SARS-CoV-2 spike immunogen is a continuous segment of at least 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1500, 2000, 2500, 3000, 3500, 4000, or 4500 nucleotides of any one of SEQ ID NOs: 118-122, 124-127, 129-132, 139-162, and 287-291. In some embodiments, the polyribonucleotide sequence encoding the SARS-CoV-2 spike immunogen is a fragment of a continuous stretch of at least 50%, 60%, 70%, 80%, 90% or 95% of the amino acids of any one of SEQ ID NOs: 118-122, 124-127, 129-132, 139-162 and 287-291.

[0169] In certain embodiments, the cyclic polyribonucleotide comprises a SARS-CoV-2 nonstructural protein (nsp) immunogen. In some embodiments, the cyclic polyribonucleotide comprises an open reading frame encoding a SARS-CoV-2 nsp immunogen having an amino acid sequence that is at least about 80% (e.g., about 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) identical to any one of SEQ ID NOs: 291-295. In some embodiments, the cyclic polyribonucleotide comprises an open reading frame encoding a SARS-CoV-2 nsp immunogen having an amino acid sequence that is at least about 90% (e.g., about 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to any one of SEQ ID NOs: 291-295. In some embodiments, the cyclic polyribonucleotide comprises an open reading frame encoding a SARS-CoV-2 nsp immunogen having an amino acid sequence that is at least about 95% (e.g., about 96%, 97%, 98%, 99%, or 100%) identical to any one of SEQ ID NOs: 291-295. In some embodiments, the cyclic polyribonucleotide comprises an open reading frame encoding a SARS-CoV-2 immunogen having an amino acid sequence that is any one of SEQ ID NOs: 291-295. In some embodiments, the SARS-CoV-2 nsp immunogen is an immunogenic fragment comprising a continuous stretch of at least 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1100, 1200, 1300, 1400, or 1500 amino acids of any one of SEQ ID NOs: 291-295. In some embodiments, the SARS-CoV-2 nsp immunogen is an immunogenic fragment comprising a continuous stretch of at least 50%, 60%, 70%, 80%, 90%, or 95% of the amino acids of any one of SEQ ID NOs: 291-295.

[0170] In certain embodiments, the cyclic polyribonucleotide comprises an open reading frame having a nucleic acid sequence encoding a SARS-CoV-2 nsp immunogen, wherein the nucleic acid sequence has at least about 80% (e.g., about 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) sequence identity with any one of SEQ ID NOs: 296-300. In some embodiments, the cyclic polyribonucleotide comprises an open reading frame having a nucleic acid sequence encoding a SARS-CoV-2 nsp immunogen, wherein the nucleic acid sequence has at least about 90% (e.g., about 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) sequence identity with any one of SEQ ID NOs: 296-300. In some embodiments, the cyclic polyribonucleotide comprises an open reading frame having a nucleic acid sequence encoding a SARS-CoV-2nsp immunogen, wherein the nucleic acid sequence has at least about 95% (e.g., about 96%, 97%, 98%, 99% or 100%) sequence identity with any one of SEQ ID NOs: 296-300. In certain embodiments, the cyclic polyribonucleotide comprises an open reading frame having a nucleic acid sequence encoding a SARS-CoV-2nsp immunogen, wherein the nucleic acid sequence is any one of SEQ ID NOs: 296-300 and 287-291. In some embodiments, the polyribonucleotide sequence encoding the SARS-CoV-2 nsp immunogen is a continuous segment of at least 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1500, 2000, 2500, 3000, 3500, 4000 or 4500 nucleotides of any one of SEQ ID NOs: 296-300. In some embodiments, the polyribonucleotide sequence encoding the SARS-CoV-2 nsp immunogen is a fragment of a continuous segment of at least 50%, 60%, 70%, 80%, 90% or 95% of the amino acids of any one of SEQ ID NOs: 296-300.

[0171] The present disclosure specifically contemplates that any of the DNA sequences described herein can be converted into a corresponding RNA sequence and contained within an RNA molecule described herein.

[0172] Table 3. SARS-CoV-2 RBD immunogen constructs

[0173]

[0174]

[0175]

[0176]

[0177] Table 4. SARS-CoV-2 spike immunogen constructs

[0178]

[0179]

[0180]

[0181] In some embodiments, the GC content of the nucleic acid sequence encoding the SARS-CoV-2 immunogen is at least 51% (e.g., at least 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, or 60%). In some embodiments, the GC content of the nucleic acid sequence encoding the SARS-CoV-2 immunogen is at most 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, or 60%. In some embodiments, the GC content of the nucleic acid sequence encoding the SARS-CoV-2 immunogen is 51% to 60%, 52% to 60%, 53% to 60%, 54% to 60%, 55% to 60%, 52% to 58%, 53% to 58%.

[0182] In some embodiments, the uridine content (for RNA) or thymidine content (for DNA) of the nucleic acid sequence encoding the SARS-CoV-2 immunogen is greater than 10% (e.g., greater than 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, or 25%). In some embodiments, the uridine content (for RNA) or thymidine content (for DNA) of the nucleic acid sequence encoding the SARS-CoV-2 immunogen is at most 30% (e.g., at most 29%, 28%, 27%, 26%, 25%, 24%, 23%, 22%, 21%, or 20%). In some embodiments, the uridine content (for RNA) or thymidine content (for DNA) of the nucleic acid sequence encoding the SARS-CoV-2 immunogen is 20% to 28%, 21% to 26%, 10% to 24%, 15% to 24%, 20% to 24%, 21% to 24%, 22% to 24%, 23% to 24%, 10% to 23%, 15% to 23%, 20% to 23%, 21% to 23%, or 22% to 23%.

[0183] The GC content of an expressed sequence encoding a SARS-CoV-2 immunogen refers to the GC content of an expressed sequence encoding only a SARS-CoV-2 immunogen, without other coding regions encoding peptides other than the SARS-CoV-2 immunogen. Similarly, the uridine content or thymidine content of an expressed sequence encoding only a SARS-CoV-2 immunogen refers to the uridine content of an expressed sequence encoding only a SARS-CoV-2 immunogen, without other coding regions encoding peptides other than the SARS-CoV-2 immunogen. In some embodiments, the calculation of the GC content or uridine (or thymidine) content of an expressed sequence encoding a SARS-CoV-2 immunogen only considers the continuous nucleic acid sequence starting from the first nucleoside of the start codon of the open reading frame encoding the SARS-CoV-2 immunogen to the last nucleoside of the stop codon of the same open reading frame in the 5' to 3' direction. In other embodiments, the calculation of the GC content or uridine (or thymidine) content of the expressed sequence encoding the SARS-CoV-2 immunogen only considers the continuous nucleic acid sequence starting from the first nucleoside of the codon encoding the N-terminal amino acid residue of the SARS-CoV-2 immunogen to the last nucleoside of the codon encoding the C-terminal amino acid residue of the SARS-CoV-2 immunogen in the 5' to 3' direction.

[0184] In some embodiments, the immunogen or epitope is from a host subject (e.g., a subject to be immunized) cell. For example, antibodies that block coronavirus entry can be produced by using an immunogen or epitope from a host cell component that the virus uses as an entry factor.

[0185] In some embodiments, a coronavirus epitope comprises or contains at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 26, at least 27, at least 28, at least 29, or at least 30 amino acids or more. In some embodiments, a coronavirus epitope comprises or contains at most 4, at most 5, at most 6, at most 7, at most 8, at most 9, at most 10, at most 11, at most 12, at most 13, at most 14, at most 15, at most 16, at most 17, at most 18, at most 19, at most 20, at most 21, at most 22, at most 23, at most 24, at most 25, at most 26, at most 27, at most 28, at most 29, or at most 30 amino acids or less. In some embodiments, the coronavirus epitope comprises or contains 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 amino acids. In some embodiments, the coronavirus epitope contains 5 amino acids. In some embodiments, the coronavirus epitope contains 6 amino acids. In some embodiments, the epitope contains 7 amino acids. In some embodiments, the coronavirus epitope contains 8 amino acids. In some embodiments, the epitope can be about 8 to about 11 amino acids. In some embodiments, the epitope can be about 9 to about 22 amino acids.

[0186] The coronavirus immunogen may comprise an immunogen recognized by a B cell, an immunogen recognized by a T cell, or a combination thereof. In some embodiments, the immunogen comprises an immunogen recognized by a B cell. In some embodiments, the coronavirus immunogen is an immunogen recognized by a B cell. In some embodiments, the coronavirus immunogen comprises an immunogen recognized by a T cell. In some embodiments, the immunogen is an immunogen recognized by a T cell.

[0187] Coronavirus epitopes include immunogens recognized by B cells, immunogens recognized by T cells, or combinations thereof. In some embodiments, coronavirus epitopes include epitopes recognized by B cells. In some embodiments, the epitope is an epitope recognized by B cells. In some embodiments, coronavirus epitopes include epitopes recognized by T cells. In some embodiments, coronavirus epitopes are epitopes recognized by T cells.

[0188] Techniques for in silico identification of immunogens and epitopes have been disclosed in, for example, Sanchez-Trincado et al. (2017), Fundamentals and methods for T-and B-cell epitope prediction. Journal of immunology research; Grifoni, Alba et al. A Sequence Homology and Bioinformatic Approach Can Predict Candidate Targets for Immune Responses to SARS-CoV-2. Cell Host & Microbe (2020); Russi et al. In silico prediction of T-and B-cell epitopes in PmpD: First step towards to the design of a Chlamydia trachomatis vaccine, Biomedical Science (2017). Journal [Biological Medicine] 41.2 (2018): 109-17; Baruah et al. Immunoinformatics-aided identification of T cell and B cell epitopes in the surface glycoprotein of 2019-nCoV. [Immunoinformatics-aided identification of T cell and B cell epitopes in the surface glycoprotein of 2019-nCoV] Journal of Medical Virology [Medical Virology] (2020); each of which is incorporated herein by reference in its entirety.

[0189] The cyclic polyribonucleotide of the present disclosure can comprise the sequence of any number of coronavirus immunogens and / or epitopes. Circular polyribonucleotides comprise for example at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 15, at least 20, at least 25, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 120, at least 140, at least 160, at least 180, at least 200, at least 250, at least 300, at least 350, at least 400, at least 450, at least 500 or more sequences of coronavirus immunogens or epitopes (for example, selected from any coronavirus immunogen and / or epitope as described herein).

[0190] In some embodiments, the circular polyribonucleotide comprises, for example, at most 1, at most 2, at most 3, at most 4, at most 5, at most 6, at most 7, at most 8, at most 9, at most 10, at most 15, at most 20, at most 25, at most 30, at most 40, at most 50, at most 60, at most 70, at most 80, at most 90, at most 100, at most 120, at most 140, at most 160, at most 180, at most 200, at most 250, at most 300, at most 350, at most 400, at most 450, at most 500 or less sequences of coronavirus immunogens or epitopes.

[0191] In some embodiments, the circular polyribonucleotide comprises, for example, about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, 120, 140, 160, 180, 200, 250, 300, 350, 400, 450, or 500 coronavirus immunogens or epitopes.

[0192] Circular polyribonucleotides may include sequences of one or more coronavirus epitopes from coronavirus immunogens. For example, coronavirus immunogens may include amino acid sequences, wherein may contain a variety of coronavirus epitopes (e.g., epitopes recognized by B cells and / or T cells), and cyclic polyribonucleotides may include or encode one or more of these coronavirus epitopes. In certain embodiments, cyclic polyribonucleotides may include one or more sequences encoding coronavirus immunogens and one or more sequences encoding an immunogen called coronavirus immunogen. For example, cyclic polyribonucleotides may include one or more sequences encoding coronavirus immunogens and one or more sequences encoding an immunogen (e.g., influenza virus immunogen) from another virus.

[0193] Circular polyribonucleotides comprise, for example, sequences of at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 15, at least 20, at least 25, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 120, at least 140, at least 160, at least 180, at least 200, at least 250, at least 300, at least 350, at least 400, at least 450, at least 500 or more epi-topes from a coronavirus immunogen.

[0194] In some embodiments, the circular polyribonucleotide comprises sequences of at most 2, at most 3, at most 4, at most 5, at most 6, at most 7, at most 8, at most 9, at most 10, at most 15, at most 20, at most 25, at most 30, at most 40, at most 50, at most 60, at most 70, at most 80, at most 90, at most 100, at most 120, at most 140, at most 160, at most 180, at most 200, at most 250, at most 300, at most 350, at most 400, at most 450 or at most 500, or fewer coronavirus epitopes, e.g., from a coronavirus immunogen.

[0195] In some embodiments, the circular polyribonucleotide comprises a sequence of, for example, about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, 120, 140, 160, 180, 200, 250, 300, 350, 400, 450, or 500 coronavirus epitopes from a coronavirus immunogen.

[0196] Circular polyribonucleotides can encode variants of coronavirus immunogens or epitopes. Variant can be naturally occurring variants (e.g., variants identified in sequence data from different coronavirus genera, species, isolates or quasispecies), or can be derived sequences generated via computer simulation as disclosed herein (e.g., compared with wild-type immunogens or epitopes, immunogens or epitopes with one or more amino acid insertions, deletions, substitutions or combinations thereof).

[0197] Circular polyribonucleotide comprises the sequence of at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 15, at least 20, at least 25, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 120, at least 140, at least 160, at least 180, at least 200, at least 250, at least 300, at least 350, at least 400, at least 450, at least 500 or more variants of a coronavirus immunogen or epitope.

[0198] In some embodiments, the circular polyribonucleotide comprises sequences of at most 2, at most 3, at most 4, at most 5, at most 6, at most 7, at most 8, at most 9, at most 10, at most 15, at most 20, at most 25, at most 30, at most 40, at most 50, at most 60, at most 70, at most 80, at most 90, at most 100, at most 120, at most 140, at most 160, at most 180, at most 200, at most 250, at most 300, at most 350, at most 400, at most 450, at most 500 or less variants of, for example, a coronavirus immunogen or epitope.

[0199] In some embodiments, the circular polyribonucleotide comprises a sequence of about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, 120, 140, 160, 180, 200, 250, 300, 350, 400, 450, or 500 variants of, for example, a coronavirus immunogen or epitope.

[0200] The coronavirus immunogen and / or epitope sequence of the cyclic polyribonucleotide may also be referred to as a coronavirus expression sequence. In some embodiments, the cyclic polyribonucleotide comprises one or more coronavirus expression sequences, each of which can encode a coronavirus polypeptide. Coronavirus polypeptides can be produced in large quantities. Coronavirus polypeptides can be coronavirus polypeptides secreted from cells or located in the cytoplasm, nucleus or membrane compartment of cells. Some coronavirus polypeptides include, but are not limited to, at least a portion of an immunogen as disclosed herein, an epitope as disclosed herein, a coronavirus protein (e.g., a viral envelope protein, a viral matrix protein, a viral spike protein, a viral receptor binding domain (RBD) of a viral spike protein, a viral membrane protein, a viral nucleocapsid protein, a viral auxiliary protein, a fragment thereof, or a combination thereof). In some embodiments, the coronavirus polypeptide encoded by the cyclic polyribonucleotide of the present disclosure comprises a fragment of a coronavirus immunogen disclosed herein. In some embodiments, the coronavirus polypeptide encoded by the cyclic polyribonucleotide of the present disclosure comprises a fusion protein, the fusion protein comprising two or more coronavirus immunogens disclosed herein or fragments thereof. In some embodiments, the coronavirus polypeptide encoded by the cyclic polyribonucleotide of the present disclosure comprises a coronavirus epitope. In some embodiments, the polypeptide encoded by the cyclic polyribonucleotide of the present disclosure comprises a fusion protein comprising two or more coronavirus epitopes disclosed herein, for example, an artificial peptide sequence comprising multiple predicted epitopes from one or more coronaviruses of the present disclosure.

[0201] In some embodiments, exemplary coronavirus proteins expressed by the cyclic polyribonucleotides disclosed herein include secreted proteins, such as proteins (e.g., immunogens and / or epitopes) that naturally include a signal peptide, or proteins that do not normally encode a signal peptide but are modified to contain a signal peptide.

[0202] In some cases, the following secretory coronavirus protein of cyclic polyribonucleotide expression, described secretory coronavirus protein has shorter half-life in blood, or can be the protein with subcellular localization signal, or have the protein of secretion signal peptide.In some cases, the following membrane spaning domain of cyclic polyribonucleotide expression, described membrane spaning domain has shorter half-life in blood, or can be the protein with subcellular localization signal, or have the protein of secretion peptide.

[0203] In certain embodiments, the cyclic polyribonucleotide comprises one or more coronavirus expression sequences, and is configured to be used for the continuous expression in the cell in experimenter (for example, want the experimenter of immunization) body.In certain embodiments, the cyclic polyribonucleotide is configured to make the expression of described one or more coronavirus expression sequences in the cell at the later time point equal to or higher than the expression at the earlier time point.In such embodiment, the expression of one or more coronavirus expression sequences can maintain parastable level or can increase in time.In certain embodiments, the expression of coronavirus expression sequence is relatively stable for a long time.

[0204] In certain embodiments, the cyclic polyribonucleotide is for example, temporarily or for a long time expressing one or more coronavirus immunogens and / or epi-positions in a subject (for example, the subject to be immunized).In certain embodiments, the expression of coronavirus expression sequence continues at least about 1 hour to about 30 days, or at least about 2 hours, 6 hours, 12 hours, 18 hours, 24 hours, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days, 22 days, 23 days, 24 days, 25 days, 26 days, 27 days, 28 days, 29 days, 30 days, 60 days or longer time or any time therebetween. In certain embodiments, expression of coronavirus immunogens and / or epitopes lasts no longer than about 30 minutes to about 7 days, or no longer than about 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, 18 hours, 19 hours, 20 hours, 21 hours, 22 hours, 24 hours. , 36 hours, 48 ​​hours, 60 hours, 72 hours, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days, 22 days, 23 days, 24 days, 25 days, 26 days, 27 days, 28 days, 29 days, 30 days, 45 days, 60 days, 75 days, 90 days, or any time in between.

[0205] In some embodiments, the length of the coronavirus expressed sequence is less than 5000 bp (e.g., less than about 5000 bp, 4000 bp, 3000 bp, 2000 bp, 1000 bp, 900 bp, 800 bp, 700 bp, 600 bp, 500 bp, 400 bp, 300 bp, 200 bp, 100 bp, 50 bp, 40 bp, 30 bp, 20 bp, 10 bp or less). In some embodiments, the coronavirus expressed sequence independently or additionally has a length greater than 10 bp (e.g., at least about 10 bp, 20 bp, 30 bp, 40 bp, 50 bp, 60 bp, 70 bp, 80 bp, 90 bp, 100 bp, 200 bp, 300 bp, 400 bp, 500 bp, 600 bp, 700 bp, 800 bp, 900 bp, 1000 kb, 1.1 kb, 1.2 kb, 1.3 kb, 1.4 kb, 1.5 kb, 1.6 kb, 1.7 kb, 1.8 kb, 1.9 kb, 2.1 kb, 2.2 kb, 2.3 kb, 2.4 kb, 2.5 kb, 2.6 kb, 2.7 kb, 2.8 kb, 2.9 kb, 3.1 kb, 3.2 kb, 3.3 kb, 3.4 kb, 3.5 kb, 3.6 kb, 3.7 kb, 3.8 kb, 3.9 kb, 4. 8kb, 1.9kb, 2kb, 2.1kb, 2.2kb, 2.3kb, 2.4kb, 2.5kb, 2.6kb, 2.7kb, 2.8kb, 2.9kb, 3kb, 3.1kb, 3.2kb, 3.3kb, 3.4kb, 3.5kb, 3.6kb, 3.7kb, 3.8kb, 3.9kb, 4kb, 4.1kb, 4.2kb, 4.3kb, 4.4kb, 4.5kb, 4.6kb, 4.7kb, 4.8kb, 4.9kb, 5kb or larger).

[0206] In certain embodiments, cyclic polyribonucleotides encode multiple immunogens (for example, one or more, two or more, three or more, four or more or five or more immunogens), and multiple immunogens share at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity. In certain embodiments, multiple immunogens also have a sequence identity less than 100%. This may indicate an immunogen related to each other due to genetic drift, therefore, a single cyclic polyribonucleotide composition or immunogenic composition may be able to induce an immune response for a target present with various mutation states in a colony, or may induce an immune response for a plurality of targets with the same immunogen, wherein the immunogen is related to genetic drift. For example, an immunogen may be related to each other by the genetic drift of a target virus (for example, coronavirus, for example SARS-Cov-2).

[0207] Derivatives and fragments

[0208] The immunogens or epitopes disclosed herein may comprise wild-type sequences. When describing an immunogen or epitope, the term "wild-type" refers to a sequence (e.g., an amino acid sequence) that occurs naturally and is encoded by a genome (e.g., a coronavirus genome). A coronavirus may have one wild-type sequence, or two or more wild-type sequences (e.g., there is a classic wild-type sequence in a reference coronavirus genome, and there are additional variant wild-type sequences produced by mutation).

[0209] When describing an immunogen or epitope, the terms "derivative" and "derived from" refer to a sequence (e.g., an amino acid sequence) that differs from the wild-type sequence by one or more amino acids, such as containing one or more amino acid insertions, deletions and / or substitutions relative to the wild-type sequence.

[0210] An immunogen- or epitope-derived sequence is one that has at least 60%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to a wild-type sequence (e.g., a wild-type protein, immunogen or epitope sequence).

[0211] In some embodiments, the immunogen or epitope contains one or more amino acid insertions, deletions, substitutions, or combinations thereof that affect the structure of the encoded protein. In some embodiments, the immunogen or epitope contains one or more amino acid insertions, deletions, substitutions, or combinations thereof that affect the function of the encoded protein. In some embodiments, the immunogen or epitope contains one or more amino acid insertions, deletions, substitutions, or combinations thereof that affect expression or processing of the encoded protein by a cell.

[0212] The insertion, deletion, substitution, or combination thereof of amino acids can introduce a site of post-translational modification (e.g., introducing a glycosylation, ubiquitination, phosphorylation, nitrosylation, methylation, acetylation, amidation, hydroxylation, sulfation, or lipidation site, or targeting a sequence for cleavage). In some embodiments, the insertion, deletion, substitution, or combination thereof of amino acids removes a site of post-translational modification (e.g., removing a glycosylation, ubiquitination, phosphorylation, nitrosylation, methylation, acetylation, amidation, hydroxylation, sulfation, or lipidation site, or targeting a sequence for cleavage). In some embodiments, the insertion, deletion, substitution, or combination thereof of amino acids modifies a site of post-translational modification (e.g., modifying a site to change a glycosylation, ubiquitination, phosphorylation, nitrosylation, methylation, acetylation, amidation, hydroxylation, sulfation, or lipidation site, or the efficiency or characteristics of cleavage).

[0213] Amino acid substitutions can be conservative or non-conservative substitutions. Conservative amino acid substitutions can be substitutions of one amino acid for another amino acid of similar biochemical properties (e.g., charge, size, and / or hydrophobicity). Non-conservative amino acid substitutions can be substitutions of one amino acid by another amino acid having different biochemical properties (e.g., charge, size, and / or hydrophobicity). Conservative amino acid changes can be substitutions that have, for example, minimal effect on the secondary or tertiary structure of a polypeptide. Conservative amino acid changes can be amino acid changes from one hydrophilic amino acid to another hydrophilic amino acid. Hydrophilic amino acids can include Thr (T), Ser (S), His (H), Glu (E), Asn (N), Gln (Q), Asp (D), Lys (K), and Arg (R). Conservative amino acid changes can be amino acid changes from one hydrophobic amino acid to another hydrophilic amino acid. Hydrophobic amino acids may include Ile (I), Phe (F), Val (V), Leu (L), Trp (W), Met (M), Ala (A), Gly (G), Tyr (Y), and Pro (P). Conservative amino acid changes may be amino acid changes from one acidic amino acid to another acidic amino acid. Acidic amino acids may include Glu (E) and Asp (D). Conservative amino acid changes may be amino acid changes from one basic amino acid to another basic amino acid. Basic amino acids may include His (H), Arg (R), and Lys (K). Conservative amino acid changes may be amino acid changes from one polar amino acid to another polar amino acid. Polar amino acids may include Asn (N), Gln (Q), Ser (S), and Thr (T). Conservative amino acid changes may be amino acid changes from one non-polar amino acid to another non-polar amino acid. Non-polar amino acids may include Leu (L), Val (V), Ile (I), Met (M), Gly (G), and Ala (A). A conservative amino acid change can be an amino acid change from one aromatic amino acid to another aromatic amino acid. Aromatic amino acids can include Phe (F), Tyr (Y) and Trp (W). A conservative amino acid change can be an amino acid change from one aliphatic amino acid to another aliphatic amino acid. Aliphatic amino acids can include Ala (A), Val (V), Leu (L) and Ile (I). In some embodiments, a conservative amino acid substitution is an amino acid change from one amino acid to another amino acid in one of the following categories: Class I: ala, pro, Gly, Gln, Asn, Ser, Thr; Class II: Cys, Ser, Tyr, Thr; Class III: Val, Ile, Leu, Met, Ala, Phe; Class IV: Lys, Arg, His; Class V: Phe, Tyr, Trp, His; and Class VI: Asp, Glu.

[0214] In some embodiments, the immunogen derivatives or epitope derivatives of the present disclosure comprise at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 60, at least 70, at least 80, at least 90, or at least 100 amino acid deletions relative to a sequence disclosed herein (e.g., a wild-type sequence).

[0215] In some embodiments, the immunogen derivatives or epitope derivatives of the present disclosure comprise at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, or at least 50 amino acid substitutions relative to a sequence disclosed herein (e.g., a wild-type sequence).

[0216] In some embodiments, the immunogen derivatives or epitope derivatives of the present disclosure comprise at most 1, at most 2, at most 3, at most 4, at most 5, at most 6, at most 7, at most 8, at most 9, at most 10, at most 11, at most 12, at most 13, at most 14, at most 15, at most 16, at most 17, at most 18, at most 19, at most 20, at most 25, at most 30, at most 35, at most 40, at most 45, or at most 50 amino acid substitutions relative to a sequence disclosed herein (e.g., a wild-type sequence).

[0217] In some embodiments, relative to a sequence disclosed herein (e.g., a wild-type sequence), an immunogen derivative or epitope derivative disclosed herein comprises 1-2, 1-3, 1-4, 1-5, 1-6, 1-7, 1-8, 1-9, 1-10, 1-15, 1-20, 1-30, 1-40, 2-3, 2-4, 2-5, 2-6, 2-7, 2-8, 2-9, 2-10, 2-15, 2-20, 2-30, 2-40, 3-3, 3-4, 3-5, 3-6, 3-7, 3-8, 3-9, 3-10, 3-15, 3-20, 3-30, 3-40, 5-6, 5-7, 5-8, 5-9, 5-10, 5-15, 5-20, 5-30, 5-40, 10-15, 15-20 or 20-25 amino acid substitutions.

[0218] In some embodiments, an immunogen derivative or epitope derivative of the disclosure comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid substitutions relative to a sequence disclosed herein (e.g., a wild-type sequence).

[0219] The one or more amino acid substitutions may be at the N-terminus, the C-terminus, within the amino acid sequence, or a combination thereof. The amino acid substitutions may be continuous, non-continuous, or a combination thereof.

[0220] In some embodiments, the immunogen derivatives or epitope derivatives of the present disclosure comprise at most 1, at most 2, at most 3, at most 4, at most 5, at most 6, at most 7, at most 8, at most 9, at most 10, at most 11, at most 12, at most 13, at most 14, at most 15, at most 16, at most 17, at most 18, at most 19, at most 20, at most 25, at most 30, at most 35, at most 40, at most 45, at most 50, at most 60, at most 70, at most 80, at most 90, at most 100, at most 120, at most 140, at most 160, at most 180, or at most 200 amino acid deletions relative to a sequence disclosed herein (e.g., a wild-type sequence).

[0221] In some embodiments, relative to a sequence disclosed herein (e.g., a wild-type sequence), an immunogenic derivative or epitope derivative disclosed herein comprises 1-2, 1-3, 1-4, 1-5, 1-6, 1-7, 1-8, 1-9, 1-10, 1-15, 1-20, 1-30, 1-40, 2-3, 2-4, 2-5, 2-6, 2-7, 2-8, 2-9, 2-10, 2-15, 2-20, 2-30 , 2-40, 3-3, 3-4, 3-5, 3-6, 3-7, 3-8, 3-9, 3-10, 3-15, 3-20, 3-30, 3-40, 5-6, 5-7, 5-8, 5-9, 5-10, 5-15, 5-20, 5-30, 5-40, 10-15, 15-20, 20-25, 20-30, 30-50, 50-100 or 100-200 amino acids are missing.

[0222] In some embodiments, an immunogen derivative or epitope derivative of the disclosure comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid deletions relative to a sequence disclosed herein (e.g., a wild-type sequence).

[0223] The one or more amino acid deletions may be at the N-terminus, the C-terminus, within the amino acid sequence, or a combination thereof. The amino acid deletions may be continuous, non-continuous, or a combination thereof.

[0224] In some embodiments, the immunogen derivatives or epitope derivatives of the present disclosure comprise at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, or at least 50 amino acid insertions relative to a sequence disclosed herein (e.g., a wild-type sequence).

[0225] In some embodiments, the immunogen derivatives or epitope derivatives of the present disclosure comprise at most 1, at most 2, at most 3, at most 4, at most 5, at most 6, at most 7, at most 8, at most 9, at most 10, at most 11, at most 12, at most 13, at most 14, at most 15, at most 16, at most 17, at most 18, at most 19, at most 20, at most 25, at most 30, at most 35, at most 40, at most 45, or at most 50 amino acid insertions relative to a sequence disclosed herein (e.g., a wild-type sequence).

[0226] In some embodiments, relative to a sequence disclosed herein (e.g., a wild-type sequence), an immunogen derivative or epitope derivative disclosed herein comprises 1-2, 1-3, 1-4, 1-5, 1-6, 1-7, 1-8, 1-9, 1-10, 1-15, 1-20, 1-30, 1-40, 2-3, 2-4, 2-5, 2-6, 2-7, 2-8, 2-9, 2-10, 2-15, 2-20, 2-30, 2-40, 3-3, 3-4, 3-5, 3-6, 3-7, 3-8, 3-9, 3-10, 3-15, 3-20, 3-30, 3-40, 5-6, 5-7, 5-8, 5-9, 5-10, 5-15, 5-20, 5-30, 5-40, 10-15, 15-20 or 20-25 amino acid insertions.

[0227] In some embodiments, an immunogen derivative or epitope derivative of the present disclosure comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid insertions relative to a sequence disclosed herein (e.g., a wild-type sequence).

[0228] The one or more amino acid insertions may be at the N-terminus, the C-terminus, within the amino acid sequence, or a combination thereof. The amino acid insertions may be continuous, non-continuous, or a combination thereof.

[0229] Circular polyribonucleotide element

[0230] Circular polyribonucleotides include elements as described below and coronavirus immunogens or epitopes as described herein. In certain embodiments, Circular polyribonucleotides include any combination of any features or features disclosed in International Patent Publication No. WO 2019 / 118919 (hereby incorporated by reference in its entirety).

[0231] In some embodiments, the circular polyribonucleotide is at least about 20 nucleotides, at least about 30 nucleotides, at least about 40 nucleotides, at least about 50 nucleotides, at least about 75 nucleotides, at least about 100 nucleotides, at least about 200 nucleotides, at least about 300 nucleotides, at least about 400 nucleotides, at least about 500 nucleotides, at least about 1,000 nucleotides, at least about 2,000 nucleotides, at least about 5,000 nucleotides, at least about 6,000 nucleotides, or at least about 75 nucleotides. nucleotides, at least about 7,000 nucleotides, at least about 8,000 nucleotides, at least about 9,000 nucleotides, at least about 10,000 nucleotides, at least about 12,000 nucleotides, at least about 14,000 nucleotides, at least about 15,000 nucleotides, at least about 16,000 nucleotides, at least about 17,000 nucleotides, at least about 18,000 nucleotides, at least about 19,000 nucleotides, or at least about 20,000 nucleotides.

[0232] In certain embodiments, cyclic polyribonucleotide is 500 nucleotide to 20,000 nucleotide, 1,000 nucleotide to 20,000 nucleotide, 2,000 nucleotide to 20,000 nucleotide or 5,000 nucleotide to 20,000 nucleotide.In certain embodiments, cyclic polyribonucleotide is 500 nucleotide to 10,000 nucleotide, 1,000 nucleotide to 10,000 nucleotide, 2,000 nucleotide to 10,000 nucleotide or 5,000 nucleotide to 10,000 nucleotide.

[0233] Internal ribosome entry site

[0234] In some embodiments, the circular or linear polyribonucleotides described herein include one or more internal ribosome entry site (IRES) elements. In some embodiments, IRES is operably connected to one or more expressed sequences (e.g., each IRES is operably connected to one or more expressed sequences, wherein each expressed sequence optionally encodes an immunogen, such as a coronavirus immunogen). In an embodiment, IRES is located between the 5' end of a heterologous promoter and a coding sequence (e.g., a coding sequence encoding a coronavirus immunogen).

[0235] Suitable IRES elements included in the polyribonucleotide include RNA sequences that can engage eukaryotic ribosomes. In certain embodiments, the IRES element is at least about 5nt, at least about 8nt, at least about 9nt, at least about 10nt, at least about 15nt, at least about 20nt, at least about 25nt, at least about 30nt, at least about 40nt, at least about 50nt, at least about 100nt, at least about 200nt, at least about 250nt, at least about 350nt or at least about 500nt.

[0236] In some embodiments, the IRES element is derived from the DNA of an organism, including but not limited to viruses, mammals, and fruit flies. Such viral DNA can be derived from, but not limited to, picornavirus complementary DNA (cDNA), encephalomyocarditis virus (EMCV) cDNA, and poliovirus cDNA. In one embodiment, the fruit fly DNA from which the IRES element is derived includes but is not limited to the antennapedia gene from Drosophila melanogaster.

[0237] In some embodiments, if present, the IRES sequence is an IRES sequence of the following viruses: Taura syndrome virus, Triatoma virus, Theiler's encephalomyelitis virus, Simian virus 40, Solenopsis invicta virus 1, Rhopalosiphum padi virus, Reticuloendotheliosis virus, Fumanpoliovirus 1, Plautia stall intestine virus, Kashmir honey bee virus, Human rhinovirus 2 (HRV-2), Homalodisca coagulata virus-1, Human immunodeficiency virus type 1, Homalodisca coagulata virus-1, Himetobi P virus, hepatitis C virus, hepatitis A virus, GB hepatitis virus, foot-and-mouth disease virus, human enterovirus 71, equine rhinitis virus, tea looper (Ectropis obliqua), picorna-like virus, encephalomyocarditis virus (EMCV), fruit fly C virus, crucifer tobacco virus, cricket paralysis virus, bovine viral diarrhea virus 1, black queen cell virus, aphid lethal paralysis virus, avian encephalomyelitis virus (AEV), acute bee paralysis virus, Hibiscus chlorotic ringspot virus (Hibiscus chlorotic ringspot virus virus), classical swine fever virus, human FGF2, human SFTPA1, human AML1 / RUNX1, Drosophila antennapedia, human AQP4, human AT1R, human BAG-1, human BCL2, human BiP, human c-IAPl, human c-myc, human eIF4G, mouse NDST4L, human LEF1, mouse HIF1α, human n.myc, mouse Gtx, human p27kipl, human PDGF2 / c-sis, human p53, human Pim-1, mouse Rbm3, Drosophila reaper, canine Scamper, Drosophila Ubx, human UNR, mouse UtrA, human VEGF-A, human XIAP, Salivirus, Cosavirus, Parechovirus, Drosophila hairless, S.cerevisiae) TFIID, Saccharomyces cerevisiae YAP1, human c-src, human FGF-1, simian picornavirus, Turnip crinkle virus, Aichivirus, Crohivirus, Echovirus 11, eIF4G aptamer, Coxsackievirus B3 (CVB3) or Coxsackievirus A (CVB1 / 2). In yet another embodiment, the IRES is the IRES sequence of Coxsackievirus B3 (CVB3). In another embodiment, the IRES is the IRES sequence of encephalomyocarditis virus. In another embodiment, the IRES is the IRES sequence of Thiele encephalomyelitis virus. .

[0238] The IRES sequence may have a modified sequence compared to the wild-type IRES sequence. In some embodiments, when the last nucleotide of the wild-type IRES is not a cytosine nucleic acid residue, the last nucleotide of the wild-type IRES sequence may be modified so that it is a cytosine residue. For example, the IRES sequence may be a CVB3 IRES sequence, in which the terminal adenosine residue is modified to a cytosine residue. In some embodiments, the modified CVB3 IRES may have the following nucleic acid sequence:

[0239] TTAAAACAGCCTGTGGGTTGATCCCACCCACAGGCCCATTGGGCGCTAGCA

[0240] CTCTGGTATCACGGTACCTTTGTGCGCCTGTTTTATACCCCCTCCCCCAACTG

[0241] TAACTTAGAAGTAACACACACCGATCAACAGTCAGCGTGGCACACCAGCCA

[0242] CGTTTTGATCAAGCACTTCTGTTACCCGGACTGAGTATCAATAGACTGCTC

[0243] ACGCGGTTGAAGGAGAAAGCGTTCGTTATCCGGCCAACTACTTCGAAAAAC

[0244] CTAGTAACACCGTGGAAGTTGCAGAGTGTTTCGCTCAGCACTACCCCAGTGT

[0245] AGATCAGGTCGATGAGTCACCGCATTCCCCACGGGCGACCGTGGCGGTGGC

[0246] TGCGTTGGCGGCCTGCCCATGGGGAAACCCATGGGACGCTTCTAATACAGAC

[0247] ATGGTGCGAAGAGTCTATTGAGCTAGTTGGTAGTCCTCCGGCCCTGAATGC

[0248] GGCTAATCCTAACTGCGGAGCACACACCCTCAAGCCAGAGGGCAGTGTGTC

[0249] GTAACGGGCAACTCTGCAGCGGAACCGACTACTTTGGGTGTCCGTGTTTCAT

[0250] TTTATTCCTATACTGGCTGCTTATGGTGACAATTGAGAGATCGTTACCATATAG

[0251] CTATTGGATTGGCCATCCGGTGACTAATAGAGCTATTATATATCCCTTTGTTGG

[0252] GTTTATACCACTTAGCTTGAAAGAGGTTAAAACATTACAATTCATTGTTAAGTTGAATACAGCAAC(SEQ ID NO:305)

[0253] In some embodiments, the IRES sequence is an enterovirus 71 (EV17) IRES. In some embodiments, the terminal guanosine residue of the EV17 IRES sequence is modified to a cytosine residue. In some embodiments, the modified EV71 IRES may have the following nucleic acid sequence:

[0254] TTAAAACAGCTGTGGGTTGTCACCCACCCACAGGGTCCACTGGGCGCTAGT

[0255] ACACTGGTATCTCGGTACCTTTGTACGCCTGTTTTATACCCCCTCCCTGATTTG

[0256] CAACTTAGAAGCAACGCAAACCAGATCAATAGTAGGTGTGACATACCAGTC

[0257] GCATCTTGATCAAGCACTTCTGTATCCCCGGACCGAGTATCAATAGACTGTGC

[0258] ACACGGTTGAAGGAGAAAACGTCCGTTACCCGGCTAACTACTTCGAGAAGC

[0259] CTAGTAACGCCATTGAAGTTGCAGAGTGTTTCGCTCAGCACTCCCCCCGTGT

[0260] AGATCAGGTCGATGAGTCACCGCATTCCCCACGGGCGACCGTGGCGGTGGC

[0261] TGCGTTGGCGGCCTGCCTATGGGGTAACCCATAGGACGCTCTAATACGGACA

[0262] TGGCGTGAAGAGTCTATTGAGCTAGTTAGTAGTCCTCCGGCCCCTGAATGCG

[0263] GCTAATCCTAACTGCGGAGCACATACCCTTAATCCAAAGGGCAGTGTGTCGT

[0264] AACGGGCAACTCTGCAGCGGAACCGACTACTTTGGGTGTCCGTGTTTCTTTT

[0265] TATTCTTGTATTGGCTGCTTATGGTGACAATTAAAGAATTGTTACCATATAGCT

[0266] ATTGGATTGGCCATCCAGTGTCAAACAGAGCTATTGTATATCTCTTTGTTGGA

[0267] TTCACACCTCTCACTCTTGAAACGTTACACACCCTCAATTACATTATACTGCTGAACACGAAGCGGCCACC(SEQ ID NO:306)

[0268] In some embodiments, the polyribonucleotide includes at least one IRES flanking at least one (e.g., 2, 3, 4, 5 or more) expressed sequence. In some embodiments, the IRES flanks at least one (e.g., 2, 3, 4, 5 or more) expressed sequence on both sides. In some embodiments, the polyribonucleotide includes one or more IRES sequences on one or both sides of each expressed sequence, resulting in the separation of one or more peptides and or one or more polypeptides. For example, the polyribonucleotides described herein may include a first IRES operably connected to a first expressed sequence (e.g., encoding a first immunogen, such as a first coronavirus immunogen) and a second IRES operably connected to a second expressed sequence (e.g., encoding a second immunogen, such as a second coronavirus immunogen).

[0269] In some embodiments, the polyribonucleotides described herein include an IRES (eg, an IRES operably linked to a coding region). For example, the polyribonucleotide may include any IRES as described in: Chen et al. Mol. Cell 81(20):4300-4318, 2021; Jopling et al. Oncogene 20:2664-2670, 2001; Baranick et al. PNAS 105(12):4733-4738, 2008; Lang et al. Molecular Biology of the Cell 13(5):1792-1801, 2002; Dorokhov et al. PNAS 99(8):5301-5306, 2002; Wang et al. Nucleic Acids Research 33(7):2248-2258, 2005; Petz et al. Nucleic Acids Research [Nucleic Acids Research] 35(8):2473-2482, 2007, Chen et al. Science [Science] 268:415-417, 1995; Fan et al. Nature Communication [Nature Communication] 13(1):3751-3765, 2022, and International Publication No. WO 2021 / 263124, each of which is hereby incorporated by reference in its entirety.

[0270] signal sequence

[0271] In some embodiments, the immunogens expressed by the circular or linear polyribonucleotides disclosed herein include secretory proteins, such as proteins that naturally include a signal sequence, or proteins that do not normally encode a signal sequence but are modified to contain a signal sequence. In some embodiments, one or more immunogens include a secretion signal. For example, the secretion signal can be a naturally encoded secretion signal of a secretory protein. In another example, the secretion signal can be a modified secretion signal of a secretory protein. In other embodiments, one or more immunogens do not include a secretion signal.

[0272] In certain embodiments, polyribonucleotides encode multiple copies (e.g., one, two, three, four, five, six, seven, eight, nine, ten or more) of the same immunogen. In certain embodiments, at least one copy of the immunogen includes a signal sequence, and at least one copy of the immunogen does not include a signal sequence. In certain embodiments, cyclic polyribonucleotides encode multiple immunogens, wherein at least one of the multiple immunogens includes a signal sequence, and at least one copy of the multiple immunogens does not include a signal sequence.

[0273] In certain embodiments, the signal sequence is a wild-type signal sequence, which is present at the N-terminal of a corresponding wild-type immunogen when endogenous expression, for example. In certain embodiments, the signal sequence is an immunogen heterologous, for example, non-existent when a wild-type immunogen is endogenously expressed. The polyribonucleotide sequence encoding the immunogen can be modified to remove the nucleotide sequence encoding the wild-type signal sequence and / or to add a sequence encoding a heterologous signal sequence.

[0274] The cyclic polyribonucleotide may further include one or more adjuvants, and each adjuvant has or does not have a signal sequence. In certain embodiments, the cyclic polyribonucleotide encodes at least one adjuvant and at least one immunogen. In certain embodiments, the adjuvant of at least one encoding includes a signal sequence and the immunogen of the at least one encoding does not include a signal sequence. In certain embodiments, the adjuvant of at least one encoding includes a signal sequence and the immunogen of the at least one encoding includes a signal sequence. In certain embodiments, the adjuvant of at least one encoding does not include a signal sequence and the immunogen of the at least one encoding includes a signal sequence. In certain embodiments, the adjuvant of at least one encoding does not include a signal sequence and the immunogen of the at least one encoding includes a signal sequence. In certain embodiments, the adjuvant of encoding and the immunogen of encoding do not include a signal sequence.

[0275] In certain embodiments, the signal sequence is a wild-type signal sequence, which is present at the N-terminus of a corresponding wild-type adjuvant, for example, when endogenously expressed. In certain embodiments, the signal sequence is heterologous to the adjuvant, for example, when the wild-type adjuvant is endogenously expressed, and is non-existent. The polyribonucleotide sequence encoding the adjuvant can be modified to remove the nucleotide sequence encoding the wild-type signal sequence and / or to add a sequence encoding a heterologous signal sequence.

[0276] The polypeptide encoded by polyribonucleotide (for example, the immunogen or adjuvant encoded by polyribonucleotide) can include the signal sequence that immunogen or adjuvant is directed to secretory pathway.In certain embodiments, the signal sequence can direct immunogen or adjuvant to reside in certain organelles (for example, endoplasmic reticulum, Golgi body or endosome).In certain embodiments, the signal sequence directs immunogen or adjuvant to secretion from cells.For secreted protein, the signal sequence can be cut after secretion, thereby producing mature protein.In other embodiments, the signal sequence can be embedded in cell membrane or certain organelles, produces transmembrane segment, and transmembrane segment anchors protein to cell membrane, endoplasmic reticulum or Golgi body.In certain embodiments, the signal sequence of transmembrane protein is the short sequence at polypeptide N end.In other embodiments, the first transmembrane domain serves as the first signal sequence, by protein targeting film.

[0277] In some embodiments, the secretion signal is a human interleukin-2 (IL-2) secretion signal. In some embodiments, the IL-2 secretion signal has an amino acid sequence having at least 90% sequence identity to MYRMQLLSCIALSLALVTNS (SEQ ID NO: 199). In some embodiments, the IL2 secretion signal has an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 199. In some embodiments, the IL-2 secretion signal has an amino acid sequence having at least 99% sequence identity to SEQ ID NO: 199. In some embodiments, the IL-2 secretion signal has an amino acid sequence having 100% sequence identity to SEQ ID NO: 199.

[0278] In some embodiments, the secretion signal is a Gaussia luciferase secretion signal. In some embodiments, the Gaussia luciferase secretion signal has an amino acid sequence having at least 90% sequence identity to MGVKVLFALICIAVAEAK (SEQ ID NO: 198). In some embodiments, the Gaussia luciferase secretion signal has an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 198. In some embodiments, the Gaussia luciferase secretion signal has an amino acid sequence having at least 99% sequence identity to SEQ ID NO: 198. In some embodiments, the Gaussia luciferase secretion signal has an amino acid sequence having 100% sequence identity to SEQ ID NO: 198.

[0279] In some embodiments, the secretion signal is an EPO (e.g., human EPO) secretion signal. In some embodiments, the EPO secretion signal has an amino acid sequence having at least 90% sequence identity to MGVHECPAWLWLLLSLLSLPLGLPVLGA (SEQ ID NO: 197). In some embodiments, the EPO secretion signal has an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 197. In some embodiments, the EPO secretion signal has an amino acid sequence having at least 99% sequence identity to SEQ ID NO: 197. In some embodiments, the EPO secretion signal has an amino acid sequence having 100% sequence identity to SEQ ID NO: 197.

[0280] In some embodiments, the secretion signal is a wild-type SARS-CoV-2 secretion signal. In some embodiments, the wild-type SARS-CoV-2 secretion signal has an amino acid sequence having at least 90% sequence identity to MFVFLVLLPLVSS (SEQ ID NO: 200). In some embodiments, the wild-type SARS-CoV-2 secretion signal has an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 200. In some embodiments, the wild-type SARS-CoV-2 secretion signal has an amino acid sequence having at least 99% sequence identity to SEQ ID NO: 200. In some embodiments, the wild-type SARS-CoV-2 secretion signal has an amino acid sequence having 100% sequence identity to SEQ ID NO: 200.

[0281] In some embodiments, the adjuvant encoded by the polyribonucleotide includes a secretion signal sequence. In some embodiments, the immunogen encoded by the polyribonucleotide includes a secretion signal sequence, a transmembrane insertion signal sequence, or does not include a signal sequence.

[0282] Regulatory elements

[0283] The regulatory element can include a sequence adjacent to the expressed sequence of the encoding expression product. The regulatory element can be operably connected to an adjacent sequence. Compared with the amount of the product expressed when there is no regulatory element, the regulatory element can increase the amount of the product expressed. The regulatory element can be used to increase the expression of one or more immunogens and / or adjuvants encoded by polyribonucleotides. Similarly, the regulatory element can be used to reduce the expression of one or more immunogens and / or adjuvants encoded by polyribonucleotides. In certain embodiments, the regulatory element can be used to increase the expression of immunogens and / or adjuvants, and another regulatory element can be used to reduce the expression of another immunogen and / or adjuvant on the same polyribonucleotide. In addition, a regulatory element can increase the amount of the product (for example, immunogen or adjuvant) expressed by multiple expressed sequences attached in series. Therefore, a regulatory element can enhance the expression of one or more expressed sequences (for example, immunogen or adjuvant). A variety of regulatory elements can also be used, for example, differentially regulating the expression of different expressed sequences.

[0284] In certain embodiments, control element provided herein can include selective translation sequence.As used herein, term " selective translation sequence " refers to the nucleotide sequence of selectively starting or activating the translation of expressed sequence in polyribonucleotide, such as some riboswitch aptamers.Control element can also include selective degradation sequence.As used herein, term " selective degradation sequence " refers to the nucleotide sequence of initial polyribonucleotide or polyribonucleotide expression product degradation.In certain embodiments, control element is translation regulator.Translation regulator can regulate the translation of expressed sequence in polyribonucleotide.Translation regulator can be translation enhancer or translation repressor.In certain embodiments, translation initiation sequence can serve as control element.

[0285] In certain embodiments, polyribonucleotide produces the expression product of stoichiometric ratio.Rolling circle translation produces expression product continuously with substantially equal ratio.In certain embodiments, polyribonucleotide has stoichiometric translation efficiency, makes expression product produce with substantially equal ratio.In certain embodiments, polyribonucleotide has the stoichiometric translation efficiency of multiple expression product (for example, from the product of 2,3,4,5,6,7,8,9,10,11,12 or more expression sequence).In certain embodiments, polyribonucleotide produces the expression product of substantially different ratio.For example, the translation efficiency of multiple expression product can have following ratio: 1:10,000,1:7000,1:5000,1:1000,1:700,1:500,1:100,1:50,1:10,1:5,1:4,1:3 or 1:2.In certain embodiments, regulating and controlling element can be used to modify the ratio of multiple expression products.

[0286] Other examples of regulatory elements are described in paragraphs

[0154] -

[0161] of International Patent Publication No. WO 2019 / 118919, which is hereby incorporated by reference in its entirety.

[0287] Cleavage domain

[0288] The circular or linear polyribonucleotides of the present disclosure may include a cleavage domain (eg, a staggered element or a cleavage sequence).

[0289] As used herein, the term "staggered element" is a portion that induces ribosome pauses during translation, such as a nucleotide sequence. In some embodiments, the staggered element is a non-conservative sequence of amino acids with a strong alpha helical tendency, followed by a consensus sequence-D(V / I)ExNPG P (SEQ ID NO: 52), where x = any amino acid. In some embodiments, the staggered element may include a chemical moiety, such as glycerol, a non-nucleic acid linking moiety, a chemical modification, a modified nucleic acid, or any combination thereof. In some embodiments, a cyclic or linear polyribonucleotide includes at least one staggered element adjacent to an expressed sequence (such as a sequence encoding a coronavirus immunogen). In some embodiments, a cyclic or linear polyribonucleotide includes a staggered element adjacent to each expressed sequence. In some embodiments, the staggered element is present on one or both sides of each expressed sequence, resulting in, for example, separation of the expression products of one or more immunogens and / or one or more adjuvants. In some embodiments, the staggered element is a part of one or more expressed sequences. In certain embodiments, circular or linear polyribonucleotide comprises one or more expressed sequences (for example, one or more immunogens and / or one or more adjuvants), and each in described one or more expressed sequences is separated by the staggered elements on circular or linear polyribonucleotide and subsequent expressed sequence (for example, one or more immunogens and / or one or more adjuvants).In certain embodiments, staggered elements prevent two rounds of translation of (a) single expressed sequence or one or more rounds of translation of (b) two or more expressed sequences to generate single polypeptide.In certain embodiments, staggered elements are the sequences separated from described one or more expressed sequences.In certain embodiments, staggered elements comprise a part for the expressed sequence of described one or more expressed sequences.

[0290] Examples of interlaced elements are described in paragraphs

[0172] -

[0175] of International Patent Publication No. WO 2019 / 118919, which is hereby incorporated by reference in its entirety.

[0291] In some embodiments, a variety of immunogens and / or adjuvants encoded by cyclic ribonucleotides can be separated by IRES between each immunogen (e.g., each immunogen is operably connected to a separate IRES). For example, a cyclic polyribonucleotide can include a first IRES operably connected to a first expressed sequence and a second IRES operably connected to a second expressed sequence. The IRES between all immunogens can be the same IRES. The IRES between different immunogens can be different.

[0292] In some embodiments, multiple immunogens and / or adjuvants can be separated by the 2A self-cleaving peptide. For example, a cyclic polyribonucleotide can encode an IRES operably linked to an open reading frame encoding a first immunogen, 2A, and a second immunogen. In some embodiments, 2A can have a sequence of GSGATNFSLLKQAGDVEENPGP (SEQ ID NO: 202).

[0293] In certain embodiments, multiple immunogens and / or adjuvants can be separated by a protease cleavage site (e.g., a furin cleavage site). For example, a cyclic polyribonucleotide can encode an IRES that is operably connected to an open reading frame encoding a first immunogen, a protease cleavage site (e.g., a furin cleavage site) and a second immunogen. In certain embodiments, the furin cleavage site can have a sequence (SEQ ID NO:201) of GRLRR. In certain embodiments, the furin cleavage site can have a sequence (SEQ ID NO:203) of GRLRR.

[0294] In certain embodiments, multiple immunogens and / or adjuvants can be separated by 2A self-cleavage peptide and protease cleavage site (e.g., furin cleavage site). For example, cyclic polyribonucleotides can encode an IRES operably connected to an open reading frame encoding the first immunogen, 2A, a protease cleavage site (e.g., furin cleavage site) and a second immunogen. Circular polyribonucleotides can also encode an IRES operably connected to an open reading frame encoding the first immunogen, a protease cleavage site (e.g., furin cleavage site), 2A and a second immunogen. Series 2A and furin cleavage site can be referred to as furin-2A (which includes furin-2A or 2A-furin arranged in either direction).

[0295] In addition, a variety of immunogens and / or adjuvants encoded by cyclic ribonucleotides can be separated by both IRES and 2A sequences. For example, an IRES can be between an immunogen and / or adjuvant and a second immunogen and / or adjuvant, and a 2A peptide can be between a second immunogen and / or adjuvant and a third immunogen and / or adjuvant. The selection of a specific IRES or 2A self-cleaving peptide can be used to control the expression level of an immunogen and / or adjuvant under the control of an IRES or 2A sequence. For example, expression on a polypeptide can be higher or lower depending on the selected IRES and / or 2A peptide.

[0296] In order to avoid producing continuous expression products, such as immunogens and / or adjuvants, while keeping rolling circle translation, staggered elements can be included to induce ribosomes to pause during translation. In certain embodiments, staggered elements are at the 3' end of at least one of the one or more expressed sequences. Staggered elements can be configured to stagnate ribosomes during the rolling circle translation of circular or linear polyribonucleotides. Staggered elements can include but are not limited to 2A samples or CHYSEL (SEQ ID NO:175) (cis-acting hydrolase elements) sequences. In certain embodiments, staggered element encoding has a sequence with a C-terminal consensus sequence, and the consensus sequence is X 1 X 2 X 3 EX 5 NPGP, where X 1 Does not exist or is G or H, X 2 Does not exist or is D or G, X 3 is D or V or I or S or M, and X 5is any amino acid (SEQ ID NO: 176). Some non-limiting examples of staggered elements include GDVESNPGP (SEQ ID NO: 177), GDIEENPGP (SEQ ID NO: 178), VEPNPGP (SEQ ID NO: 179), IETNPGP (SEQ ID NO: 180), GDIESNPGP (SEQ ID NO: 181), GDVELNPGP (SEQ ID NO: 182), GDIETNPGP (SEQ ID NO: 183), GDVENPGP (SEQ ID NO: 184), GDVEENPGP (SEQ ID NO: 185), GDVEQNPGP (SEQ ID NO: 186), IESNPGP (SEQ ID NO: 187), GDIELNPGP (SEQ ID NO: 188), HDIETNPGP (SEQ ID NO: 189), HDVETNPGP (SEQ ID NO: 190), HDVEMNPGP (SEQ ID NO: 191), GDMESNPGP (SEQ ID NO: 192), GDVETNPGP (SEQ ID NO: 193), NO:193), GDIEQNPGP (SEQ ID NO:194) and DSEFNPGP (SEQ ID NO:195).

[0297] In certain embodiments, staggered element cracking expression product as herein described, such as between G and P of consensus sequence as herein described.As a non-limiting example, circular or linear polyribonucleotide comprises at least one staggered element with cracking expression product.In certain embodiments, circular or linear polyribonucleotide comprises the staggered element adjacent to at least one expressed sequence.In certain embodiments, circular or linear polyribonucleotide is included in the staggered element after each expressed sequence.In certain embodiments, circular or linear polyribonucleotide comprises the staggered element that is present in one side or both sides of each expressed sequence, causes one or more individual peptides and / or polypeptides to be translated by each expressed sequence.

[0298] In certain embodiments, the staggered elements include one or more modified nucleotides or non-natural nucleotides that induce ribosomes to pause during translation. Non-natural nucleotides can include peptide nucleic acids (PNA), morpholinos and locked nucleic acids (LNA), and glycol nucleic acids (GNA) and threose nucleic acids (TNA). Examples such as these are different from naturally occurring DNA or RNA by changing the molecular backbone. Exemplary modifications can include any modification and any combination thereof that can induce ribosomes to pause during translation to sugar, core bases, internucleoside bonds (e.g., to the phosphate ester connected / to the phosphodiester bond / to the phosphodiester backbone). Some exemplary modifications provided herein are described elsewhere herein.

[0299] In certain embodiments, staggered elements are present in cyclic or linear polyribonucleotides in other forms.For example, in some exemplary cyclic or linear polyribonucleotides, staggered elements include the terminator element of the first expressed sequence in cyclic or linear polyribonucleotides, and the nucleotide spacer sequence of the first translation initiation sequence separating the terminator element and the first expressed sequence subsequent expression.In some instances, the first staggered element of the first expressed sequence is upstream (5 ') of the first translation initiation sequence of the first expressed sequence subsequent expression in cyclic or linear polyribonucleotides.In some cases, the first expressed sequence and the first expressed sequence subsequent expression sequence are two separated expressed sequences in cyclic or linear polyribonucleotides.The distance between the first staggered element and the first translation initiation sequence can enable the first expressed sequence and its subsequent expressed sequence to be continuously translated.In certain embodiments, the first staggered element includes the terminator element, and the expression product of the first expressed sequence is separated from the expression product of its subsequent expressed sequence, thereby producing discrete expression products. In some cases, the first translation initiation sequence upstream of subsequent sequence in circular or linear polyribonucleotide comprises the circular or linear polyribonucleotide of the first staggered element and is translated continuously, and the corresponding circular or linear polyribonucleotide comprising the staggered element of the second expressed sequence upstream of the second translation initiation sequence of the second expressed sequence subsequent expressed sequence is not translated continuously.In some cases, there is only an expressed sequence in circular or linear polyribonucleotide, and the first expressed sequence and its subsequent expressed sequence are identical expressed sequences.In some exemplary circular or linear polyribonucleotides, staggered element comprises the first termination element of the first expressed sequence in circular or linear polyribonucleotide, and separates the nucleotide spacer sequence of termination element and downstream translation initiation sequence.In some such examples, the first staggered element in circular or linear polyribonucleotide is upstream (5 ') of the first translation initiation sequence of the first expressed sequence.In some cases, the distance between the first staggered element and the first translation initiation sequence enables the first expressed sequence and any subsequent expressed sequence to be translated continuously. In certain embodiments, the first staggered element separates a round expression product of the first expressed sequence from the next round expression product of the first expressed sequence, thereby produces discrete expression product.In some cases, the first translation initiation sequence upstream of the first expressed sequence in ring-type or linear polyribonucleotide comprises that the ring-type or linear polyribonucleotide of the first staggered element is translated continuously, and the second translation initiation sequence upstream of the second expressed sequence in corresponding ring-type or linear polyribonucleotide comprises that the corresponding ring-type or linear polyribonucleotide of staggered element is not translated continuously.In some cases, the distance between the second staggered element and the second translation initiation sequence in corresponding ring-type or linear polyribonucleotide is at least 2 times, 3 times, 4 times, 5 times, 6 times, 7 times, 8 times, 9 times or 10 times of the distance between the first staggered element and the first translation initiation sequence in ring-type or linear polyribonucleotide.In some cases, the distance between the first staggered element and the first translation start is at least 2nt, 3nt, 4nt, 5nt, 6nt, 7nt, 8nt, 9nt, 10nt, 11nt, 12nt, 13nt, 14nt, 15nt, 16nt, 17nt, 18nt, 19nt, 20nt, 25nt, 30nt, 35nt, 40nt, 45nt, 50nt, 55nt, 60nt, 65nt, 70nt, 75nt or more. In certain embodiments, the distance between the second staggered element and the second translation initiation is at least 2nt, 3nt, 4nt, 5nt, 6nt, 7nt, 8nt, 9nt, 10nt, 11nt, 12nt, 13nt, 14nt, 15nt, 16nt, 17nt, 18nt, 19nt, 20nt, 25nt, 30nt, 35nt, 40nt, 45nt, 50nt, 55nt, 60nt, 65nt, 70nt, 75nt or greater than the distance between the first staggered element and the first translation initiation.In certain embodiments, ring-type or linear polyribonucleotide comprise more than one expressed sequence.

[0300] In some embodiments, the cyclic or linear polyribonucleotide includes at least one cleavage sequence. In some embodiments, the cleavage sequence is adjacent to the expressed sequence. In some embodiments, the cleavage sequence is between two expressed sequences. In some embodiments, the cleavage sequence is included in the expressed sequence. In some embodiments, the cyclic or linear polyribonucleotide includes 2 to 10 cleavage sequences. In some embodiments, the cyclic or linear polyribonucleotide includes 2 to 5 cleavage sequences. In some embodiments, multiple cleavage sequences are between multiple expressed sequences; for example, the cyclic or linear polyribonucleotide may include three expressed sequences and two cleavage sequences, so that there is a cleavage sequence between each expressed sequence. In some embodiments, the cyclic or linear polyribonucleotide includes a cleavage sequence, such as in a sacrificial circRNA or a cleavable circRNA or a self-cleaving circRNA. In some embodiments, the cyclic or linear polyribonucleotide includes two or more cleavage sequences, resulting in the separation of the cyclic or linear polyribonucleotide into multiple products, such as miRNA, linear RNA, smaller cyclic or linear polyribonucleotides, etc.

[0301] In certain embodiments, the cleavage sequence includes a ribozyme RNA sequence. Ribozyme (from ribonuclease, also referred to as RNA enzyme or catalytic RNA) is an RNA molecule that catalyzes chemical reactions. Many natural ribozymes catalyze the hydrolysis of one of the phosphodiester bonds of themselves, or catalyze the hydrolysis of the bonds in other RNAs, but it is also found that natural ribozymes catalyze the aminotransferase activity of ribosomes. Catalytic RNA can be "evolved" by in vitro methods. Similar to the riboswitch activity discussed above, ribozymes and their reaction products can regulate gene expression. In certain embodiments, catalytic RNA or ribozyme can be placed in a larger non-coding RNA, which makes the ribozyme present in the cell with many copies, for the purpose of chemical conversion of bulky molecules. In certain embodiments, aptamers and ribozymes can be encoded in identical non-coding RNA.

[0302] In certain embodiments, the cleavage sequence encodes a cleavable polypeptide linker. For example, polyribonucleotides can encode two or more immunogens, for example, wherein the two or more immunogens are encoded by a single open reading frame (ORF). For example, two or more immunogens can be encoded by a single open reading frame, and the expression of the open reading frame is controlled by IRES. In certain embodiments, ORF further encodes a polypeptide linker, for example, so that the expression product of ORF encodes two or more immunogens, and each immunogen is separated by the sequence of the encoded polypeptide linker (for example, 5-200, 5 to 100, 5 to 50, 5 to 20, 50 to 100 or 50 to 200 amino acid linkers). The polypeptide linker can include a cleavage site, for example, a cleavage site recognized and cut by a protease (for example, an endogenous protease in a subject after the polyribonucleotide is applied to the subject). In such an embodiment, a single expression product comprising the amino acid sequence of two or more immunogens is cracked when expressed, so that the two or more immunogens are separated after expression. Exemplary protease cleavage sites are known to those skilled in the art, for example, amino acid sequences that serve as protease cleavage sites recognized by metalloproteinases (e.g., matrix metalloproteinases (MMPs), such as any one or more of MMP 1-28), disintegrins and metalloproteinases (ADAMs, such as any one or more of ADAM 2, 7-12, 15, 17-23, 28-30, and 33), serine proteases, urokinase-type plasminogen activators, matriptases, cysteine ​​proteases, aspartic proteases, or cathepsins. In some embodiments, the protease is MMP9 and / or MMP2. In some embodiments, the protease is a matriptase.

[0303] In certain embodiments, the cyclic or linear polyribonucleotides described herein are sacrificial cyclic or linear polyribonucleotides, cleavable cyclic or linear polyribonucleotides or self-cleavable cyclic or linear polyribonucleotides. Circular or linear polyribonucleotides can deliver cell components, including, for example, RNA, lncRNA, lincRNA, miRNA, tRNA, rRNA, snoRNA, ncRNA, siRNA or shRNA. In certain embodiments, cyclic or linear polyribonucleotides include miRNA separated by: (i) self-cleavable elements; (ii) cutting recruitment sites; (iii) degradable joints; (iv) chemical joints; and / or (v) spacer sequences. In certain embodiments, circRNA includes siRNA separated by: (i) self-cleavable elements; (ii) cutting recruitment sites (e.g., ADAR); (iii) degradable joints (e.g., glycerol); (iv) chemical joints; and / or (v) spacer sequences. Non-limiting examples of self-cleavable elements include hammerhead structures, splicing elements, hairpins, hepatitis delta virus (HDV), Varkud satellite (VS), and glmS ribozyme.

[0304] In certain embodiments, the cyclic polyribonucleotide comprises at least one staggered element adjacent to an expressed sequence. In certain embodiments, the cyclic polyribonucleotide comprises staggered elements adjacent to each expressed sequence. In certain embodiments, staggered elements are present in one or both sides of each expressed sequence, causing for example the expression product of one or more peptides and / or one or more polypeptides to be separated. In certain embodiments, staggered elements are a part for one or more expressed sequences. In certain embodiments, the cyclic polyribonucleotide comprises one or more expressed sequences, and each of the one or more expressed sequences is separated from the subsequent expressed sequence by the staggered elements on the cyclic polyribonucleotide. In certain embodiments, staggered elements prevent two rounds of translation of (a) a single expressed sequence or one or more rounds of translation of (b) two or more expressed sequences to generate a single polypeptide. In certain embodiments, staggered elements are sequences separated from the one or more expressed sequences. In certain embodiments, staggered elements comprise a part for the expressed sequence in one or more expressed sequences.

[0305] Examples of interlaced elements are described in paragraphs

[0172] -

[0175] of WO 2019 / 118919, which is hereby incorporated by reference in its entirety.

[0306] Translation start sequence

[0307] In certain embodiments, circular or linear polyribonucleotides encode immunogens and include translation initiation sequences, such as start codons. In certain embodiments, circular polyribonucleotides encode immunogens that produce target human polyclonal antibodies and include translation initiation sequences, such as start codons. In certain embodiments, translation initiation sequences include Kozak or Shine-Dalgarno sequences. In certain embodiments, translation initiation sequences include Kozak sequences. In certain embodiments, circular or linear polyribonucleotides include translation initiation sequences adjacent to expressed sequences, such as Kozak sequences. In certain embodiments, translation initiation sequences are non-coding start codons. In certain embodiments, translation initiation sequences, such as Kozak sequences, are present on one or both sides of each expressed sequence, resulting in the separation of expression products. In certain embodiments, circular or linear polyribonucleotides include at least one translation initiation sequence adjacent to expressed sequences. In certain embodiments, translation initiation sequences provide conformational flexibility for circular or linear polyribonucleotides. In certain embodiments, translation initiation sequences are substantially in the single-stranded region of circular or linear polyribonucleotides. Other examples of translation initiation sequences are described in paragraphs

[0163] -

[0165] of International Patent Publication No. WO 2019 / 118919, which is hereby incorporated by reference in its entirety.

[0308] Circular or linear polyribonucleotide can comprise more than 1 start codon, such as but not limited to at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 25, at least 30, at least 35, at least 40, at least 50, at least 60 or more than 60 start codons.Translation can start on first start codon or can start in the downstream of first start codon.

[0309] In certain embodiments, circular or linear polyribonucleotides may be initiated from a codon that is not the first start codon (such as AUG). The translation of circular or linear polyribonucleotides may be initiated at alternative translation initiation sequences, such as those described in

[0164] of International Patent Publication No. WO 2019 / 118919 A1, which are incorporated herein by reference in their entirety.

[0310] In some embodiments, translation is initiated by treating eukaryotic initiation factor 4A (eIF4A) with Rocaglates (repressing translation by blocking 43S scanning, resulting in premature upstream translation initiation and reduced protein expression of transcripts carrying RocA-eIF4A target sequences, see e.g., nature.com / articles / nature17978).

[0311] Untranslated region

[0312] In certain embodiments, circular or linear polyribonucleotides include untranslated regions (UTRs). The UTRs including the genomic regions of genes can be transcribed but not translated. In certain embodiments, UTRs can be included in the upstream of the translation initiation sequence of expressed sequences as described herein. In certain embodiments, UTRs can be included in the downstream of expressed sequences as described herein. In some cases, a UTR of the first expressed sequence is identical or continuous or overlapping with another UTR of the second expressed sequence. In certain embodiments, introns are human introns. In certain embodiments, introns are full-length human introns, such as ZKSCAN1.

[0313] Exemplary untranslated regions are described in paragraphs

[0197] -

[201] of International Patent Publication No. WO 2019 / 118919, which is hereby incorporated by reference in its entirety.

[0314] In certain embodiments, the cyclic polyribonucleotide includes a poly A sequence. Exemplary poly A sequences are described in paragraphs

[0202] -

[0205] of International Patent Publication No. WO 2019 / 118919, which are hereby incorporated by reference in their entirety. In certain embodiments, the cyclic polyribonucleotide lacks a poly A sequence.

[0315] In some embodiments, the cyclic or linear polyribonucleotide comprises a UTR in which one or more stretches of adenosine and uridine are embedded. These AU-enriched signatures may increase the conversion rate of the expression product.

[0316] The introduction, removal or modification of UTR AU enrichment elements (AU rich element, ARE) can be used to regulate the stability or immunogenicity (e.g., the level of one or more markers of immune or inflammatory response) of cyclic or linear polyribonucleotides. During engineering of specific cyclic polyribonucleotides, one or more copies of ARE can be introduced into the cyclic polyribonucleotide, and the copies of ARE can regulate the translation and / or production of the expression product. Similarly, ARE can be identified and removed or engineered to cyclic polyribonucleotides to regulate intracellular stability, thereby affecting the translation and production of the resulting protein.

[0317] It will be appreciated that any UTR from any gene may be incorporated into the corresponding flanking regions of a circular polyribonucleotide.

[0318] In some embodiments, the cyclic polyribonucleotide lacks 5'-UTR, and can express proteins from one or more expressed sequences. In some embodiments, the cyclic or linear polyribonucleotide lacks 3'-UTR, and can express proteins from one or more expressed sequences. In some embodiments, the cyclic or linear polyribonucleotide lacks a poly-A sequence, and can express proteins from one or more expressed sequences. In some embodiments, the cyclic or linear polyribonucleotide lacks a termination element, and can express proteins from one or more expressed sequences. In some embodiments, the cyclic or linear polyribonucleotide lacks an internal ribosome entry site, and can express proteins from one or more expressed sequences. In some embodiments, the cyclic or linear polyribonucleotide lacks a cap, and can express proteins from one or more expressed sequences. In some embodiments, the cyclic or linear polyribonucleotide lacks 5'-UTR, 3'-UTR and IRES, and can express proteins from one or more expressed sequences. In some embodiments, the circular or linear polyribonucleotide comprises one or more of the following sequences: sequences encoding one or more miRNAs, sequences encoding one or more replication proteins, sequences encoding exogenous genes, sequences encoding therapeutic agents, regulatory elements (e.g., translation regulators, e.g., translation enhancers or repressors), translation initiation sequences, one or more regulatory nucleic acids targeting endogenous genes (e.g., siRNA, lncRNA, shRNA), and sequences encoding therapeutic mRNA or proteins.

[0319] In some embodiments, cyclic or linear polyribonucleotides lack 5'-UTR. In some embodiments, cyclic polyribonucleotides lack 3'-UTR. In some embodiments, cyclic polyribonucleotides lack poly A sequences. In some embodiments, cyclic or linear polyribonucleotides lack termination elements. In some embodiments, cyclic or linear polyribonucleotides lack internal ribosome entry sites. In some embodiments, cyclic or linear polyribonucleotides lack susceptibility to degradation by exonucleases. In some embodiments, the fact that cyclic polyribonucleotides lack degradation susceptibility can mean that cyclic polyribonucleotides are not degraded by exonucleases, or only degrade to a limited extent in the presence of exonucleases, for example, quite or similar to the absence of exonucleases. In some embodiments, cyclic polyribonucleotides are not degraded by exonucleases. In some embodiments, when exposed to exonucleases, cyclic polyribonucleotide degradation is reduced. In some embodiments, cyclic polyribonucleotides lack the combination with cap-bound proteins. In some embodiments, cyclic polyribonucleotides lack 5' caps.

[0320] Termination element

[0321] In certain embodiments, polyribonucleotide as herein described comprises at least one termination element.In certain embodiments, polyribonucleotide comprises the termination element operably connected with expressed sequence.In certain embodiments, polynucleotide lacks termination element.

[0322] In certain embodiments, polyribonucleotide comprises one or more expressed sequences, and each expressed sequence may or may not have a terminator. In certain embodiments, polyribonucleotide comprises one or more expressed sequences, and expressed sequence lacks a terminator so that polyribonucleotide is translated continuously. The exclusion of the terminator can cause rolling circle translation or the continuous expression of expression product.

[0323] In certain embodiments, the cyclic polyribonucleotide includes one or more expressed sequences, and each expressed sequence may or may not have a termination element. In certain embodiments, the cyclic polyribonucleotide includes one or more expressed sequences, and the expressed sequence lacks a termination element so that the cyclic polyribonucleotide is translated continuously. Due to the lack of ribosome stagnation or falling off, the exclusion of the termination element can cause rolling circle translation or continuous expression of expression product (such as peptide or polypeptide). In such embodiments, rolling circle translation expresses continuous expression product by each expressed sequence. In some other embodiments, the termination element of an expressed sequence can be a part of an interlaced element. In certain embodiments, one or more expressed sequences in the cyclic polyribonucleotide include a termination element. However, rolling circle translation or subsequent (such as, the second, third, fourth, fifth, etc.) expression of an expressed sequence is carried out in the cyclic polyribonucleotide. In such cases, when ribosome encounters a termination element (such as, a stop codon) and stops translation, the expression product can fall off from the ribosome. In certain embodiments, translation stops when ribosome such as at least one subunit of the ribosome keeps contact with the cyclic polyribonucleotide.

[0324] In certain embodiments, the cyclic polyribonucleotide comprises a terminator at the end of one or more expressed sequences. In certain embodiments, one or more expressed sequences comprise two or more continuous terminators. In such embodiments, translation stops and rolling circle translation stops. In certain embodiments, ribosomes are completely separated from cyclic polyribonucleotides. In some such embodiments, producing subsequent (for example, the second, third, fourth, fifth, etc.) expressed sequences in cyclic polyribonucleotides may require ribosomes to reengage with cyclic polyribonucleotides before translation initiation. Usually, terminator comprises a nucleotide triplet (for example, UAA, UGA, UAG) in the frame that sends a translation termination signal. In certain embodiments, one or more terminators in cyclic polyribonucleotides are terminators of frame shifts, such as but not limited to the reading frame shift that can stop translation or the reading frame (for example, hidden terminator) of -1 and +1 shifts. The terminator of frame shifts comprises the nucleotide triplet that appears in the second reading frame and the third reading frame of the expressed sequence, TAA, TAG and TGA. The terminator of frame shifts may be important to prevent the mRNA misreading that is usually harmful to cells. In some embodiments, the termination element is a stop codon.

[0325] In some embodiments, the expressed sequence includes a poly A sequence (e.g., at the 3' end of the expressed sequence, such as 3' of the termination element). In some embodiments, the poly A sequence is greater than 10 nucleotides in length. In one embodiment, the poly A sequence is greater than 15 nucleotides in length (e.g., at least or greater than about 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, 120, 140, 160, 180, 200, 250, 300, 350, 400, 450, 500, 600, 700, 800, 900, 1,000, 1,100, 1,200, 1,300, 1,400, 1,500, 1,600, 1,700, 1,800, 1,900, 2,000, 2,500, and 3,000 nucleotides). In some embodiments, the poly A sequence is designed according to the description of the poly A sequence in

[0202] -

[0204] of International Patent Publication No. WO 2019 / 118919 A1, which is incorporated herein by reference in its entirety. In some embodiments, the expressed sequence lacks a poly A sequence (e.g., at the 3' end of the expressed sequence).

[0326] In certain embodiments, cyclic polyribonucleotide comprises poly-A, lacks poly-A or has modified poly-A to regulate one or more features of cyclic polyribonucleotide.In certain embodiments, lack poly-A or have modified cyclic polyribonucleotide of poly-A to improve one or more functional characteristics, such as immunogenicity (for example, the level of one or more marks of immunity or inflammatory response), half-life and / or expression efficiency.

[0327] Other examples of termination elements are described in paragraphs

[0169] -

[0170] of International Patent Publication No. WO 2019 / 118919, which is hereby incorporated by reference in its entirety.

[0328] Spacer sequence

[0329] In certain embodiments, polyribonucleotides as described herein include spacer sequences. In certain embodiments, polyribonucleotides as described herein include one or more spacer sequences. Spacer refers to any continuous nucleotide sequence (for example, one or more nucleotides) providing distance or flexibility between two adjacent polynucleotide regions. Spacer can be present between any nucleic acid element as described herein. Spacer can also be present in nucleic acid elements as described herein.

[0330] The length of the spacer can be, for example, at least 5 (for example, at least 10, at least 15, at least 20) ribonucleotides. In certain embodiments, the length of each spacer region is at least 5 (for example, at least 10, at least 15, at least 20) ribonucleotides. The length of each spacer region can be, for example, 5 to 500 (for example, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450 or 500) ribonucleotides. The first spacer region, the second spacer region, or the first spacer region and the second spacer region may include a poly-A sequence. The first spacer region, the second spacer region, or the first spacer region and the second spacer region may include a poly-AC sequence. In certain embodiments, the first spacer region, the second spacer region, or the first spacer region and the second spacer region include a poly-AG sequence. In certain embodiments, the first spacer region, the second spacer region, or the first spacer region and the second spacer region include a poly-AT sequence. In some embodiments, the first spacer region, the second spacer region, or both the first spacer region and the second spacer region comprise a random sequence.

[0331] In certain embodiments, the length of the spacer sequence can be, for example, at least 10 nucleotides, at least 15 nucleotides, or at least 30 nucleotides. In certain embodiments, the length of the spacer sequence is at least 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25 or 30 nucleotides. In certain embodiments, the length of the spacer sequence is no more than 100, 90, 80, 70, 60, 50, 45, 40, 35 or 30 nucleotides. In certain embodiments, the length of the spacer sequence is 20 to 50 nucleotides. In certain embodiments, the length of the spacer sequence is 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 nucleotides.

[0332] The spacer sequence can be a poly A sequence, a poly AC sequence, a poly C sequence, or a poly U sequence.

[0333] In some embodiments, the spacer sequence can be poly-AT, poly-AC, poly-AG, or a random sequence.

[0334] Exemplary spacer sequences are described in paragraphs

[0293] -

[0302] of International Patent Publication No. WO 2019 / 118919, which is hereby incorporated by reference in its entirety.

[0335] Modification

[0336] Relative to a reference sequence (particularly a parent polyribonucleotide), a polyribonucleotide may include one or more substitutions, insertions and / or additions, deletions and covalent modifications included within the scope of the present disclosure.

[0337] In some embodiments, polyribonucleotides include one or more post-transcriptional modifications (e.g., capping, cutting, polyadenylation, splicing, poly A sequence, methylation, acylation, phosphorylation, methylation of lysine and arginine residues, acetylation, and nitrosylation of thiol groups and tyrosine residues, etc.). The one or more post-transcriptional modifications can be any post-transcriptional modifications, such as any of more than one hundred different nucleoside modifications identified in RNA (Rozenski, J, Crain, P and McCloskey, J. (1999). The RNA Modification Database: 1999update [RNA modification database: 1999 update]. Nucl Acids Res [nucleic acid research] 27: 196-197). In some embodiments, the first isolated nucleic acid includes messenger RNA (mRNA). In some embodiments, polyribonucleotides include at least one nucleoside selected from the group consisting of: as described in

[0311] of International Patent Publication No. WO 2019 / 118919A1, which are incorporated herein by reference in their entirety.

[0338] Polyribonucleotides can include any useful modification, such as for sugar, core base or internucleoside bond (for example for connected phosphate / for phosphodiester bond / for phosphodiester backbone). One or more atoms of pyrimidine core base can be replaced or substituted by optionally substituted amino, optionally substituted thiol, optionally substituted alkyl (for example, methyl or ethyl) or halo (for example, chloro or fluoro). In certain embodiments, there is modification (for example, one or more modifications) in each sugar and internucleoside bond. Modification can be to ribonucleic acid (RNA) modification of deoxyribonucleic acid (DNA), threose nucleic acid (TNA), ethylene glycol nucleic acid (GNA), peptide nucleic acid (PNA), locked nucleic acid (LNA) or its hybrid. Other modifications are described herein.

[0339] In some embodiments, the polyribonucleotide includes at least one N (6) methyladenosine (m6A) modification to increase translation efficiency. In some embodiments, the m6A modification can reduce the immunogenicity of the polyribonucleotide (e.g., reduce the level of one or more markers of immune or inflammatory response).

[0340] In some embodiments, the modification may include chemical or cell-induced modification. For example, some non-limiting examples of RNA modification in cells are described in Lewis and Pan, "RNA modifications and structures cooperate to guide RNA-protein interactions", Nat Reviews Mol Cell Biol, 2017, 18: 202-210.

[0341] In certain embodiments, the chemical modification of the ribonucleotide of polyribonucleotide can enhance immune escape.Polyribonucleotide can be synthesized and / or modified by methods well known in the art, such as Current protocols innucleic acid chemistry [current scheme of nucleic acid chemistry], Beaucage, SL et al. (editor), John Wiley & Sons [John Wiley and Sons Publishing Company], New York City, New York, those methods described in the U.S. (which are hereby incorporated by reference).Modification includes, for example, terminal modification, such as 5' terminal modification (phosphorylation (single, di and triphosphorylation), conjugation, reverse connection, etc.), 3' terminal modification (conjugation, DNA nucleotide, reverse connection, etc.), base modification (for example, with stable base, unstable base or with the base of extended partner library base pairing) Replacement), base removal (absence base nucleotide) or base conjugation.Modified ribonucleotide base can also include 5-methylcytidine and pseudouridine.In certain embodiments, give a few functional effects, base modification can regulate the expression, immune response, stability, subcellular localization of polyribonucleotide. In some embodiments, the modification includes a bi-orthogonal nucleotide, such as an unnatural base. See, for example, Kimoto et al., Chem Commun (Camb), 2017, 53: 12309, DOI: 10.1039 / c7cc06661a, which is hereby incorporated by reference in its entirety.

[0342] In certain embodiments, the sugar modification (for example, at 2' position or 4' position) or sugar substitution and main chain modification of one or more ribonucleotides of polyribonucleotides may include modification or substitution of phosphodiester bond.The specific example of polyribonucleotides includes but is not limited to polyribonucleotides including modified main chain or non-natural internucleoside bond (such as internucleoside modification, including modification or substitution of phosphodiester bond).Polyribonucleotides with modified main chain are especially included in those without phosphorus atom in main chain.For the purpose of the application, and as sometimes mentioned in the art, modified RNA without phosphorus atom in its internucleoside main chain may also be considered as oligonucleoside.In a specific embodiment, polyribonucleotides will include ribonucleotides with phosphorus atom in its internucleoside main chain.

[0343] Modified polyribonucleotide backbone can include, for example, phosphorothioate, chiral phosphorothioate, phosphorodithioate, phosphotriester, aminoalkyl phosphotriester, methyl and other alkyl phosphonates (such as 3'-alkylene phosphonates and chiral phosphonates), phosphinate, phosphoramidate (such as 3'-amino phosphoramidate and aminoalkyl phosphoramidate), thionophosphoramidate, thionoalkyl phosphonates, thionoalkyl phosphotriester and the borane phosphate with normal 3'-5' key, the analog of these 2'-5' connections, and those with opposite polarity, wherein adjacent nucleoside unit is connected to 3'-5' to 5'-3' or 2'-5' to 5'-2'.Also comprise various salts, mixed salts and free acid form.In certain embodiments, polyribonucleotide can be negatively charged or positively charged.

[0344] The modified nucleotide that can be incorporated into the polyribonucleotide can be modified on the internucleoside bond (for example phosphate backbone).Here, in the context of the polynucleotide backbone, the phrases "phosphate" and "phosphodiester" are used interchangeably.The backbone phosphate group can be modified by replacing one or more oxygen atoms with different substituents.In addition, modified nucleosides and nucleotides can include the overall replacement of the unmodified phosphate moiety carried out by another internucleoside bonding as described herein.The example of modified phosphate group includes but is not limited to phosphorothioate, phosphite selenate, boric acid phosphate (boranophosphate or boranophosphate ester), hydrogen phosphonate, phosphoramidate, diaminophosphorate, alkyl or aryl phosphonate and phosphotriester.Two non-connected oxygens of dithiophosphate are replaced by sulfur.It is also possible to modify the phosphate joint by replacing the connection oxygen with nitrogen (bridged phosphoramidate), sulfur (bridged phosphorothioate) and carbon (bridged methylene phosphonate).

[0345] Providing α-thiosubstituted phosphate moieties to impart RNA and DNA polymer stability through non-natural thiophosphate backbone bonds. Phosphorothioate DNA and RNA have enhanced nuclease resistance and therefore have a longer half-life in the cellular environment. Phosphorothioates attached to polyribonucleotides are expected to reduce innate immune responses by weakening the binding / activation of cellular innate immune molecules.

[0346] In particular embodiments, modified nucleosides include α-thio-nucleosides (e.g., 5'-0-(l-phosphothioate)-adenosine, 5'-0-(l-phosphothioate)-cytidine (a-thiocytidine), 5'-0-(l-phosphothioate)-guanosine, 5'-0-(l-phosphothioate)-uridine, or 5'-0-(1-phosphothioate)-pseudouridine).

[0347] Other internucleoside linkages that can be used in accordance with the present disclosure are described herein, including internucleoside linkages that do not include a phosphorus atom.

[0348] In certain embodiments, polyribonucleotides may include one or more cytotoxic nucleosides.For example, cytotoxic nucleosides may be incorporated into polyribonucleotides, such as bifunctional modifications.Cytotoxic nucleosides may include but are not limited to adenosine, 5-azacytidine, 4'-thioarabinoside, cyclopentenylcytosine, cladribine, clofarabine, cytosine arabinoside, cytosine arabinoside, 1-(2-C-cyano-2-deoxy-β-D-arabino-pentofuranosyl)-cytosine, decitabine, 5-fluorouracil, fludarabine, floxuridine, gemcitabine, a combination of tegafur and uracil, tegafur ((RS)-5-fluoro-1-(tetrahydrofuran-2-yl) pyrimidine-2,4 (1H, 3H)-dione), troxacitabine, tezcitabine, 2'-deoxy-2'-methylene cytidine (DMDC) and 6-mercaptopurine. Other examples include fludarabine phosphate, N4-behenoyl-l-β-D-arabinopentaofuranosyl cytosine, N4-octadecyl-l-β-D-arabinopentaofuranosyl cytosine, N4-palmitoyl-l-(2-C-cyano-2-deoxy-β-D-arabino-pentofuranosyl)cytosine, and P-4055 (cytarabine 5'-arachidate).

[0349] Polyribonucleotides may be uniformly modified or not along the entire length of the molecule. For example, one or more or all types of nucleotides (for example, naturally occurring nucleotides, purines or pyrimidines, or any one or more or all of A, G, U, C, I, pU) may be or may not be uniformly modified in a polyribonucleotide, or in a given predetermined sequence region thereof. In certain embodiments, polyribonucleotides include pseudouridine. In certain embodiments, polyribonucleotides include inosine, and relative to viral RNA, inosine can help the immune system characterize polyribonucleotides as endogenous. The incorporation of inosine can also mediate improved RNA stability / reduced degradation. See, for example, Yu, Z et al., (2015) RNA editing by ADAR1 marks dsRNA as "self". [RNA editing performed by ADAR1 marks dsRNA as "self"] Cell Res [Cell Research]. 25, 1283-1284, which is incorporated herein by reference in its entirety.

[0350] In some embodiments, all nucleotides in a polyribonucleotide (or a given sequence region thereof) are modified. In some embodiments, modifications may include m6A, which may enhance expression; inosine, which may attenuate immune responses; pseudouridine, which may increase RNA stability or translation read-through (interlaced elements); m5C, which may increase stability; and 2,2,7-trimethylguanosine, which may facilitate subcellular translocation (e.g., nuclear localization).

[0351] Different sugar modifications, nucleotide modifications and / or internucleoside linkages (e.g., backbone structures) may be present at various positions of the polyribonucleotide. It will be appreciated by those of ordinary skill in the art that nucleotide analogs or other one or more modifications may be located at any one or more positions of the polyribonucleotide so that the function of the polyribonucleotide is not substantially reduced. The modification may also be a non-coding region modification. The polyribonucleotide may include about 1% to about 100% of modified nucleotides (relative to the total nucleotide content, or relative to one or more types of nucleotides, i.e., any one or more of A, G, U or C) or any intermediate percentage (e.g., 1% to 20%>, 1% to 25%, 1% to 50%, 1% to 60%, 1% to 70%, 1% to 80%, 1% to 90%, 1% to 95%, 10% to 20%, 10% to 25%, 10% to 50%, 10% to 60%, 10% to 70%, 10% to 80%, 10% to 90%, 10% to 95%, 10% to 10%>, ... % to 100%, 20% to 25%, 20% to 50%, 20% to 60%, 20% to 70%, 20% to 80%, 20% to 90%, 20% to 95%, 20% to 100%, 50% to 60%, 50% to 70%, 50% to 80%, 50% to 90%, 50% to 95%, 50% to 100%, 70% to 80%, 70% to 90%, 70% to 95%, 70% to 100%, 80% to 90%, 80% to 95%, 80% to 100%, 90% to 95%, 90% to 100%, and 95% to 100%).

[0352] Polymerization

[0353] In certain embodiments, the cyclic polyribonucleotide may include a polymerized domain. For example, the cyclic polyribonucleotide may encode a first polypeptide as an immunogen (for example, a coronavirus immunogen) and a second polypeptide as a polymerized domain. For example, a polymerized domain may be encoded on an open reading frame identical to an immunogen (for example, a coronavirus immunogen) and expressed as a fusion protein with an immunogen. In certain embodiments, the cyclic polyribonucleotide may encode two or more immunogens, and each immunogen may optionally be fused with a polymerized domain. A polymerized domain may promote the formation of an immunogenic complex (for example, a complex comprising multiple immunogens).

[0354] The polymerization of the encoded immunogen can be conducive to inducing an immune response. The fusion of an immunogen and one or more polymerizing elements (e.g., dimerizing elements, trimerizing elements, tetramerizing elements and oligomerizing elements) can lead to the formation of a polymeric immunogen complex (e.g., forming a polymeric immunogen complex after expression in an immune subject). In certain embodiments, the formation of a polymeric immunogen complex increases the immunogenicity of the immunogen. For example, the formation of a polymeric immunogen complex can increase the immunogenicity of the immunogen by simulating the infection of an exogenous pathogen (e.g., a virus), wherein a variety of potential immunogens are generally located at the envelope of the pathogen (e.g., hemagglutinin (HA) immunogen of influenza virus). In certain embodiments, the polymerized complex includes at least 2, 3, 4, 6, 8, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 70, 80, 90 or 100 kinds of immunogens. In some embodiments, the immunogen complex comprises 2 to 10, 2 to 50, 2 to 100, 5 to 10, 5 to 15, 5 to 20, 5 to 50, 5 to 100, 10 to 20, 10 to 30, 10 to 40, 10 to 50, 10 to 60, 10 to 100, 20 to 50, or 20 to 100 immunogens. In some embodiments, the immunogen complex comprises 6 copies of an immunogen (e.g., a cyclic polyribonucleotide encoding an immunogen-foldon-immunogen fusion protein). In some embodiments, the immunogen complex comprises 24 copies of an immunogen (e.g., a cyclic polyribonucleotide encoding an immunogen-ferritin fusion protein). In some embodiments, the immunogen complex comprises 60 copies of an immunogen (e.g., a cyclic polyribonucleotide encoding an immunogen-AaLS fusion protein or encoding an immunogen-β-loop peptide).

[0355] When used in combination with a polypeptide immunogen of interest in the context of the present disclosure, such a multimerization element may be located at the N-terminus or C-terminus of the polypeptide of interest. At the nucleic acid level, the coding sequence of such a multimerization element is typically located in the same reading frame, 5' or 3', of the coding sequence of the polypeptide or protein of interest.

[0356] The multimerization domain can have 10 to 500 amino acid residues (e.g., 10 to 450, 10 to 400, 10 to 350, 10 to 300, 10 to 250, 10 to 200, 10 to 150, 10 to 100, 10 to 50, 50 to 500, 100 to 500, 150 to 500, 200 to 500, 250 to 500, 300 to 500, 350 to 500, 400 to 500, and 450 to 500 residues). In some embodiments, the multimerization domain can comprise 20 to 2500 amino acid residues (e.g., 20 to 250, 20 to 225, 20 to 200, 20 to 175, 20 to 150, 20 to 150, 20 to 125, 20 to 100, 20 to 75, 20 to 50, 50 to 250, 75 to 250, 100 to 250, 125 to 250, 150 to 250, 175 to 250, 200 to 250, and 225 to 250 residues).

[0357] In some embodiments, the immunogen fused to the multimerization domain is at least 2-fold, 5-fold, or 10-fold more immunogenic than the immunogen (e.g., in a human subject). In some embodiments, the immunogen fused to the multimerization domain is at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 200%, 300%, 400%, or 500% more immunogenic than the immunogen not fused to the multimerization domain (e.g., in a human subject).

[0358] Specific multimerization element is oligomerization element, tetramerization element, trimerization element or dimerization element.Dimerization element can be selected from, for example, dimerization element / domain of heat shock protein, immunoglobulin Fc domain and leucine zipper (the basic region leucine zipper class dimerization domain of transcription factor).Trimerization and tetramerization elements can be selected from, for example, engineered leucine zipper (engineered α-helical coiled coil peptide adopting parallel trimer state), fibrin foldon domain, GCN4pll, CCN4-pLI and p53 from Enterobacter phage T4.In certain embodiments, cyclic polyribonucleotide includes T4 foldon domain.In certain embodiments, T4 foldon domain has an amino acid sequence with at least 95% identity with GYIPEAPRDGQAYVRKDGEWVLLSTFL (SEQ ID NO:204).In certain embodiments, T4 foldon has the amino acid sequence of SEQ ID NO:204. In some embodiments, the multimerization domain is a beta loop peptide (see Matsuura et al. (2010), Angew. Chem. Int. Ed. [German Angew. Chem], 49: 9662-65). In some embodiments, the beta loop peptide has an amino acid sequence of INHVGGTGGAIMAPVAVTRQLVGS (SEQ ID NO: 205) (wherein the C-terminal serine residue is optionally present or absent), or has an amino acid sequence with at least 95% identity to SEQ ID NO: 205. In some embodiments, the cyclic polyribonucleotide comprises an AaLS peptide. In a specific embodiment, the AaLS peptide has an amino acid sequence with at least 95% identity to TDILGKYVINYLNKLKKKEDIFKEFLKW (SEQ ID NO: 282). In some embodiments, the AaLS peptide has an amino acid sequence of SEQ ID NO: 282.

[0359] The oligomerization element can be selected from, for example, ferritin, surfactant D, the oligomerization domain of paramyxovirus phosphoprotein, the complement inhibitor C4 binding protein (C4bp) oligomerization domain, the viral infectivity factor (Vif) oligomerization domain, the sterile alpha motif (SAM) domain and the von Willebrand factor D-type domain.

[0360] Ferritin forms oligomers and is a highly conserved protein present in all animals, bacteria, and plants. Ferritin is a protein that spontaneously forms nanoparticles of 24 identical subunits. Ferritin-immunogen fusion constructs potentially form oligomeric aggregates or "clusters" of immunogens that can enhance immune responses. In some embodiments, the cyclic polyribonucleotide includes a ferritin domain. In some embodiments, the cyclic polyribonucleotide includes a ferritin domain having the following amino acid sequence:

[0361] DIIKLLNEQVNKEMNSSNLYMSMSSWCYTHSLDGAGLFLFDHAAEEYEHAKK

[0362] LIVFLNENNVPVQLTSISAPEHKFESLTQIFQKAYEHEQHISESINNIVDHAIKGK

[0363] DHATFNFLQWYVSEQHEEEVLFKDILDKIELIGNENHGLYLADQYVKGIAKSR

[0364] KS (SEQ ID NO: 207).

[0365] Surfactant protein D (SPD) is a hydrophilic glycoprotein that spontaneously self-assembles to form oligomers. SPD-immunogen fusion constructs can form oligomeric aggregates or "clusters" of the immunogen that can enhance the immune response.

[0366] The phosphoprotein of paramyxovirus (negative sense RNA virus) functions as a transcriptional transactivator of the viral polymerase. Oligomerization of the phosphoprotein is essential for viral genome replication. Phosphoprotein-immunogen fusion constructs can form oligomeric aggregates or "clusters" of the immunogen that can enhance immune responses.

[0367] The complement inhibitor C4 binding protein (C4bp) can also be used as a fusion partner to produce oligomeric immunogen aggregates. The C-terminal domain of C4bp (57 amino acid residues in humans and 54 amino acid residues in mice) is necessary and sufficient for the oligomerization of C4bp or other polypeptides fused thereto. C4bp-immunogen fusion constructs can form oligomeric aggregates or "clusters" of immunogens that can enhance immune responses. The viral infectivity factor (Vif) multimerization domain has been shown to form oligomers both in vitro and in vivo. The oligomerization of Vif involves a sequence mapped between residues 1 51 to 1 64 in the C-terminal domain, i.e., the 161PPLP1 64 motif (for human HIV-1: TPKKIKPPLP (SEQ ID NO: 205)). Vif-immunogen fusion constructs can form oligomeric aggregates or "clusters" of immunogens that can enhance immune responses.

[0368] Sterility alpha motif (SAM) domains are protein interaction modules present in a variety of proteins involved in many biological processes. SAM domains distributed over approximately 70 residues are found in a variety of eukaryotic organisms. SAM domains have been shown to homo- and hetero-oligomerize, forming multiple self-associating oligomeric structures. SAM-immunogen fusion constructs can form oligomeric aggregates or "clusters" of immunogens that can enhance immune responses. Von Willebrand factor (vWF) contains several D-type domains: D1 and D2 are present in the N-terminal propeptide, while the remaining D domain is required for oligomerization. vWF domains are present in a variety of plasma proteins: complement factors B, C2, C 3, and CR4; integrins (l-domain); collagen types VI, VII, XII, and XIV; and other extracellular proteins. vWF-immunogen fusion constructs can form oligomeric aggregates or "clusters" of immunogens that can enhance immune responses.

[0369] In certain embodiments, the cyclic polyribonucleotide may include one or more polymerized domains. For example, the cyclic polyribonucleotide may include 2, 3, 4, 5, 6, 7, 8, 9 or 10 polymerized domains. In certain embodiments, the cyclic polyribonucleotide includes two polymerized domains. Two or more polymerized domains may be adjacent to each other. Alternatively, two or more polymerized domains may be separated by one or more other elements. For example, two polymerized domains may be separated by an immunogen. In certain embodiments, the cyclic polyribonucleotide includes a ferritin domain and a T4 foldon domain. Ferritin and T4 foldon domains may be connected by a Gly-Ser joint. In certain embodiments, the ferritin domain connected to the T4 foldon domain has the following amino acid sequence:

[0370] PGSGYIPEAPRDGQAYVRKDGEWVLLSTFLSGRSGGDIIKLLNEQVNKEMNSS

[0371] NLYMSMSSWCYTHSLDGAGLFLFDHAAEEYEHAKKLIVFLNENNVPVQLTSIS

[0372] APEHKFESLTQIFQKAYEHEQHISESINNIVDHAIKGKDHATNFLQWYVSEQHEEEVLFKDILDKIELIGNENHGLYLADQYVKGIAKSRKS (SEQ ID NO: 206).

[0373] In some embodiments, the multimerization domain is a dioxetidine synthase domain. The dioxetidine synthase can assemble into a complex comprising 60 copies of a dioxetidine synthase domain, wherein each dioxetidine synthase domain can be fused to one or more immunogens. In some embodiments, the dioxetidine synthase domain comprises the amino acid sequence of any one of SEQ ID NOs: 206-209 and 325, or an amino acid sequence having at least 95% sequence identity with any one of SEQ ID NOs: 206-209 and 325.

[0374] SEQ ID NO:206

[0375] MQIYEGKLTAEEGLRFGIVASRFNHALVDRLVEGAIDAIVRHGGREEDITLVRVPG

[0376] SWEIPVAAGELARKEDIDAVIAIGVLIRGATPHFDYIASEVSKGLADLSLELRKPI

[0377] TFGVITADTLEQAIERAGTKHGNKGWEAALSAIEMANLFKSLR

[0378] SEQ ID NO:207

[0379] QIYEGKLTAEEGLRFGIVASRFNHALVDRLVEGCIDCIVRHGGREEDITLVRVPGS

[0380] WEIPVAAGELARKEDIDAVIAIGVLIRGATPHFDYIASEVSKGLANLSLELRKPIT

[0381] FGVITADTLEQAIERAGTKHGNKCWEAALSAIEMANLFKSLR

[0382] SEQ ID NO:208

[0383] QIYEGKLTAEEGLRFGIVASRFNHALVDRLVEGAIDAIVRHGGREEDITLVRVPGS

[0384] WEIPVAAGELARKENISAVIAIGVLIRGATPHFDYIASEVSKGLADLSLELRKPIT

[0385] FGVITADTLEQAIERAGTKHGNKGWEAALSAIEMANLFKSLR

[0386] SEQ ID NO:209

[0387] QIYEGKLTAEEGLRFGIVASRFNHALVDRLVEGAIDCIVRHGGREEDITLVRVPGS

[0388] WEIPVAAGELARKEDIDAVIAIGVLIRGATPHFDYIASEVSKGLADLSLELRKPIT

[0389] FGVITADTLEQAIERAGTKHGNKGWEAALSAIEMANLFKSLR

[0390] SEQ ID NO:325

[0391] MQIYEGKLTAEEGLRFGIVASRFNHALVDRLVEGAIDCIVRHGGREEDITLVRVPG

[0392] SWEIPVAAGELARKEDIDAVIAIGVLIRGATPHFDYIASEVSKGLANLSLELRKPI

[0393] TFGVITADTLEQAIERAGTKHGNKGWEAALSAIEMANLFKSLR

[0394] The dioxetidine synthase domain has one or more cysteine ​​substitutions to introduce one or more non-natural disulfide bonds that stabilize the dioxetidine synthase complex formed by the self-assembled subunits. In some embodiments, one or more non-natural disulfide bonds are introduced by: L121C-K131C, L121CG-K131C, L121GC-K131C, K7C-R40C, I3C-L50C, I82C-K131CG, E5C-R52C or E95C-A101C substitutions or combinations thereof (such as I3C-L50C and I82C-K131CG; E5C-R52C and I82C-K131CG; or E95C-A101C and I82C-K131CG). Residue numbering refers to the dioxetidine synthase subunit shown in SEQ ID NO: 206. Non-limiting examples include:

[0395] SEQ ID NO:210(L121C-K131C)

[0396] QIYEGKLTAEEGLRFGIVASRFNHALVDRLVEGAIDAIVRHGGREEDITLVRVPGSWEI

[0397] PVAAGELARKENISAVIAIGVLIRGATPHFDYIASEVSKGLADLSLELRKPITFGVITA

[0398] DTcEQAIERAGTcHGNKGWEAALSAIEMANLFKSLR

[0399] SEQ ID NO:211(L121CG-K131C)

[0400] QIYEGKLTAEGLRFGIVASRFNHALVDRLVEGAIDAIVRHGGREEDITLVRVPGSWEI

[0401] PVAAGELARKENISAVIAIGVLIRGATPHFDYIASEVSKGLADLSLELRKPITFGVITA

[0402] DTcCfEQAIERAGTcHGNKGWEAALSAIEMANLFKSLR

[0403] SEQ ID NO:212(L121GC-K131C)

[0404] QIYEGKLTAEGLRFGIVASRFNHALVDRLVEGAIDAIVRHGGREEDITLVRVPGSWEI

[0405] PVAAGELARKENISAVIAIGVLIRGATPHFDYIASEVSKGLADLSLELRKPITFGVITA

[0406] DTCfcEQAIERAGTcHGNKGWEAALSAIEMANLFKSLR

[0407] SEQ ID NO:213(K7C-R40C)

[0408] QIYEGCLTAEGLRFGIVASRFNHALVDRLVEGAIDAIVCHGGREEDITLVRVPGSWEI

[0409] PVAAGELARKENISAVIAIGVLIRGATPHFDYIASEVSKGLADLSLELRKPITFGVITA

[0410] DTLEQAIERAGTKHGNKGWEAALSAIEMANLFKSLR

[0411] SEQ ID NO:214(I3C-L50C, I82C-K131CG)

[0412] QCYEGKLTAEEGLRFGIVASRFNHALVDRLVEGAIDCIVRHGGREEDITCVRVPGSWE

[0413] IPVAAGELARKEDIDAVIAIGVLCRGATPHFDYIASEVSKGLADLSLELRKPITFGVIT

[0414] ADTLEQAIERAGTCGHGNKGWEAALSAIEMANLFKSLR

[0415] SEQ ID NO:215(E5C-R52C, I82C-K131CG)

[0416] QIYCGKLTAEEGLRFGIVASRFNHALVDRLVEGAIDCIVRHGGREEDITLVCVPGSWEI

[0417] PVAAGELARKEDIDAVIAIGVLCRGATPHFDYIASEVSKGLADLSLELRKPITFGVIT

[0418] ADTLEQAIERAGTCGHGNKGWEAALSAIEMANLFKSLR

[0419] SEQ ID NO:216(E95C-A101C, I82C-K131CG)

[0420] QIYEGKLTAEEGLRFGIVASRFNHALVDRLVEGAIDCIVRHGGREEDITLVRVPGSWEI

[0421] PVAAGELARKEDIDAVIAIGVLCRGATPHFDYIASCVSKGLCDLSLELRKPITFGVIT

[0422] ADTLEQAIERAGTCGHGNKGWEAALSAIEMANLFKSLR

[0423] International Publication No. WO 2020 / 061564, page 25, line 1 to page 26, line 20, describes various methods for polypeptide multimerization, which is incorporated herein by reference.

[0424] In some embodiments, the multimerization domain is a riboflavin synthase domain. For example, the riboflavin synthase domain can have an amino acid sequence having at least 95% sequence identity to TDILGKYVINYLNKLKKKEDIFKEFLKW (SEQ ID NO: 326). In some embodiments, the riboflavin synthase domain can have an amino acid sequence of SEQ ID NO: 326.

[0425] Suitable multimerization domains can be selected, for example, from the list of amino acid sequences of SEQ ID NO: 1116-1167 according to international patent application WO 2017 / 081082, or fragments or variants of these sequences.

[0426] Production method

[0427] The present disclosure provides a method for producing cyclic polyribonucleotides, and the method includes, for example, recombinant technology or chemical synthesis. For example, the DNA molecule for producing RNA rings can include the DNA sequence of naturally occurring nucleotide sequence, its modified form or the DNA sequence (for example, chimeric molecule or fusion protein) of the synthetic polypeptide that is not usually present in nature. DNA and RNA molecules can be modified using a variety of techniques, and the technology includes, but is not limited to, classical mutagenesis techniques and recombinant technology, such as site-directed mutagenesis, chemical treatment nucleic acid molecules with induced mutations, restriction enzyme cutting nucleic acid fragments, connection nucleic acid fragments, polymerase chain reaction (PCR) amplification or mutagenesis nucleic acid sequence selected region, synthetic oligonucleotide mixtures and connection mixture groups with "building" nucleic acid molecule mixtures and combinations thereof.

[0428] Circular polyribonucleotides can be prepared according to any available technology, including but not limited to chemical synthesis and enzymatic synthesis. In some embodiments, linear primary constructs or linear RNAs can be cyclized or connected to produce circRNAs as described herein. The mechanism of cyclization or connection can occur by the following methods: such as chemical, enzymatic, splint connection or ribozyme catalysis. The newly formed 5'-3' linkage can be an intramolecular bond or an intermolecular bond. For example, a splint ligase (such as Ligase) can be used for splint connection. According to this method, single-stranded polynucleotide (splint) (such as single-stranded DNA or RNA) can be designed to hybridize with the two ends of linear polyribonucleotide, so that the two ends can be parallel when hybridizing with the single-stranded splint. Therefore, splint ligase can catalyze the connection of the two ends of linear polyribonucleotide parallel to produce circRNA. In certain embodiments, DNA or RNA ligase can be used for the synthesis of circular polynucleotide. As a non-limiting example, ligase can be circ ligase or circular ligase.

[0429] In another example, the 5' or 3' end of a linear polyribonucleotide can encode a ligase ribozyme sequence so that during in vitro transcription, the resulting linear circRNA includes an active ribozyme sequence that can connect the 5' end of a linear polyribonucleotide to the 3' end of a linear polyribonucleotide. The ligase ribozyme can be derived from Group I intron, hepatitis delta virus, hairpin ribozyme, or can be selected by SELEX (systematic evolution of ligands by exponential enrichment).

[0430] In another example, linear polyribonucleotides can be cyclized or connected by using at least one non-nucleic acid part.For example, at least one non-nucleic acid part can react with the region or characteristics near the 5' end or 3' end of linear polyribonucleotides, to cyclize or connect linear polyribonucleotides.In another example, at least one non-nucleic acid part can be located at or connected to or near the 5' end or 3' end of linear polyribonucleotides.The non-nucleic acid part can be homologous or heterologous.As non-limiting examples, the non-nucleic acid part can be a key, such as hydrophobic bond, ionic bond, biodegradable key or cleavable key.As another non-limiting examples, the non-nucleic acid part is a connecting part.As another non-limiting examples, the non-nucleic acid part can be an oligonucleotide or peptide part, such as, aptamers or non-nucleic acid joints as described herein.

[0431] In another example, linear polyribonucleotide can be by self-splicing cyclization or connection.In certain embodiments, linear polyribonucleotide can comprise the ring E sequence of self connection.In another embodiment, linear polyribonucleotide can comprise self-cyclization intron (for example, 5 ' and 3 ' splicing connection) or self-cyclization catalysis intron, as I type, II type or III type intron.I type intron can comprise self-splicing arrangement intron-exon sequence that is derived from T4 bacteriophage gene td from the limiting examples of splicing sequence, and intercalated sequence (IVS) rRNA of tRNA-Leu gene before tRNA-Leu gene or tetrahymena before rRNA.

[0432] In certain embodiments, polyribonucleotides may include catalytic intron fragments, such as 3' half of I type catalytic intron fragments and 5' half of I type catalytic intron fragments. The first and second annealing zones may be located within the catalytic intron fragments. I type catalytic introns are self-splicing ribozymes that catalyze themselves from mRNA, tRNA and rRNA precursors by a bimetallic ion phosphoryl transfer mechanism. Importantly, RNA itself self-catalyzes the removal of introns without the need for exogenous enzymes, such as ligases.

[0433] In some embodiments, the 3' half of the type I catalytic intron fragment and the 5' half of the type I catalytic intron fragment are from the Anabaena pre-tRNA-Leu gene or the Tetrahymena pre-rRNA.

[0434] In some embodiments, the 3' half of the type I catalytic intron fragment and the 5' half of the type I catalytic intron fragment are from the anabaena cyanobacterium pre-tRNA-Leu gene, and the 3' exon fragment includes a first annealing zone, and the 5' exon fragment includes a second annealing zone. The first annealing zone may include, for example, 5 to 50, for example, 10 to 15 (e.g., 10, 11, 12, 13, 14, or 15) ribonucleotides, and the second annealing zone may include, for example, 5 to 50, for example, 10 to 15 (e.g., 10, 11, 12, 13, 14, or 15) ribonucleotides.

[0435] In some embodiments, the 3' half of the type I catalytic intron fragment and the 5' half of the type I catalytic intron fragment are from Tetrahymena pre-rRNA, and the 3' half of the type I catalytic intron fragment includes a first annealing region, and the 5' exon fragment includes a second annealing region. In some embodiments, the 3' exon includes a first annealing region, and the 5' half of the type I catalytic intron fragment includes a second annealing region. The first annealing region may include, for example, 6 to 50, such as 10 to 16 (e.g., 10, 11, 12, 13, 14, 15, or 16) ribonucleotides, and the second annealing region may include, for example, 6 to 50, such as 10 to 16 (e.g., 10, 11, 12, 13, 14, 15, or 16) ribonucleotides.

[0436] In some embodiments, the 3' half of the type I catalytic intron fragment and the 5' half of the type I catalytic intron fragment are from the Anabaena pre-tRNA-Leu gene, the Tetrahymena pre-rRNA gene, or the T4 bacteriophage td gene.

[0437] In certain embodiments, the 3' half of the I-type catalytic intron fragment and the 5' half of the I-type catalytic intron fragment are from the T4 phage td gene. The 3' exon fragment may include a first annealing zone, and the 5' portion of the I-type catalytic intron fragment may include a second annealing zone. The first annealing zone may include, for example, 2 to 16, for example, 10 to 16 (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16) ribonucleotides, and the second annealing zone may include, for example, 2 to 16, for example, 10 to 16 (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16) ribonucleotides.

[0438] In some embodiments, the 3' half of the type I catalytic intron fragment is the 5' end of the linear polynucleotide.

[0439] In some embodiments, the 5' half of the type I catalytic intron fragment is the 3' end of the linear polyribonucleotide.

[0440] In some embodiments, the 3' half of the type I catalytic intron fragment has at least 80% (e.g., at least 85%, 90%, 95%, 97%, 99%, or 100%) sequence identity to the sequence of 5'-AACAACAGATAACTTACAGCTAGTCGGAAGGTGCAGAGACTCGACGGGAGCTA CCCTAACGTCAAGACGAGGGTAAAGAGAGAGTCCAATTCTCAAAGCCAATAGG CAGTAGCGAAAGCTGCGGGAGAATG-3' (SEQ ID NO: 307).

[0441] In some embodiments, the 5' half of the type I catalytic intron fragment has at least 80% (e.g., at least 85%, 90%, 95%, 97%, 99%, or 100%) sequence identity to the sequence of 5'-AAATAATTGAGCCTTAGAGAAGAAATTCTTTAAGTGGATGCTCTCAAACTCAGG GAAACCTAAATCTAGCTATAGACAAGGCAATCCTGAGCCAAGCCGAAGTAGTAA TTAGTAAGTT-3' (SEQ ID NO: 308).

[0442] In some embodiments, the 3' half of the type I catalytic intron fragment has the sequence of SEQ ID NO:307, and the 5' half of the type I catalytic intron fragment has the sequence of SEQ ID NO:308.

[0443] In some embodiments, the 3' half of the type I catalytic intron fragment has at least 80% (e.g., at least 85%, 90%, 95%, 97%, 99%, or 100%) sequence identity to the sequence of 5'-CTTCTGTTGATATGGATGCAGTTCACAGACTAAATGTCGGTCGGGGAAGATGTATTCTTCTCATAAGATATAGTCGGACCTCTCCTTAATGGGAGCTAGCGGATGAAGTGATGCAACACTGGAGCCGCTGGGAACTAATTTGTATGCGAAAGTATATTGATTAGTTTTGGAGTACTCG-3' (SEQ ID NO: 309).

[0444] In some embodiments, the 5' half of the type I catalytic intron fragment has at least 80% (e.g., at least 85%, 90%, 95%, 97%, 99%, or 100%) sequence identity to the sequence of 5'-AAATAGCAATATTTACCTTTGGAGGGAAAAGTTATCAGGCATGCACCTGGTAGCTAGTCTTTAAACCAATAGATTGCATCGGTTTAAAAGGCAAGACCGTCAAATTGCGGGAAAGGGGTCAACAGCCGTTCAGTACCAAGTCTCAGGGGAAACTTTGAGATGGCCTTGCAAAGGGTATGGTAATAAGCTGACGGACATGGTCCTAACCACGCAGCCAAGTCCTAAGTCAACAGAT-3' (SEQ ID NO: 310).

[0445] In some embodiments, the 3' half of the type I catalytic intron fragment has the sequence of SEQ ID NO:309 and the 5' half of the type I catalytic intron fragment has the sequence of SEQ ID NO:310.

[0446] In some embodiments, the 3' half of the type I catalytic intron fragment has at least 80% (e.g., at least 85%, 90%, 95%, 97%, 99%, or 100%) sequence identity to the sequence of 5'-GGTTCTACATAAATGCCTAACGACTATCCCTTTGGGGAGTAGGGTCAAGTGACTCGAAACGATAGACAACTTGCTTTAACAAGTTGGAGATATAGTCTGCTCTGCATGGTGACATGCAGCTGGATATAATTCCGGGGTAAGATTAACGACCTTATCTGAACATAATG-3' (SEQ ID NO: 311).

[0447] In some embodiments, the 5' half of the type I catalytic intron fragment has at least 80% (e.g., at least 85%, 90%, 95%, 97%, 99%, or 100%) sequence identity to the sequence of 5'-TAATTGAGGCCTGAGTATAAGGTGACTTATACTTGTAATCTATCTAAACGGGGAA CCTCTCTAGTAGACAATCCCGTGCTAAATTGTAGGACT-3' (SEQ ID NO: 312).

[0448] In some embodiments, the 3' half of the type I catalytic intron fragment has the sequence of SEQ ID NO:311 and the 5' half of the type I catalytic intron fragment has the sequence of SEQ ID NO:312.

[0449] In some embodiments, the 3' half of the type I catalytic intron fragment has at least 80% (e.g., at least 85%, 90%, 95%, 97%, 99%, or 100%) sequence identity to the sequence of 5'-TAAACAACTAACAGCTTTAGAAGGTGCAGAGACTAGACGGGAGCTACCCTAACGGATTCAGCCGAGGGTAAAGGGATAGTCCAATTCTCAACATCGCGATTGTTGATGGCAGCGAAAGTTGCAGAGAGAATGAAAATCCGCTGACTGTAAAGGTCGTGAGGGTTCGAGTCCCTCCGCCCCCA-3' (SEQ ID NO: 313).

[0450] In some embodiments, the 5' half of the type I catalytic intron fragment has at least 80% (e.g., at least 85%, 90%, 95%, 97%, 99%, or 100%) sequence identity to the sequence of 5'-ACGGTAGACGCAGCGGACTTAGAAAACTGGGCCTCGATCGCGAAAGGGATCGA GTGGCAGCTCTCAAACTCAGGGAAACCTAAAACTTTAAACATTMAAGTCATGG CAATCCTGAGCCAAGCTAAAGC-3' (SEQ ID NO: 314).

[0451] In some embodiments, the 3' half of the type I catalytic intron fragment has the sequence of SEQ ID NO:313 and the 5' half of the type I catalytic intron fragment has the sequence of SEQ ID NO:314.

[0452] In some embodiments, the 3' half of the type I catalytic intron fragment has at least 80% (e.g., at least 85%, 90%, 95%, 97%, 99%, or 100%) sequence identity to the sequence of 5'-TTAAACTCAAAATTTAAAATCCCAAATTCAAAATTCCGGGAAGGTGCAGAGACTCGACGGGAGCTACCCTAACGTAAAGCCGAGGGTAAAGGGAGAGTCCAATTCTCAAAGCCTGAAGTTGCTGAAGCAACAAGGCAGTAGTGAAAGCTGCGAGAGAATGAAAATCCGTTGACTGTAAAAAGTCGTGGGGGTTCAAGTCCCCCCACCCCC-3' (SEQ ID NO: 315).

[0453] In some embodiments, the 5' half of the type I catalytic intron fragment has at least 80% (e.g., at least 85%, 90%, 95%, 97%, 99%, or 100%) sequence identity to the sequence of 5'-ATGGTAGACGCTACGGACTTAGAAAACTGAGCCTTGATAGAGAAATCTTTTAAG TGGAAGCTCTCAAATTCAGGGAAACCTAAATCTGAATACAGATATGGCAATCCT GAGCCAAGCCCAGAAAATTTAGACTTGAGATTTGATTTTGGAG-3' (SEQ ID NO: 316).

[0454] In some embodiments, the 3' half of the type I catalytic intron fragment has the sequence of SEQ ID NO:315 and the 5' half of the type I catalytic intron fragment has the sequence of SEQ ID NO:316.

[0455] In some embodiments, the 3' half of the type I catalytic intron fragment has at least 80% (e.g., at least 85%, 90%, 95%, 97%, 99%, or 100%) sequence identity to the sequence of 5'-GGCTTTCAATTTGAAATCAGAAATTCAAAATTCAGGGAAGGTGCAGAGACTCGACGGGAGCTACCCTAACGTAAAGGCGAGGGTAAAGGGAGAGTCCAATTCTTAAAGCCTGAAGTTGTGCAAGCAACAAGGCAACAGTGAAAGCTGTGGAAGAATGAAAATCCGTTGACCTTAAACGGTCGTGGGGGTTCAAGTCCCCCCACCCCC-3' (SEQ ID NO: 317).

[0456] In some embodiments, the 5' half of the type I catalytic intron fragment has at least 80% (e.g., at least 85%, 90%, 95%, 97%, 99%, or 100%) sequence identity to the sequence of 5'-ATGGTAGACGCTACGGACTTAGAAAACTGAGCCTTGATAGAGAAATCTTTCAAG TGGAAGCTCTCAAATTCAGGGAAACCTAAATCTGAATACAGATATGGCAATCCT GAGCCAAGCCCGGAAATTTTAGAATCAAGATTTTATTTT-3' (SEQ ID NO: 318).

[0457] In some embodiments, the 3' half of the type I catalytic intron fragment has the sequence of SEQ ID NO:317 and the 5' half of the type I catalytic intron fragment has the sequence of SEQ ID NO:318.

[0458] In some embodiments, the 3' half of the type I catalytic intron fragment has at least 80% (e.g., at least 85%, 90%, 95%, 97%, 99%, or 100%) sequence identity to the sequence of 5'-AGAAATGGAGAAGGTGTAGAGACTGGAAGGCAGGCACCCTAACGTTAAAGGCGAGGGTGAAGGGACAGTCCAGACCACAAACCAGTAAATCTGGGCAGCGAAAGCTGTAGATGGTAAGCATAACCCGAAGGTCAGTGGTTCAAATCCACTTCCCGCCACCAAATTAAAAAAACAATAA-3' (SEQ ID NO:319).

[0459] In some embodiments, the 5' half of the type I catalytic intron fragment has at least 80% (e.g., at least 85%, 90%, 95%, 97%, 99%, or 100%) sequence identity to the sequence of 5'-AGAAATGGAGAAGGTGTAGAGACTGGAAGGCAGGCACCCTAACGTTAAAGGCGAGGGTGAAGGGACAGTCCAGACCACAAACCAGTAAATCTGGGCAGCGAAAGCTGTAGATGGTAAGCATAACCCGAAGGTCAGTGGTTCAAATCCACTTCCCGCCACCAAATTAAAAAAACAATAA-3' (SEQ ID NO:320).

[0460] In some embodiments, the 3' half of the type I catalytic intron fragment has the sequence of SEQ ID NO:319 and the 5' half of the type I catalytic intron fragment has the sequence of SEQ ID NO:320.

[0461] In some embodiments, the 3' half of the type I catalytic intron fragment has at least 80% (e.g., at least 85%, 90%, 95%, 97%, 99%, or 100%) sequence identity to the sequence of 5'-ACAACAGATAACTTACTAACTTACAGCTAGTCGGAAGGTGCAGAGACTCGACGGGAGCTACCCTAACGTCAAGACGAGGGTAAAGAGAGAGTCCAATTCTCAAAGCCAATAGGCAGTAGCGAAAGCTGCGGGAGAATGAAAATCCGTAGCGTCTAAACGGTCGTGTGGGTTCAAGTCCCTCCACCCCCA-3' (SEQ ID NO: 321).

[0462] In some embodiments, the 5' half of the type I catalytic intron fragment has at least 80% (e.g., at least 85%, 90%, 95%, 97%, 99%, or 100%) sequence identity to the sequence of 5'-AGACGCTACGGACTTAAATAATTGAGCCTTAGAGAAGAAATTCTTTAAGTGGAT GCTCTCAAACTCAGGGAAACCTAAATCTAGCTATAGACAAGGCAATCCTGAGCC AAGCCGAAGTAGTAATTAGTAAGTTAGTAAGTT-3' (SEQ ID NO: 322).

[0463] In some embodiments, the 3' half of the type I catalytic intron fragment has the sequence of SEQ ID NO:321 and the 5' half of the type I catalytic intron fragment has the sequence of SEQ ID NO:322.

[0464] In some embodiments, the 3' half of the type I catalytic intron fragment has at least 80% (e.g., at least 85%, 90%, 95%, 97%, 99%, or 100%) sequence identity to the sequence of 5'-AACAACAGATAACTTACTAGTTACTAGTCGGAAGGTGCAGAGACTCGACGGGAGCTACCCTAACGTCAAGACGAGGGTAAAGAGAGAGTCCAATTCTCAAAGCCAATAGGCAGTAGCGAAAGCTGCGGGAGAATGAAAATCCGTAGCGTCTAAACGGTCGTGTGGGTTCAAGTCCCTCCACCCCCA-3' (SEQ ID NO: 323).

[0465] In some embodiments, the 5' half of the type I catalytic intron fragment has at least 80% (e.g., at least 85%, 90%, 95%, 97%, 99%, or 100%) sequence identity to the sequence of 5'-AGACGCTACGGACTTAAATAATTGAGCCTTAGAGAAGAAATTCTTTAAGTGGAT GCTCTCAAACTCAGGGAAACCTAAATCTAGCTATAGACAAGGCAATCCTGAGCC AAGCCGAAGTAGTAATTAGTAAGTT-3' (SEQ ID NO: 324).

[0466] In some embodiments, the 3' half of the type I catalytic intron fragment has the sequence of SEQ ID NO:323 and the 5' half of the type I catalytic intron fragment has the sequence of SEQ ID NO:324.

[0467] In another example, linear polyribonucleotide can be cyclized or connected by non-nucleic acid part, and described non-nucleic acid part causes the attraction between 5 ' and 3 ' end, near or connected atom, molecular surface of linear polyribonucleotide.Can cyclize or connect one or more linear polyribonucleotide by intermolecular force or intramolecular force.The limiting examples of intermolecular force comprises dipole-dipole force, dipole induced dipole force, induced dipole induced dipole force, van der Waals force and dispersion force.The limiting examples of intramolecular force comprises covalent bond, metallic bond, ionic bond, resonance bond, grasping hydrogen bond (agnostic bond), dipole bond, put together, super put together and reverse key.

[0468] In another example, linear polyribonucleotide can comprise the ribozyme RNA sequence near 5 ' end and near 3 ' end.When sequence is exposed to the remainder of ribozyme, ribozyme RNA sequence can be covalently connected to peptide.The peptide covalently connected to the ribozyme RNA sequence near 5 ' end and 3 ' end can associate mutually, thereby cause linear polyribonucleotide cyclization or connection.In another example, after using various methods known in the art (such as but not limited to protein connection) to connect, the peptide covalently connected to the ribozyme RNA near 5 ' end and 3 ' end can cause linear primary construct or linear mRNA cyclization or connection.The non-limiting examples of the ribozyme used in linear primary construct of the present invention or linear polyribonucleotide, or the non-exhaustive list of the method for mixing or covalently connecting peptide is described in U.S. Patent Application No. US20030082768, and the content of described patent application is incorporated herein in full by citing.

[0469] In another example again, the chemical method of cyclization can be used for producing cyclic polyribonucleotide.Such method can include but is not limited to click chemistry (for example, based on the method of alkynes and azide, or clickable base), olefin metathesis, phosphoramidate connection, hemiaminal-imine cross-linking, base modification and any combination thereof.

[0470] In another example, the deoxyribonucleotide templates transcribed in the cell-free system (for example, by in vitro transcription) can be used to produce linear RNA to produce circular polyribonucleotides.Linear polyribonucleotides produce splicing compatible polyribonucleotides, and the polyribonucleotides can be self-splicing to produce circular polyribonucleotides.

[0471] In some embodiments, present disclosure provides a method for producing cyclic polyribonucleotides (e.g., in a cell-free system) by: providing linear polyribonucleotides; and self-splicing linear polyribonucleotides under conditions suitable for splicing 3' and 5' splice sites of linear polyribonucleotides; thereby producing cyclic polyribonucleotides.

[0472] In some embodiments, the present disclosure provides a method for producing cyclic polyribonucleotides by: providing deoxyribonucleotides encoding linear polyribonucleotides; transcribing the deoxyribonucleotides in a cell-free system to produce linear polyribonucleotides; optionally purifying compatible linear polyribonucleotides for splicing; and self-splicing linear polyribonucleotides under conditions suitable for splicing 3' and 5' splice sites of linear polyribonucleotides, thereby producing cyclic polyribonucleotides.

[0473] In certain embodiments, the present disclosure provides a method for producing cyclic polyribonucleotides by: providing a deoxyribonucleotide encoding a linear polyribonucleotide; transcribing deoxyribonucleotides in a cell-free system to produce a linear polyribonucleotide (wherein said transcription occurs in solution under the conditions of 3' and 5' splice sites suitable for splicing linear polyribonucleotides), thereby producing cyclic polyribonucleotides. In certain embodiments, the linear polyribonucleotides include 5' fracture introns and 3' fracture introns (for example, for producing a self-splicing construct of a cyclic polyribonucleotide). In certain embodiments, the linear polyribonucleotides include 5' annealing regions and 3' annealing regions.

[0474] Suitable conditions for in vitro transcription and / or self-splicing may include any conditions (e.g., solutions or buffers, such as aqueous buffers or solutions) that mimic physiological conditions in one or more aspects. In some embodiments, suitable conditions include Mg2+ ions or salts thereof between 0.1-100 mM (e.g., 1-100 mM, 1-50 mM, 1-20 mM, 5-50 mM, 5-20 mM, or 5-15 mM). In some embodiments, suitable conditions include K between 1-1000 mM. +Ions or salts thereof, such as KCl (e.g., 1-1000 mM, 1-500 mM, 1-200 mM, 50-500 mM, 100-500 mM, or 100-300 mM). In some embodiments, suitable conditions include Cl- ions or salts thereof, such as KCl (e.g., 1-1000 mM, 1-500 mM, 1-200 mM, 50-500 mM, 100-500 mM, or 100-300 mM) between 1-1000 mM. In some embodiments, suitable conditions include between 0.1-100 mM Mn2+ ions or a salt thereof, such as MnCl2 (e.g., 0.1-100 mM, 0.1-50 mM, 0.1-20 mM, 0.1-10 mM, 0.1-5 mM, 0.1-2 mM, 0.5-50 mM, 0.5-20 mM, 0.5-15 mM, 0.5-5 mM, 0.5-2 mM, or 0.1-10 mM). In some embodiments, suitable conditions include dithiothreitol (DTT) (e.g., 1-1000 μM, 1-500 μM, 1-200 μM, 50-500 μM, 100-500 μM, 100-300 μM, 0.1-100 mM, 0.1-50 mM, 0.1-20 mM, 0.1-10 mM, 0.1-5 mM, 0.1-2 mM, 0.5-50 mM, 0.5-20 mM, 0.5-15 mM, 0.5-5 mM, 0.5-2 mM, or 0.1-10 mM). In some embodiments, suitable conditions include ribonucleoside triphosphates (NTPs) between 0.1 mM and 100 mM (e.g., 0.1-100 mM, 0.1-50 mM, 0.1-10 mM, 1-100 mM, 1-50 mM, or 1-10 mM). In some embodiments, suitable conditions include a pH of 4 to 10 (e.g., a pH of 5 to 9, a pH of 6 to 9, or a pH of 6.5 to 8.5). In some embodiments, suitable conditions include a temperature of 4°C to 50°C (e.g., 10°C to 40°C, 15°C to 40°C, 20°C to 40°C, or 30°C to 40°C).

[0475] In certain embodiments, linear polyribonucleotide is produced from deoxyribonucleic acid (for example, deoxyribonucleic acid as described herein, as DNA vector, linearized DNA vector or cDNA).In certain embodiments, linear polyribonucleotide is transcribed from deoxyribonucleic acid by transcribing (for example, in vitro transcription) in a cell-free system.

[0476] In another example, cyclic polyribonucleotides can be produced in cells, such as prokaryotic cells or eukaryotic cells. In certain embodiments, exogenous polyribonucleotides (e.g., linear polyribonucleotides as described herein or DNA molecules encoding the transcription of linear polyribonucleotides as described herein) are provided to cells. Linear polyribonucleotides can be transcribed in cells from the exogenous DNA molecules provided to cells. Linear polyribonucleotides can be transcribed in cells from the exogenous recombinant DNA molecules provided to the cells instantaneously. In certain embodiments, the exogenous DNA molecules are not integrated into the genome of the cell. In certain embodiments, linear polyribonucleotides are transcribed in cells from the recombinant DNA molecules integrated into the cell genome.

[0477] In some embodiments, the cell is a prokaryotic cell. In some embodiments, the prokaryotic cell comprising the polyribonucleotides described herein can be a bacterial cell or an archaeal cell. For example, the prokaryotic cell comprising the polyribonucleotides described herein can be Escherichia coli, halophilic archaea (e.g., Haloferax volcaniii), Sphingomonas, cyanobacteria (e.g., Synechococcuse longatus, Spirulina (Arthrospira) species, and Synechocystis spp.), Streptomyces, actinomycetes (e.g., Nonomuraea, Kitasatospora, or Thermobifida), Bacillus spp. (e.g., Bacillus subtilis, Bacillus anthracis, Bacillus cereus, Bacillus spp.), or a prokaryotic cell comprising a polyribonucleotide described herein. cereus), beta proteobacteria (e.g., Burkholderia), alpha proteobacteria (e.g., Agrobacterium), Pseudomonas (e.g., Pseudomonas putida), and Enterobacter. Prokaryotic cells can be grown in culture medium. Prokaryotic cells can be contained in a bioreactor.

[0478] The cell can be a eukaryotic cell. In some embodiments, the eukaryotic cell is a unicellular eukaryotic cell. In some embodiments, the unicellular eukaryotic organism is a unicellular fungal cell, such as a yeast cell (e.g., Saccharomyces cerevisiae and other Saccharomyces species, Brettanomyces species, Schizosaccharomyces species, Torulaspora species, and Pichia species). In some embodiments, the unicellular eukaryotic cell is a unicellular animal cell. The unicellular animal cell can be a cell separated from a multicellular animal and grown in culture, or a daughter cell thereof. In some embodiments, the unicellular animal cell can be dedifferentiated. In some embodiments, the unicellular eukaryotic cell is a unicellular plant cell. The unicellular plant cell can be a cell separated from a multicellular plant and grown in culture, or a daughter cell thereof. In some embodiments, the unicellular plant cell can be dedifferentiated. In some embodiments, the unicellular plant cell is from a plant callus. In an embodiment, the unicellular cell is a plant cell protoplast. In certain embodiments, the unicellular eukaryotic cell is a unicellular eukaryotic algae cell, such as a unicellular green algae, a diatom, an euglena, or a dinoflagellate. The non-limiting examples of the unicellular eukaryotic algae of interest include Dunaliella salina, Chlorella vulgaris, Chlorella zofingiensis, Haematococcus pluvialis, Neochloris oleoabundans and other Neochloris spp, Protosiphon botryoides, Botryococcus braunii, Botryococcus braunii, Chlamydomonas reinhardtii and other Chlamydomonas spp. In certain embodiments, the unicellular eukaryotic cell is a protist cell. In certain embodiments, the unicellular eukaryotic cell is a protozoan cell.

[0479] In some embodiments, the eukaryotic cell is a cell of a multicellular eukaryotic organism. For example, a multicellular eukaryotic organism can be selected from the group consisting of vertebrates, invertebrates, multicellular fungi, multicellular algae, and multicellular plants. In some embodiments, the eukaryotic organism is a human. In some embodiments, the eukaryotic organism is a non-human vertebrate. In some embodiments, the eukaryotic organism is an invertebrate. In some embodiments, the eukaryotic organism is a multicellular fungi. In some embodiments, the eukaryotic organism is a multicellular plant. In some embodiments, the eukaryotic cell is a human cell or a non-human mammal cell, such as a non-human primate (e.g., monkey, ape), ungulate (e.g., bovine, including cattle, buffalo, bison, sheep, goat, and musk ox; pig; camelid, including camel, llama, and alpaca; deer, antelope; and equine, including horse and donkey), carnivore (e.g., dog, cat), rodent (e.g., rat, mouse, guinea pig, hamster, squirrel) or lagomorph (e.g., rabbit, hare). In some embodiments, the eukaryotic cell is a cell of a bird, such as a member of the following avian taxa: Galliformes (e.g., chicken, turkey, pheasant, quail), Anseriformes (e.g., duck, goose), Paleognathus (e.g., ostrich, emu), Columbiformes (e.g., pigeon, pigeon), or Psittaciformes (e.g., parrot). In some embodiments, the eukaryotic cell is a cell of an arthropod (e.g., insect, arachnid, crustacean), nematode, annelid, worm, or mollusk. In embodiments, the eukaryotic cell is a cell of a multicellular plant, such as an angiosperm (which can be a dicot or a monocot) or a gymnosperm (e.g., conifer, cycad, gnetum, ginkgo), a fern, a horsetail plant, a lycophyte, or a bryophyte. In embodiments, the eukaryotic cell is a cell of a eukaryotic multicellular algae.

[0480] The eukaryotic cells may be grown in a culture medium. The eukaryotic cells may be contained in a bioreactor.

[0481] The example of bioreactor includes but is not limited to stirred tank (for example, fully mixed) bioreactor and tubular (for example, plug flow) bioreactor, airlift bioreactor, membrane stirred tank, rotary filtration stirred tank, vibrating mixer, fluidized bed reactor and membrane bioreactor. The mode of operating bioreactor can be intermittent or continuous process. When reagent and product flow continuously enter and exit system, bioreactor is continuous. Intermittent bioreactor can have continuous recirculation flow, but there is no continuous reagent feeding or product harvesting. Some methods of present disclosure relate to large-scale production of cyclic polyribonucleotide. For large-scale production method, described method can be carried out in the volume of 1 liter (L) to 50L or more (for example, 5L, 10L, 15L, 20L, 25L, 30L, 35L, 40L, 45L, 50L or more). In some embodiments, the method can be performed in a volume of 5 L to 10 L, 5 L to 15 L, 5 L to 20 L, 5 L to 25 L, 5 L to 30 L, 5 L to 35 L, 5 L to 40 L, 5 L to 45 L, 10 L to 15 L, 10 L to 20 L, 10 L to 25 L, 20 L to 30 L, 10 L to 35 L, 10 L to 40 L, 10 L to 45 L, 10 L to 50 L, 15 L to 20 L, 15 L to 25 L, 15 L to 30 L, 15 L to 35 L, 15 L to 40 L, 15 L to 45 L, or 15 L to 50 L. In some embodiments, the bioreactor can produce at least 1 g of circular RNA. In some embodiments, the bioreactor can produce 1-200 g of circular RNA (e.g., 1-10 g, 1-20 g, 1-50 g, 10-50 g, 10-100 g, 50-100 g, 50-200 g of circular RNA). In some embodiments, the amount produced is measured per liter (e.g., 1-200 g per liter), per batch or reaction (e.g., 1-200 g per batch or reaction), or per unit time (e.g., 1-200 g per hour or per day). In some embodiments, more than one bioreactor can be used in series to increase production capacity (e.g., one, two, three, four, five, six, seven, eight, or nine bioreactors can be used in series).

[0482] Methods for preparing the cyclic polyribonucleotides described herein are described in, for example, Khudyakov and Fields, Artificial DNA: Methods and Applications, CRC Press (2002); Zhao, Synthetic Biology: Tools and Applications (First Edition), Academic Press (2013); and Egli and Herdewijn, Chemistry and Biology of Artificial Nucleic Acids, (First Edition), Wiley-VCH (2012).

[0483] Various methods for synthesizing cyclic polyribonucleotides have also been described elsewhere (see, e.g., U.S. Patent No. 6210931, U.S. Patent No. 5773244, U.S. Patent No. 5766903, U.S. Patent No. 5712128, U.S. Patent No. 5426180, U.S. Publication No. US20100137407, International Publication No. WO 1992001813 and International Publication No. WO2010084371, and Petkovic et al., Nucleic Acids Res [nucleic acid research]. 43: 2454-65 (2015); the contents of each of which are incorporated herein by reference in their entirety).

[0484] In certain embodiments, cyclic polyribonucleotide is purification, for example, has removed free ribonucleic acid, linear or nicked RNA, DNA, protein etc.In certain embodiments, can be by any known method purification cyclic polyribonucleotide commonly used in this area.The limiting examples of purification process comprises column chromatography, gel excision, size exclusion etc.

[0485] Linear polyribonucleotides

[0486] The linear polyribonucleotide disclosed herein comprises one or more expressed sequences encoding one or more immunogens and / or epitopes from coronavirus. This linear polyribonucleotide expresses the sequence encoding one or more immunogens and / or epitopes from coronavirus in a subject. In certain embodiments, the linear polyribonucleotide comprising one or more coronavirus immunogens and / or epitopes is used to produce an immune response in a subject. In certain embodiments, the linear polyribonucleotide comprising one or more coronavirus immunogens and / or epitopes is used to produce a polyclonal antibody as described herein.

[0487] Coronavirus immunogens and epitopes

[0488] Linear polyribonucleotides include sequences encoding coronavirus immunogens or epitopes. Immunogens and / or epitopes disclosed herein are related to coronaviruses. In certain embodiments, immunogens and / or epitopes are expressed by coronaviruses, or derived from immunogens and / or epitopes expressed by coronaviruses.

[0489] In some embodiments, the immunogens and / or epitopes disclosed herein are derived from predicted transcripts from the SARS-CoV genome. In some embodiments, the immunogens and / or epitopes disclosed herein are derived from proteins encoded by open reading frames from the SARS-CoV genome. Non-limiting examples of open reading frames in the SARS-CoV genome may include ORF1a, ORF1b, spikes (S), ORF3a, ORF3b, envelope (E), membrane (M), ORF6, ORF7a, ORF7b, ORF8, ORF8a, ORF8b, ORF9a, ORF9b, nucleocapsid (N) and ORF10. In some embodiments, the open reading frame from the SARS-CoV genome includes SEQ ID NO: 11.

[0490] In certain embodiments, the linear polyribonucleotide comprises a SARS-CoV-2 immunogen described in Table 6.

[0491] Table 6: Description of designed linear constructs.

[0492]

[0493] In Table 6, "proline substitution" means proline substitution of residues 986 and 987, and "GSAS" substitution at furin cleavage site (residues 682-685). For cloning optimization, single base substitution was performed at coordinate 2541 to destroy the BsaI site to assist in the construction of Golden Gate cloning of plasmid DNA templates. For cyclization optimization, four mononucleotides - at positions 2307, 2709, 159 and 315 - were substituted to destroy sites that could potentially bind splint nucleic acid sequence cyclization elements, thereby potentially inhibiting effective connection. All single base pair substitutions were designed to be translationally silent. In addition, in Table 6, 5' element is globin (SEQ ID NO:32); and 3' element is globin (SEQ ID NO:33).

[0494] In some embodiments, the linear polyribonucleotide includes an open reading frame encoding a SARS-CoV-2 immunogen having an amino acid sequence that is at least about 80% (e.g., about 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to any one of SEQ ID NOs: 63-111 and 293-295. In some embodiments, the linear polyribonucleotide comprises an open reading frame encoding a SARS-CoV-2 immunogen having an amino acid sequence that is at least about 90% (e.g., about 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to any one of SEQ ID NOs: 63-111 and 293-295. In some embodiments, the linear polyribonucleotide comprises an open reading frame encoding a SARS-CoV-2 immunogen having an amino acid sequence that is at least about 95% (e.g., about 96%, 97%, 98%, 99%, or 100%) identical to any one of SEQ ID NOs: 63-111 and 293-295. In some embodiments, the linear polyribonucleotide comprises an open reading frame encoding a SARS-CoV-2 immunogen having an amino acid sequence that is any one of SEQ ID NOs: 63-111 and 293-295. In some embodiments, the SARS-CoV-2 immunogen is an immunogenic fragment comprising a continuous stretch of at least 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1100, 1200, 1300, 1400, or 1500 amino acids of any one of SEQ ID NOs: 63-111 and 293-295. In some embodiments, the SARS-CoV-2 immunogen is an immunogenic fragment comprising a continuous stretch of at least 50%, 60%, 70%, 80%, 90%, or 95% of the amino acids of any one of SEQ ID NOs: 63-111 and 293-295.

[0495] In certain embodiments, the linear polyribonucleotide comprises an open reading frame having a nucleic acid sequence encoding a SARS-CoV-2 immunogen, wherein the nucleic acid sequence has at least about 80% (e.g., about 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 112-174 and 292-300. In some embodiments, the linear polyribonucleotide comprises an open reading frame having a nucleic acid sequence encoding a SARS-CoV-2 immunogen, wherein the nucleic acid sequence has at least about 90% (e.g., about 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) sequence identity with any one of SEQ ID NOs: 112-174 and 292-300. In some embodiments, the linear polyribonucleotide comprises an open reading frame having a nucleic acid sequence encoding a SARS-CoV-2 immunogen, wherein the nucleic acid sequence has at least about 95% (e.g., about 96%, 97%, 98%, 99% or 100%) sequence identity with any one of SEQ ID NOs: 112-174 and 292-300. In certain embodiments, the linear polyribonucleotide comprises an open reading frame having a nucleic acid sequence encoding a SARS-CoV-2 immunogen, wherein the nucleic acid sequence is any one of SEQ ID NOs: 112-174 and 292-300. In some embodiments, the polyribonucleotide sequence encoding a SARS-CoV-2 immunogen is a continuous stretch of at least 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1500, 2000, 2500, 3000, 3500, 4000, or 4500 nucleotides of any one of SEQ ID NOs: 112-174 and 292-300. In some embodiments, the polyribonucleotide sequence encoding the SARS-CoV-2 immunogen is a fragment of a continuous stretch of at least 50%, 60%, 70%, 80%, 90% or 95% of the amino acids of any one of SEQ ID NOs: 112-174 and 292-300.

[0496] In certain embodiments, the linear polyribonucleotide comprises an open reading frame having a nucleic acid sequence encoding a SARS-CoV-2 immunogen, wherein the nucleic acid sequence has at least about 80% (e.g., about 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) sequence identity to any one of SEQ ID NOs: 219-281. In some embodiments, the linear polyribonucleotide comprises an open reading frame having a nucleic acid sequence encoding a SARS-CoV-2 immunogen, wherein the nucleic acid sequence has at least about 90% (e.g., about 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) sequence identity to any one of SEQ ID NOs: 219-281. In some embodiments, the linear polyribonucleotide comprises an open reading frame having a nucleic acid sequence encoding a SARS-CoV-2 immunogen, wherein the nucleic acid sequence has at least about 95% (e.g., about 96%, 97%, 98%, 99% or 100%) sequence identity with any one of SEQ ID NOs: 219-281. In certain embodiments, the linear polyribonucleotide comprises an open reading frame having a nucleic acid sequence encoding a SARS-CoV-2 immunogen, wherein the nucleic acid sequence is any one of SEQ ID NOs: 219-281. In some embodiments, the polyribonucleotide sequence encoding a SARS-CoV-2 immunogen is a fragment of a continuous stretch of at least 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1500, 2000, 2500, 3000, 3500, 4000 or 4500 nucleotides of any one of SEQ ID NOs: 219-281. In some embodiments, the polyribonucleotide sequence encoding the SARS-CoV-2 immunogen is a fragment of a continuous stretch of at least 50%, 60%, 70%, 80%, 90% or 95% of the amino acids of any one of SEQ ID NOs: 219-281.

[0497] The present disclosure specifically contemplates that any of the DNA sequences described herein can be converted into a corresponding RNA sequence and contained within an RNA molecule described herein.

[0498] In some embodiments, a coronavirus epitope comprises or contains at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 26, at least 27, at least 28, at least 29, or at least 30 amino acids or more. In some embodiments, a coronavirus epitope comprises or contains at most 4, at most 5, at most 6, at most 7, at most 8, at most 9, at most 10, at most 11, at most 12, at most 13, at most 14, at most 15, at most 16, at most 17, at most 18, at most 19, at most 20, at most 21, at most 22, at most 23, at most 24, at most 25, at most 26, at most 27, at most 28, at most 29, or at most 30 amino acids or less. In some embodiments, the coronavirus epitope comprises or contains 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 amino acids. In some embodiments, the coronavirus epitope contains 5 amino acids. In some embodiments, the coronavirus epitope contains 6 amino acids. In some embodiments, the epitope contains 7 amino acids. In some embodiments, the coronavirus epitope contains 8 amino acids. In some embodiments, the epitope can be about 8 to about 11 amino acids. In some embodiments, the epitope can be about 9 to about 22 amino acids.

[0499] The coronavirus immunogen may comprise an immunogen recognized by a B cell, an immunogen recognized by a T cell, or a combination thereof. In some embodiments, the immunogen comprises an immunogen recognized by a B cell. In some embodiments, the coronavirus immunogen is an immunogen recognized by a B cell. In some embodiments, the coronavirus immunogen comprises an immunogen recognized by a T cell. In some embodiments, the immunogen is an immunogen recognized by a T cell.

[0500] Coronavirus epitopes include epitopes recognized by B cells, epitopes recognized by T cells, or a combination thereof. In some embodiments, coronavirus epitopes include epitopes recognized by B cells. In some embodiments, the epitope is an epitope recognized by B cells. In some embodiments, coronavirus epitopes include epitopes recognized by T cells. In some embodiments, coronavirus epitopes are epitopes recognized by T cells.

[0501] Techniques for identifying immunogens and epitopes via computer simulation have been disclosed in, for example, Sanchez-Trincado, et al. (2017), Fundamentals and methods for T-and B-cell epitope prediction. Journal of immunology research; Grifoni, Alba, et al. A Sequence Homology and Bioinformatic Approach Can Predict Candidate Targets for Immune Responses to SARS-CoV-2. Cell hostµbe (2020); Russi et al. In silico prediction of T-and B-cell epitopes in PmpD: First step towards to the design of a Chlamydiatrachomatis vaccine. Biomedical Journal [Biological Medicine] 41.2 (2018): 109-17; Baruah, et al., Immunoinformatics-aided identification of T cell and B cell epitopes in the surface glycoprotein of 2019-nCoV, Journal of Medical Virology (2020); each of which is incorporated herein by reference in its entirety.

[0502] The linear polyribonucleotide of this disclosure can comprise the sequence of any number of coronavirus immunogens and / or epitopes.Linear polyribonucleotide comprises for example at least 1 kind, at least 2 kinds, at least 3 kinds, at least 4 kinds, at least 5 kinds, at least 6 kinds, at least 7 kinds, at least 8 kinds, at least 9 kinds, at least 10 kinds, at least 15 kinds, at least 20 kinds, at least 25 kinds, at least 30 kinds, at least 40 kinds, at least 50 kinds, at least 60 kinds, at least 70 kinds, at least 80 kinds, at least 90 kinds, at least 100 kinds, at least 120 kinds, at least 140 kinds, at least 160 kinds, at least 180 kinds, at least 200 kinds, at least 250 kinds, at least 300 kinds, at least 350 kinds, at least 400 kinds, at least 450 kinds, at least 500 kinds or more kinds of coronavirus immunogens or the sequence of epitopes. In some embodiments, the linear polyribonucleotide comprises, for example, at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 15, at least 20, at least 25, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 120, at least 140, at least 160, at least 180, at least 200, at least 250, at least 300, at least 350, at least 400, at least 450, at least 500 or more immunogens or epitopes derived from a target other than a coronavirus.

[0503] In some embodiments, the linear polyribonucleotide comprises, for example, at most 1, at most 2, at most 3, at most 4, at most 5, at most 6, at most 7, at most 8, at most 9, at most 10, at most 15, at most 20, at most 25, at most 30, at most 40, at most 50, at most 60, at most 70, at most 80, at most 90, at most 100, at most 120, at most 140, at most 160, at most 180, at most 200, at most 250, at most 300, at most 350, at most 400, at most 450, at most 500 or less sequences of coronavirus immunogens or epitopes. In some embodiments, the linear polyribonucleotide comprises at most 1, at most 2, at most 3, at most 4, at most 5, at most 6, at most 7, at most 8, at most 9, at most 10, at most 15, at most 20, at most 25, at most 30, at most 40, at most 50, at most 60, at most 70, at most 80, at most 90, at most 100, at most 120, at most 140, at most 160, at most 180, at most 200, at most 250, at most 300, at most 350, at most 400, at most 450, at most 500 or less immunogens or epitopes derived from a target other than a coronavirus.

[0504] In certain embodiments, linear polyribonucleotides include, for example, about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, 120, 140, 160, 180, 200, 250, 300, 350, 400, 450 or 500 kinds of coronavirus immunogens or epi-position sequences. In certain embodiments, linear polyribonucleotides include, for example, about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, 120, 140, 160, 180, 200, 250, 300, 350, 400, 450 or 500 kinds of immunogens or epi-position sequences derived from sources other than coronavirus.

[0505] Linear polyribonucleotide can comprise the sequence of one or more coronavirus epitopes from coronavirus immunogen.For example, coronavirus immunogen can comprise amino acid sequence, wherein can contain multiple coronavirus epitopes (for example, by the epitope of B cell and / or T cell recognition), and linear polyribonucleotide can comprise or encode one or more in these coronavirus epitopes.

[0506] Linear polyribonucleotides comprise sequences of, for example, at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 15, at least 20, at least 25, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 120, at least 140, at least 160, at least 180, at least 200, at least 250, at least 300, at least 350, at least 400, at least 450, at least 500 or more epi-topes from a coronavirus immunogen.

[0507] In some embodiments, the linear polyribonucleotide comprises sequences of at most 2, at most 3, at most 4, at most 5, at most 6, at most 7, at most 8, at most 9, at most 10, at most 15, at most 20, at most 25, at most 30, at most 40, at most 50, at most 60, at most 70, at most 80, at most 90, at most 100, at most 120, at most 140, at most 160, at most 180, at most 200, at most 250, at most 300, at most 350, at most 400, at most 450 or at most 500, or fewer coronavirus epitopes, e.g., from a coronavirus immunogen.

[0508] In some embodiments, the linear polyribonucleotide comprises a sequence of, for example, about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, 120, 140, 160, 180, 200, 250, 300, 350, 400, 450, or 500 coronavirus epitopes from a coronavirus immunogen.

[0509] Linear polyribonucleotides can encode variants of coronavirus immunogens or epi-positions. Variant can be naturally occurring variants (e.g., variants identified in sequence data from different coronavirus genera, species, isolates or quasispecies), or can be derived sequences generated via computer simulation as disclosed herein (e.g., compared with wild-type immunogens or epi-positions, immunogens or epi-positions with one or more amino acid insertions, deletions, substitutions or combinations thereof).

[0510] The linear polyribonucleotide comprises the sequence of at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 15, at least 20, at least 25, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 120, at least 140, at least 160, at least 180, at least 200, at least 250, at least 300, at least 350, at least 400, at least 450, at least 500 or more variants of a coronavirus immunogen or epitope.

[0511] In some embodiments, the linear polyribonucleotide comprises sequences of at most 2, at most 3, at most 4, at most 5, at most 6, at most 7, at most 8, at most 9, at most 10, at most 15, at most 20, at most 25, at most 30, at most 40, at most 50, at most 60, at most 70, at most 80, at most 90, at most 100, at most 120, at most 140, at most 160, at most 180, at most 200, at most 250, at most 300, at most 350, at most 400, at most 450, at most 500 or less variants of, for example, a coronavirus immunogen or epitope.

[0512] In some embodiments, the linear polyribonucleotide comprises the sequence of about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, 120, 140, 160, 180, 200, 250, 300, 350, 400, 450, or 500 variants of, for example, a coronavirus immunogen or epitope.

[0513] The coronavirus immunogen and / or epitope sequence of linear polyribonucleotides may also be referred to as coronavirus expression sequences. In some embodiments, the linear polyribonucleotides include one or more coronavirus expression sequences, each of which may encode coronavirus polypeptides. Coronavirus polypeptides may be produced in large quantities. Coronavirus polypeptides may be coronavirus polypeptides secreted from cells or coronavirus polypeptides located in the cytoplasm, nucleus or membrane compartment of cells. Some coronavirus polypeptides include, but are not limited to, at least a portion of immunogens as disclosed herein, epitopes as disclosed herein, coronavirus proteins (e.g., viral envelope proteins, viral matrix proteins, viral spike proteins, viral membrane proteins, viral nucleocapsid proteins, viral auxiliary proteins, fragments thereof, or combinations thereof) as disclosed herein. In some embodiments, the coronavirus polypeptides encoded by the linear polyribonucleotides disclosed herein include fragments of coronavirus immunogens disclosed herein. In some embodiments, the coronavirus polypeptides encoded by the linear polyribonucleotides disclosed herein include fusion proteins, the fusion proteins including two or more coronavirus immunogens disclosed herein or fragments thereof. In some embodiments, the coronavirus polypeptides encoded by the linear polyribonucleotides disclosed herein include coronavirus epitopes. In some embodiments, the polypeptide encoded by the linear polyribonucleotide of the present disclosure comprises a fusion protein comprising two or more coronavirus epitopes disclosed herein, for example, an artificial peptide sequence comprising multiple predicted epitopes from one or more coronaviruses of the present disclosure.

[0514] In some embodiments, exemplary coronavirus proteins expressed by the linear polyribonucleotides disclosed herein include secreted proteins, such as proteins (e.g., immunogens and / or epitopes) that naturally include a signal peptide, or proteins that do not normally encode a signal peptide but are modified to include a signal peptide.

[0515] Linear polyribonucleotide element

[0516] The linear polyribonucleotide comprises the elements described below and a coronavirus immunogen or epitope as described herein.

[0517] Linear polyribonucleotides as described herein are polyribonucleotide molecules with 5' ends and 3' ends. In some embodiments, linear RNA has a free 5' end or 3' end. In some embodiments, linear RNA has a 5' end or 3' end that is modified or protected from degradation. In some embodiments, linear RNA has a non-covalently linked 5' or 3' end. In some embodiments, linear RNA is mRNA.

[0518] In some embodiments, the linear polyribonucleotide is at least about 20 nucleotides, at least about 30 nucleotides, at least about 40 nucleotides, at least about 50 nucleotides, at least about 75 nucleotides, at least about 100 nucleotides, at least about 200 nucleotides, at least about 300 nucleotides, at least about 400 nucleotides, at least about 500 nucleotides, at least about 1,000 nucleotides, at least about 2,000 nucleotides, at least about 5,000 nucleotides, at least about 6,000 nucleotides, or at least about 75 nucleotides. nucleotides, at least about 7,000 nucleotides, at least about 8,000 nucleotides, at least about 9,000 nucleotides, at least about 10,000 nucleotides, at least about 12,000 nucleotides, at least about 14,000 nucleotides, at least about 15,000 nucleotides, at least about 16,000 nucleotides, at least about 17,000 nucleotides, at least about 18,000 nucleotides, at least about 19,000 nucleotides, or at least about 20,000 nucleotides.

[0519] The linear polyribonucleotide of this disclosure may include any element as described herein or the combination of element, for example, any element described above about the cyclic polyribonucleotide or the combination of element.Linear polyribonucleotide may include any one or more IRES, signal sequence, regulatory element, cleavage domain, translation initiation sequence, non-translational region, termination element or modification (for example, about above-mentioned cyclic polyribonucleotide) as described herein.Linear polyribonucleotide may include such element (for example, about above-mentioned cyclic polyribonucleotide) of any quantity as described herein or configuration.

[0520] Methods of generating an immune response

[0521] The present disclosure provides immunogenic compositions comprising the above-mentioned cyclic polyribonucleotides. The present disclosure provides immunogenic compositions comprising the above-mentioned linear polyribonucleotides. The immunogenic compositions of the present invention may include a diluent or a carrier, an adjuvant or any combination thereof. The immunogenic compositions of the present invention may also include one or more immunomodulators, such as one or more adjuvants. The adjuvant may include TH1 adjuvants and / or TH2 adjuvants discussed further below. In certain embodiments, the immunogenic compositions include a diluent without any carrier, and are used to deliver the cyclic polyribonucleotides naked to a subject (e.g., a subject to be immunized). In certain embodiments, the immunogenic compositions include a diluent without any carrier, and are used to deliver the linear polyribonucleotides naked to a subject.

[0522] The immunogenic composition of the present invention is used to induce an immune response in a subject (e.g., a subject to be immunized). The immune response may include an antibody response (generally including IgG) and / or a cell-mediated immune response. In some embodiments, the immunogenic composition is used to produce polyclonal antibodies as described herein. For example, the subject is immunized with an immunogenic composition comprising a cyclic polyribonucleotide, the cyclic polyribonucleotide comprising a coronavirus immunogen and / or an epitope to stimulate the production of polyclonal antibodies bound to the coronavirus immunogen and / or an epitope. In another example, the subject is immunized with an immunogenic composition comprising a linear polyribonucleotide, the linear polyribonucleotide comprising a coronavirus immunogen and / or an epitope to stimulate the production of polyclonal antibodies bound to the coronavirus immunogen and / or an epitope. In some embodiments, the subject is a human. In some embodiments, the subject is a non-human animal. In some embodiments, the non-human animal has a humanized immune system. In some embodiments, the subject is further immunized with an adjuvant. In some embodiments, the subject is further immunized with a vaccine. Optionally, after immunization with an immunogenic composition comprising a cyclic polyribonucleotide, the polyclonal antibodies produced are collected and purified from the subject. Optionally, following immunization with an immunogenic composition comprising linear polyribonucleotides, the polyclonal antibodies produced are collected and purified from the subject.In some embodiments, the composition comprises plasma collected following administration of an immunogenic composition described herein.

[0523] Immunization

[0524] In some embodiments, the method of the present disclosure includes an immunogenic composition comprising a cyclic polyribonucleotide as disclosed herein for immunization of a subject (e.g., a subject to be immunized). In some embodiments, coronavirus immunogens and / or epitopes are expressed by cyclic polyribonucleotides. In some embodiments, immunization induces an immune response to coronavirus immunogens and / or epitopes expressed by cyclic polyribonucleotides in a subject. In some embodiments, immunization induces the generation of polyclonal antibodies that bind to coronavirus immunogens and / or epitopes expressed by immunogenic compositions. In some embodiments, the immunogenic composition comprises cyclic polyribonucleotides and a diluent, a carrier, a first adjuvant, or a combination thereof in a single composition. In some embodiments, the subject is further immunized with a second adjuvant. In some embodiments, the subject is further immunized with a vaccine.

[0525] In some embodiments, the method of the present disclosure includes an immunogenic composition comprising a linear polyribonucleotide as disclosed herein for immunization of a subject (e.g., a subject to be immunized). In some embodiments, coronavirus immunogens and / or epitopes are expressed by linear polyribonucleotides. In some embodiments, immunization induces an immune response to coronavirus immunogens and / or epitopes expressed by linear polyribonucleotides in a subject. In some embodiments, immunization induces the generation of polyclonal antibodies bound to coronavirus immunogens and / or epitopes expressed by linear polyribonucleotides. In some embodiments, the immunogenic composition comprises linear polyribonucleotides and a diluent, a carrier, a first adjuvant, or a combination thereof in a single composition. In some embodiments, the subject is further immunized with a second adjuvant. In some embodiments, the subject is further immunized with a vaccine.

[0526] Cyclic polyribonucleotides as disclosed herein stimulate the production of human polyclonal antibodies by stimulating adaptive immune responses after immunization of a subject (e.g., a subject to be immunized). In some embodiments, the adaptive immune response of the subject comprises stimulating B lymphocytes to release polyclonal antibodies, which specifically bind to the coronavirus immunogen expressed by the cyclic polyribonucleotides. Linear polyribonucleotides as disclosed herein stimulate the production of human polyclonal antibodies by stimulating adaptive immune responses after immunization of the subject. In some embodiments, the adaptive immune response of the subject comprises stimulating B lymphocytes to release polyclonal antibodies specifically bound to the coronavirus immunogen expressed by the linear polyribonucleotides. In some embodiments, the adaptive immune response of the subject comprises stimulating a cell-mediated immune response.

[0527] The subject (for example, the subject to be immunized) is inoculated with one or more immunogenic compositions comprising any number of cyclic polyribonucleotides. The subject is inoculated with one or more immunogenic compositions such as comprising at least 1 cyclic polyribonucleotide. The non-human animal with non-humanized immune system is inoculated with at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 20 different cyclic polyribonucleotides or more different cyclic polyribonucleotides. In certain embodiments, the subject is inoculated with one or more immunogenic compositions comprising at most 1 cyclic polyribonucleotide. In certain embodiments, the subject is inoculated with one or more immunogenic compositions comprising about 1 cyclic polyribonucleotide. In some embodiments, a subject is immunized with one or more immunogenic compositions comprising about 1-20, 1-15, 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 2-20, 2-15, 2-10, 2-9, 2-8, 2-7, 2-6, 2-5, 2-4, 2-3, 3-20, 3-15, 3-10, 3-9, 3-8, 3-7, 3-6, 3-5, 3-4, 4-20, 4-15, 4-10, 4-9, 4-8, 4-7, 4-6, 4-5, 4-4, 4-3, 5-20, 5-15, 5-10, 5-9, 5-8, 5-7, 5-6, 5-10, 10-15 or 15-20 different cyclic polyribonucleotides. The invention relates to the invention of the present invention.Different cyclic polyribonucleotides have sequences different from each other.For example, they can comprise or encode different immunogens and / or epi-positions, overlapping immunogens and / or epi-positions, similar immunogens and / or epi-positions or identical immunogens and / or epi-positions (for example, with identical or different regulating and controlling elements, starting sequences, promoters, terminators or other elements of this disclosure).In the case of experimenter with one or more immunogenic compositions immunizations comprising tw...

Claims

1. A cyclic polyribonucleotide comprising an open reading frame encoding a coronavirus immunogen, wherein the coronavirus immunogen comprises an amino acid sequence having at least 95% sequence identity with the amino acid sequence of any one of SEQ ID NOs: 63-111 and 283-291.

2. A cyclic polyribonucleotide as claimed in claim 1, wherein the coronavirus immunogen is a RBD immunogen having at least 95% identity with the amino acid sequence of any one of SEQ ID NOs: 63-68, 74, 79, 81-86 and 98-111.

3. A cyclic polyribonucleotide as claimed in claim 1, wherein the coronavirus immunogen is a spike immunogen with at least 95% identity to the amino acid sequence of any one of SEQ ID NO:69-73, 75-78, 80, 87-97 and 283-286.

4. cyclic polyribonucleotide as claimed in claim 1, wherein the coronavirus immunogen is a non-structural protein (nsp) with at least 95% identity to the amino acid sequence of any one of SEQ ID NO:291-295.

5. cyclic polyribonucleotide as claimed in claim 1, wherein the coronavirus immunogen comprises the amino acid sequence of any one of SEQ ID NO:63-111 and 283-291.

6. as the circular polyribonucleotide described in any one among the claim 1-5, wherein said open reading frame comprises the nucleotide sequence that has at least 95% sequence identity with the nucleotide sequence of any one among SEQID NO:112-174 and 292-300.

7. Circular polyribonucleotide as claimed in claim 6, wherein the coronavirus immunogen is a RBD immunogen with at least 95% identity to the nucleotide sequence of any one of SEQ ID NO:112-117, 123, 128, 133-138 and 163-174.

8. A circular polyribonucleotide as described in claim 6, wherein the coronavirus immunogen is a spike immunogen with at least 95% identity to the nucleic acid sequence of any one of SEQ ID NO:118-122, 124-127, 129-132, 139-162 and 287-291.

9. cyclic polyribonucleotide as claimed in claim 6, wherein the coronavirus immunogen is an nsp with at least 95% homology to the nucleotide sequence of any one of SEQ ID NO:296-300.

10. The cyclic polyribonucleotide of any one of claims 1-9, wherein the open reading frame encoding the second polypeptide of the encoding coronavirus immunogen.

11. cyclic polyribonucleotide as claimed in claim 10, wherein said second polypeptide is a polypeptide immunogen.

12. cyclic polyribonucleotide as claimed in claim 10, wherein said second polypeptide is a viral immunogen.

13. cyclic polyribonucleotide as claimed in claim 12, wherein the second polypeptide is a coronavirus immunogen.

14. cyclic polyribonucleotide as claimed in claim 12, wherein the second polypeptide is an influenza immunogen.

15. cyclic polyribonucleotide as claimed in claim 11, wherein the second polypeptide is a polypeptide adjuvant.

16. A cyclic polyribonucleotide comprising a first sequence encoding a coronavirus immunogen and a second sequence encoding a polypeptide adjuvant.

17. A cyclic polyribonucleotide comprising a first sequence encoding a coronavirus immunogen and a second sequence encoding a multimerization domain.

18. An immunogenic composition comprising a cyclic polyribonucleotide as described in any one of claims 1 to 17 and a pharmaceutically acceptable carrier or excipient.

19. The immunogenic composition of claim 18, wherein the composition further comprises a second cyclic polyribonucleotide.

20. The immunogenic composition of claim 19, wherein the second cyclic polyribonucleotide comprises an open reading frame encoding a second polypeptide immunogen.

21. immunogenic compositions as claimed in claim 19, wherein the second cyclic polyribonucleotide comprises an open reading frame encoding a polypeptide adjuvant.

22. A linear polyribonucleotide comprising an open reading frame encoding a coronavirus immunogen, wherein the coronavirus immunogen comprises an amino acid sequence having at least 95% sequence identity with the amino acid sequence of any one of SEQ ID NOs: 63-111 and 283-291.

23. linear polyribonucleotide as claimed in claim 22, wherein the coronavirus immunogen comprises the amino acid sequence of any one of SEQ ID NO:63-111.

24. The linear polyribonucleotide of claim 22 or claim 23, wherein the open reading frame comprises a nucleic acid sequence having at least 95% sequence identity with a nucleic acid sequence of any one of SEQ ID NOs: 112-174 and 292-300.

25. linear polyribonucleotide as claimed in claim 24, wherein said open reading frame comprises the nucleic acid sequence of any one among SEQ ID NO:112-174 and 292-300.

26. A linear polyribonucleotide as described in any one of claims 22-25, wherein the open reading frame encoding the coronavirus immunogen second polypeptide.

27. linear polyribonucleotide as claimed in claim 26, wherein said second polypeptide is a polypeptide immunogen.

28. linear polyribonucleotide as claimed in claim 27, wherein the second polypeptide is a coronavirus immunogen.

29. linear polyribonucleotide as claimed in claim 26, wherein said second polypeptide is a polypeptide adjuvant.

30. A linear polyribonucleotide comprising a first sequence encoding a coronavirus immunogen and a second sequence encoding a multimerization domain.

31. An immunogenic composition comprising a linear polyribonucleotide as described in any one of claims 22-30 and a pharmaceutically acceptable carrier or excipient.

32. The immunogenic composition of claim 31, wherein the composition further comprises a second linear polyribonucleotide.

33. The immunogenic composition of claim 32, wherein the second linear polyribonucleotide comprises an open reading frame encoding a second polypeptide immunogen.

34. immunogenic compositions as claimed in claim 32, wherein the second linear polyribonucleotide comprises an open reading frame encoding a polypeptide adjuvant.

35. A method of inducing an immune response to SARS-CoV-2 in a subject, the method comprising administering to the subject a cyclic polyribonucleotide, a linear polyribonucleotide or an immunogenic composition as described in any one of claims 1 to 34.

36. A method for preventing SARS-CoV-2 infection in a subject, the method comprising administering to the subject a cyclic polyribonucleotide or an immunogenic composition as described in any one of claims 1-34.

Citation Information

Patent Citations

  • Methods for the preparation of organotin compounds

    EP0002019A1

  • Device for conveying a textile web

    EP0678615A2

  • Amino acid-, peptide- and polypeptide-lipids, isomers, compositions, and uses thereof

    US10086013B2

  • Lipids and lipid nanoparticle formulations for delivery of nucleic acids

    US10221127B2

  • Lipid-based formulations

    US20030077829A1